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Abstract 
Autoimmune neuropathies are a group of conditions resulting from inflammatory 
attack of the peripheral nervous system (PNS). Guillain-Barré syndrome (GBS), 
an acute autoimmune neuropathy, presents in both axonal and demyelinating 
forms. Axonal forms of GBS are caused by autoantibodies which target 
gangliosides on peripheral nerves. Here, they cause axonal damage via activation 
of the complement pathway. In ex vivo preparations, anti-ganglioside antibodies 
have been shown to cause complement-mediated injury to the node of Ranvier 
and the motor nerve terminal. Of these two vulnerable sites, the motor nerve 
terminal has recently been shown to be able to internalise anti-ganglioside 
antibody while the node of Ranvier does not. Rabbit models have demonstrated 
that immunisation with ganglioside results in a motor axonal neuropathy but no 
such model currently exists in mice. This is partially due to the fact that 
wildtype mice respond poorly when immunised with ganglioside and partially due 
to the requirement of an exogenous complement source to cause injury. This 
laboratory has recently developed GalNAcT-/--Tg(neuronal) and GalNAcT-/--
Tg(glial) mice with complex ganglioside expression restricted to neurons and 
glia, respectively. This thesis aimed to develop a mouse model of GBS by 
actively immunising these mice with ganglioside liposomes. Subsequently, the 
aims were expanded to look at the clearance of the antibodies by membranes 
which express their ganglioside target. To complete these aims, wildtype, 
GalNAcT-/-, GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mice were 
compared. 
Following immunisation with liposomes containing GD1b, wildtype mice 
responded poorly as demonstrated by low presence of immunoglobulin in their 
sera. Conversely, GalNAcT-/- mice, which lack complex gangliosides, showed high 
presence of immunoglobulin in their sera. GalNAcT-/--Tg(neuronal) and GalNAcT-
/--Tg(glial) mice showed intermediate levels. This was assumed to be due to 
varying levels of tolerance to “self” lipids among the mice. However, when 
normal human serum was introduced, GalNAcT-/--Tg(neuronal) and GalNAcT-/--
Tg(glial) mice did not show any complement-mediated injury. Based upon 
evidence from ELISpots from the splenocytes of these mice, there did not appear 
to be any major differences in anti-GD1b antibody-producing cells among 
genotypes. The possibility that the antibodies produced by these mice were 
being removed by internalisation was investigated at the NMJ ex vivo and in 
vivo. Ex vivo, antibodies against complex gangliosides were demonstrated to be 
cleared in a receptor-dependent and activity-dependent manner. Following 
passive immunisation with pathogenic monoclonal antibody in vivo, serum levels 
of the antibody were cleared rapidly in wildtype mice but remain elevated at 7 
days in GalNAcT-/- mice. GalNAcT-/--Tg(neuronal) mice cleared antibody at an 
intermediate rate. Non-pathogenic antibodies were not cleared from the 
circulation over the 7 days from any of the three genotypes. 
These results have demonstrated that levels of anti-ganglioside antibody can be 
regulated by receptor-dependent internalisation, especially at the motor nerve 
terminal. These studies have highlighted this structure as a novel regulator of 
anti-ganglioside antibody in vivo. The clearance of antibody is also dependent on 
the ability of the antibody to bind to living tissue; therefore antibodies detected 
in patient serum may not represent pathogenic, disease-causing antibodies. 
These factors may profoundly influence host vulnerability to antibody-mediated 
disease by affecting circulating levels of pathological antibodies.  
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1 Introduction 
1.1 Guillain-Barré syndrome 
Autoimmune neuropathies are a group of conditions resulting from inflammatory 
attack of the peripheral nervous system (PNS) which can present in both chronic 
and acute forms. Guillain-Barré syndrome (GBS) is an acute form of such a 
disorder, affecting around 1000 people per year in the United Kingdom 
(McGrogan et al., 2009). Although a rare condition, approximately 10% of GBS 
cases are fatal and 10-30% leave the patient with some form of disability 
(Bersano et al., 2006;Soysal et al., 2011;Vedeler et al., 1997). For this reason, 
GBS remains a problem both in the UK and worldwide, where it is now 
recognised as the leading cause of acute flaccid paralysis (AFP), accounting for 
over 50% of AFP cases following the eradication of poliomyelitis (Olive et al., 
1997). 
1.1.1 Discovery  
The first mention of the condition now known as GBS was in 1859, when Jean 
Landry described an ascending symmetric muscular paralysis in a cohort of 10 
patients (Landry, 1859). However, it was not until the early 20th century that the 
recently developed lumbar puncture technique allowed further characterisation 
of the disorder. This technique allowed three army physicians, Georges Guillain, 
Jean Barré and André Strohl, to describe two patients who had a paralysis 
similar to that of poliomyelitis, suffering from both ataxia and areflexia (Guillain 
et al., 1916). Analysis of the cerebrospinal fluid (CSF) revealed elevated albumin 
and an absence of pleocytosis which allowed a diagnostic distinction to be made 
between this acute condition and poliomyelitis. This significant finding led 
people to refer to the condition as Guillain-Barré syndrome.  
1.1.2 Clinical presentation and diagnosis 
During the period following its first description, GBS cases became more 
commonly recognised and there began a discussion over diagnostic criteria. 
Guillain-Barré syndrome is characterised by ascending symmetric muscular 
paralysis. The condition is rapid in onset, presenting with ataxia and areflexia. 
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This can progress to complete paralysis of the affected muscles, with around 25% 
of patients requiring artificial ventilation (Eldar and Chapman, 2014). Generally 
the illness will reach its nadir at around 4 weeks following its onset, with 
recovery time ranging from weeks to months. Around 10% of GBS patients cannot 
walk independently within 6 months of disease onset, with some individuals 
taking over a year to complete such a task unaided (Hiraga et al., 2005). 
Diagnostic criteria were set down by the National Institute of Neurological and 
Communicative Disorders and Stroke (NINCDS), in response to the increased rate 
of GBS cases following the swine flu outbreak in 1976-1977 (Asbury, 1978). The 
vaccine provided for this outbreak is thought to have triggered autoimmune 
responses leading to the disease. The criteria were again updated in 1990, 
adding more detail (Asbury and Cornblath, 1990). Current diagnostic criteria are 
detailed below in Table 1.  
Table 1.1: Diagnostic criteria for typical Guillain-Barré syndrome as taken from 
Asbury and Cornblath, (1990) 
Diagnostic Criteria for typical Guillain-Barré Syndrome 
 
I . Features Required for Diagnosis 
A. Progressive motor weakness of more than one limb. The degree ranges from minimal weakness of the 
legs, with or without mild ataxia, to total paralysis of the muscles of all four extremities and the trunk, 
bulbar and facial paralysis, and external ophthalmoplegia. 
B. Areflexia (loss of tendon jerks). Universal areflexia is the rule, though distal areflexia with definite 
hyporeflexia of the biceps and knee jerks will suffice if other features are consistent. 
 
II. Features Strongly Supportive of the Diagnosis 
A. Clinical features (ranked in order of importance) 
1. Progression. Symptoms and signs of motor weakness develop rapidly but cease to progress by 
four weeks into the illness. Approximately 50% will reach the nadir by two weeks, 80% by three 
weeks, and more than 90% by four weeks.  
2. Relative symmetry. Symmetry is seldom absolute, but usually, if one limb is affected, the 
opposite is as well. 
3. Mild sensory symptoms or signs. 
4. Cranial nerve involvement. Facial weakness occurs in approximately 50% and is frequently 
bilateral. Other cranial nerves may be involved, particularly those innervating the tongue and muscles of 
deglutition, and sometimes the extraocular motor nerves. On occasion (less than 5%), the neuropathy may 
begin in the nerves to the extraocular muscles or other cranial nerves. 
5. Recovery. It usually begins two to four weeks after progression stops. Recovery may be delayed 
for months. Most patients recover functionally. 
6. Autonomic dysfunction. Tachycardia and other arrhythmias, postural hypotension, hypertension, 
and vasomotor symptoms, when present, support the diagnosis. These findings may fluctuate. Care must be 
exercised to exclude other bases for these symptoms, such as pulmonary embolism. 
7. Absence of fever at the onset of neuritic symptoms. 
Variants (not ranked) 
1. Fever at onset of neuritic symptoms. 
2. Severe sensory loss with pain. 
3. Progression beyond four weeks. Occasionally, a patient’s disease will continue to progress for 
many weeks longer than four or the patient will have a minor relapse. 
4. Cessation of progression without recovery or with major permanent residual deficit remaining. 
5. Sphincter function. Usually the sphincters are not affected, but transient bladder paralysis may 
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occur during the evolution of symptoms. 
6. Central nervous system involvement. Ordinarily, Guillain-Barre syndrome is thought of as a 
disease of the peripheral nervous system. Evidence of central nervous system involvement is controversial. 
In occasional patients, such findings as severe ataxia interpretable as cerebellar in origin, dysarthria, 
extensor plantar responses, and ill-defined sensory levels are demonstrable, and these need not exclude 
the diagnosis if other features are typical. 
B. Cerebrospinal fluid features strongly supportive of the diagnosis 
1. CSF protein. After the first week of symptoms, CSF protein is elevated or has been shown to rise 
on serial lumbar punctures. 
2. CSF cells. Counts of 10 or fewer mononuclear leukocytes/mm3 in CSF. 
Variants 
1. No CSF protein rise in the period of one to ten 
2. Counts of 11 to 50 mononuclear leukocytes/mm3 
C. Electrodiagnostic features strongly supportive of the diagnosis 
Approximately 80% will have evidence of nerve conduction slowing or block at some point during 
the illness. Conduction velocity is usually less than 60% of normal, but the process is patchy and not all 
nerves are affected. Distal latencies may be increased to as much as three times normal. Use of F-wave 
responses often gives good indication of slowing over proximal portions of nerve trunks and roots. Up to 20% 
of patients will have normal conduction studies. Conduction studies may not become abnormal until several 
weeks into the illness. 
 
III. Features Casting Doubt on the Diagnosis 
1. Marked, persistent asymmetry of weakness. 
2. Persistent bladder or bowel dysfunction. 
3. Bladder or bowel dysfunction at onset. 
4. More than 50 mononuclear leukocytes/mm3 in CSF. 
5. Presence of polymorphonuclear leukocytes in CSF. 
6. Sharp sensory level. 
 
IV. Features That Rule Out the Diagnosis 
1. A current history of hexacarbon abuse (volatile solvents; n-hexane and methyl n-butyl ketone). 
This includes huffing of paint lacquer vapours or addictive glue sniffing. 
2. Abnormal porphyrin metabolism indicating a diagnosis of acute intermittent porphyria. This 
would manifest as increased excretion of porphobilinogen and 6-aminolevulinic acid in the urine. 
3. A history or finding of recent diphtheritic infection, either faucial or wound, with or without 
myocarditis.  
4. Features clinically consistent with lead neuropathy (upper limb weakness with prominent wrist 
drop; may be asymmetrical) and evidence of lead intoxication. 
5. The occurrence of a purely sensory syndrome.  
6. A definite diagnosis of a condition such as poliomyelitis, botulism, hysterical paralysis, or toxic 
neuropathy (e.g., from nitrofurantoin, dapsone, or organophosphorus compounds), which occasionally may 
be confused with Guillain-Barre syndrome. 
 
1.1.3 GBS Subtypes 
Several subtypes of GBS have now been described, with differing clinical 
presentation and pathology, however all subtypes appear to conform to two 
major mechanisms of pathology: demyelination or axonal damage (Figure1.1). 
The incidence of these subtypes also appears to vary between different parts of 
the world.  
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Figure 1.1: The major pathogenic mechanisms in GBS. A: Demyelination caused by 
antibody binding to an unknown antigen, causing complement activation and subsequent 
myelin injury. This can be followed by clearance of myelin debris by macrophages. B: 
Motor axonal damage caused by anti-ganglioside antibody binding to nodes of Ranvier, 
followed by complement activation and nodal injury via MAC pore formation. This may 
be followed by axonal degeneration and clearance of axon debris by macrophages. 
Electron microscopy images in A and B taken with permission from Hughes, (1990) and 
Griffin et al., (1996) respectively.   
1.1.3.1 Acute Inflammatory Demyelinating Polyneuropathy 
In Western countries such as Europe and North America, the predominant form 
of GBS is by far acute inflammatory demyelinating polyneuropathy (AIDP), 
representing around 70% of GBS cases (Hadden et al., 1998). This subtype is 
much less common (around 30% of cases) in Asian and Latin American countries 
(Ho et al., 1995;Islam et al., 2010;Nachamkin et al., 2007). Initially, AIDP 
represented the “classical” picture of GBS pathogenesis: the demyelination of 
the peripheral motor nerves, by two possible mechanisms. Firstly, macrophages 
may be targeted towards the Schwann cell (SC) membrane or myelin sheath, 
resulting in the denuding of the axon. Alternatively, antibodies may be directed 
against SC membrane or myelin sheath, resulting in complement-mediated 
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membrane lysis. Macrophage infiltration in this instance would be as a 
consequence of this preceding event (Hughes, 1990). Identifying precisely which 
SC or myelin targets these macrophages or antibodies are directed at in AIDP has 
proven difficult and currently remains unresolved.  
1.1.3.2 Acute Motor Axonal Neuropathy (AMAN) 
Initially all GBS cases were thought to be demyelinating (potentially with only 
secondary bystander axonal damage). Soon however, cases began to emerge 
which had electrophysiological signs of axonal damage (Albers et al., 1985). 
Following an investigation of a cohort of Chinese patients by McKhann et al, who 
initially named this condition Chinese paralytic syndrome, it became clear that 
this was indeed a subtype of GBS, and was termed acute motor axonal 
neuropathy (AMAN) (McKhann et al., 1991). This subtype of GBS is very common 
in Asia and Latin America (40-70% of GBS cases) (Ho et al., 1995;Islam et al., 
2010;Nachamkin et al., 2007). Commonly referred to as axonal GBS, AMAN is a 
result of axonal damage mediated by antibodies which bind to the axolemma 
and are followed by complement activation, most likely at nodes of Ranvier 
(NoR) or at the nerve terminal, where the axon membrane is exposed (Hafer-
Macko et al., 1996a). At the node, this can also be followed by macrophage 
infiltration into the nodal gap. These insert beneath the myelin sheath to target 
the axon, causing transection and subsequent Wallerian degeneration (Griffin et 
al., 1996). However, as many patients with AMAN recover rapidly, it is likely that 
these patients have only localised nerve terminal degeneration (Ho et al., 
1997;Rupp et al., 2012) or reversible conduction block caused by antibody 
binding to the NoR, or localised Node of ranvier damage caused by antibody 
binding plus complement (Ho et al., 1997;McGonigal et al., 2010;Susuki et al., 
2007b;Takigawa et al., 1995) 
1.1.3.3 Miller Fisher Syndrome (MFS) 
First described in 1956 by Charles Miller-Fisher, the syndrome which bears his 
name is recognised by the three cardinal symptoms of ophthalmoplegia, ataxia 
and areflexia, targeting mainly the muscles of the face (Fisher, 1956). This 
subtype of GBS has been shown to overlap with GBS as Miller-Fisher syndrome 
(MFS) patients can also show limb weakness and respiratory involvement. 
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Similarly, patients presenting with typical GBS can also have some ophthalmic 
involvement. Three such GBS patients were also described by Miller-Fisher, one 
of which died of respiratory failure, allowing him to show that the oculomotor 
symptoms were due to myelin destruction. An overlapping syndrome, 
Bickerstaff’s brainstem encephalitis (BBE), also presents with the three cardinal 
symptoms of MFS, but with additional brainstem involvement, resulting in 
drowsiness and even, in extreme cases, coma (Shahrizaila and Yuki, 2013). These 
CNS symptoms are thought to be due to a transient inflammatory injury to the 
brainstem. 
1.1.4 Chronic autoimmune neuropathies 
In 1958, James Austin described a group of recurring polyneuropathies which 
also present with elevated CSF protein count and progressive motor weakness 
progressing over a much longer time course than GBS and relapsing months to 
years after the initial recovery phase (Austin, 1958). The presence of conduction 
block and the improvement of disease in response to steroid treatment led to 
this chronic GBS-like disease being termed chronic inflammatory demyelinating 
neuropathy (CIDP). This condition may present as pure motor or motor-sensory 
and has a variety of subvarients (Eldar and Chapman, 2014). 
Multifocal motor neuropathy (MMN), a purely motor form of autoimmune 
neuropathy, was described most recently, by Lewis et al, when he was 
presented with patients who had multifocal asymmetric weakness and 
conduction block in motor nerves only (Lewis et al., 1982). Initially thought to 
be a variation of CIDP, the term MMN was coined in 1988 by Pestronk et al who 
delineated the differences seen between two patients with this condition and 
other immune-mediated demyelinating neuropathies (Pestronk et al., 1988). 
These were namely the multifocal, asymmetric nature of the condition, the 
predominant involvement of the upper limbs, the pure motor involvement, the 
normal or only slightly elevated CSF protein count and the finding of antibodies 
against nerve glycosphingolipids called gangliosides. Again MMN is chronic and 
generally progresses slowly and is associated with a demyelinating pathology. 
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1.1.5 Molecular mimicry 
GBS is an acute post-infectious disease, normally manifesting 2-3 weeks 
following infection or other causative agent. Many triggering factors have been 
associated with GBS, including H1N1 vaccination (Salmon et al., 2013) and 
respiratory and gastrointestinal infections (Leneman, 1966;McGrogan et al., 
2009). The most frequently noted infection preceding GBS is that of 
Campylobacter jejuni (C. jejuni) (McCarthy and Giesecke, 2001;Tam et al., 
2007), a gram-negative bacterium found in the faeces of many animal species. 
Indeed when AMAN was first described, it was one of the first studies 
demonstrating a clear link between C. jejuni infection and GBS and giving an 
explanation to the somewhat seasonal pattern of AMAN in China, where it 
coincided with summer epidemics of C. jejuni infection (McKhann et al., 1991). 
This form of disease was found to be predominant in children, presumably due to 
the poor hygiene of children in these areas, and their increased likelihood of 
contracting antecedent C. jejuni infections (McKhann et al., 1991;McKhann et 
al., 1993;Nachamkin et al., 2007;Liu et al., 2003).  
One particular serotype of C.jejuni, O:19, appeared to be more common in 
patients who developed GBS than in other gastrointestinal infection cases 
(Fujimoto et al., 1992;Kuroki et al., 1993). A great step in GBS research was 
made when it was discovered that the core oligosaccharides of O:19 which can 
cause GBS were similar in structure to the saccharide moiety of gangliosides GM1 
and GD1a (Aspinall et al., 1994;Yuki et al., 1993b). Animal models of disease 
have provided further evidence of the link between molecular mimicry, 
especially that of C. jejuni, and GBS (see section 1.6). Thus, GBS fulfils all of the 
criteria which must be fulfilled for a disease to be autoimmune in origin, 
triggered by molecular mimicry (see table 1.2).  
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Table 1.2: Fulfilment of the criteria of GBS as caused by molecular mimicry. Criteria 
are set out in Ang et al based on Witebsky’s postulates on criteria for autoimmune 
disease (Ang et al., 2004;Witebsky et al., 1957). 
Criteria Fulfilment References 
Association with 
infectious agent 
Associated with C. jejuni and 
other infections 
(Salmon et al., 2013;Leneman, 
1966;McGrogan et al., 2009;McCarthy 
and Giesecke, 2001;Tam et al., 2007) 
Presence of T cell or 
antibodies directed 
against self-antigen 
Autoantibodies directed 
against gangliosides 
(Ilyas et al., 1988b;Ilyas et al., 1988a) 
Microbial mimic of 
target antigen 
C. jejuni LOS mimic 
gangliosides 
(Aspinall et al., 1994;Yuki et al., 
1993b) 
Disease can be 
reproduced in animal 
model 
Rabbits immunised with GM1 
or GM1-like LOS develop 
AMAN-like disease 
(Yuki et al., 2004;Yuki et al., 2001) 
 
1.1.6 Anti-ganglioside antibodies 
The first association made between anti-ganglioside antibodies and GBS was 
made by Ilyas and colleagues in 1988, when serum from patients was shown to 
react with gangliosides from peripheral nerves (Ilyas et al., 1988b;Ilyas et al., 
1988a). This association between these antibodies, which are generally of the 
IgG subclass, and GBS is now well established. In some cases different GBS 
subtypes have been linked to specific anti-ganglioside antibody profiles. In the 
case of MFS, the primary target has been defined for a number of years. The 
complex ganglioside GQ1b was first seen to be associated with MFS by Chiba et 
al in 1992, when they found that 100% of patients they tested had IgG reactivity 
to GQ1b, with many subsequent studies confirming this link (Chiba et al., 
1992;Ichikawa et al., 2002;Ohtsuka et al., 1998;Yuki et al., 1998). In addition, it 
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has been shown that the nerves controlling eye movement have a high GQ1b 
composition compared to other nervous system tissue, providing rationale for 
the anti-GQ1b antibody’s localised pathogenesis in this disease (Chiba et al., 
1993;Chiba et al., 1997). Already sharing all the symptoms of MFS plus the 
addition of brainstem involvement, it was later discovered that BBE is also 
associated with high titres of GQ1b antibody, providing further evidence that the 
two disorders are linked (Yuki et al., 1993a). It is hypothesised that in the case 
of BBE, the circulating anti-GQ1b antibodies which bind to the oculomotor nerve 
node of Ranvier and nerve terminal, also permeate the BBB and bind to regions 
of the brainstem (Shahrizaila and Yuki, 2013). 
Motor axonal and sensory forms of GBS have been linked to anti-GM1, GD1a and 
GD1b antibodies (Ho et al., 1995;Kuwabara et al., 1998;Ogawara et al., 
2000;Ilyas et al., 1988c;Ho et al., 1999;Yuki et al., 1992b;Kaida et al., 2000). 
The relative specificity of cholera toxin for binding GM1 ganglioside allowed 
early studies to show enrichment of GM1 at node of Ranvier and at motor nerve 
terminals, but not on the internodal SC surfaces (Hansson et al., 1977;Ganser et 
al., 1983). It is therefore unsurprising that antibodies to GM1 are often present 
in motor axonal but not demyelinating forms of GBS (Kuwabara et al., 1998;Yuki 
et al., 1999). Similarly, GD1a has been found to be enriched in motor nerve 
fibres (Gong et al., 2002) and in sensory and motor nerves, both GM1 and GD1a 
have been shown to be enriched in the axonal compared to the myelin fraction. 
This again indicates why antibodies against these gangliosides are associated 
with axonal forms of GBS (Ogawa-Goto et al., 1990).  
Ganglioside GD1b is most classically associated with sensory forms of GBS. 
Antibodies binding to GD1b stain human dorsal root ganglia and bind well to 
sensory fibres in animal models (Gong et al., 2002;Kusunoki et al., 1997). 
However, GD1b can also be found in cases of AMAN (Ilyas et al., 1988c;Ogawara 
et al., 2000;Vriesendorp et al., 1993) and immunohistology has also shown that 
anti-GD1b antibodies bind motor fibres and motor nerve terminal (Gong et al., 
2002) suggesting they may also contribute to motor axonal damage. 
As first described by Pestronk in 1988, anti-GM1 antibodies are also associated 
with MMN, though these antibodies are exclusively IgM in nature (Pestronk et al., 
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1988). Though not present in all MMN patients, the presence of anti-GM1 IgM 
antibodies is supportive of an MMN diagnosis and can help distinguish it from 
amyotrophic lateral sclerosis, for which it can often be misdiagnosed. The 
primary antigen in AIDP remains elusive. As AIDP symptoms are related to myelin 
damage, it is likely that the primary target for this disease is SC or myelin-
associated.  Thus far, no single ganglioside has been identified as a target in 
AIDP, leading many to look for protein targets, a few of which have been 
identified as potential candidates (Ng et al., 2012;Sawai et al., 2014). However, 
it is also now recognised that antibodies formed against gangliosides in GBS may 
in fact target new epitopes formed by the cis-interaction of two or more 
glycolipids in the membrane (Rinaldi et al., 2013). Thus, antibodies are expected 
to form against complexes of gangliosides, rather than single gangliosides alone. 
This novel concept may be the key to understanding why no single ganglioside or 
glycolipid AIDP target has been found. Using combinatorial lipid array 
technology, Rinaldi et al 2013 screened serum from AIDP patients against 
glycolipid complexes and found an increase in positivity versus single epitopes 
alone, though no particular complex was identified as a novel AIDP target 
(Rinaldi et al., 2013).  
1.1.7 Pathophysiology of GBS 
Due to the high association of anti-ganglioside antibodies with Guillain-Barré 
syndrome, it was surmised that these antibodies may be a causative factor in 
disease pathogenesis. Although the mechanism of GBS pathology is not fully 
understood, many studies have added pieces to the puzzle, resulting in a general 
understanding of some of the factors involved. Using C. jejuni as an example, in 
response to infection, endothelial cells in the gut may first recruit antigen 
presenting cells (APCs) by secretion of a variety of cytokines and chemokines. In 
a patient who is not susceptible to GBS, this results in an inflammatory Th1 
response which eliminates the bacteria by recruitment of macrophages, nitric 
oxide toxicity and B cell IgA antibody response (Willison and Goodyear, 2013). 
Although it is unknown why some individuals lack the robust tolerance normally 
seen to glycolipids, these people instead go on to develop IgM, IgA, IgG1 and 
IgG3 antibodies against ganglioside-like lipooligosaccharides (LOS) found on the 
C. jejuni coat (Willison and Veitch, 1994). These antibodies then bind to 
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gangliosides on peripheral nerves, driving complement-mediated pathology 
(Figure 1.2). Macrophages may also be activated as part of a Th1 response to 
directly target peripheral nerve. This type of response is increased when the 
bacterial LOS is disialylated (Bax et al., 2011). Though APCs such as dendritic 
cells (DCs) and neutrophils may directly activate B cells, the class switching seen 
in GBS indicates that T cell help must be involved, despite the exposed portion 
of the LOS/ganglioside being carbohydrate in nature. As yet the mechanisms 
behind glycolipid presentation and antibody production are unclear and research 
is still attempting to elucidate the underlying mechanisms, though evidence has 
been conflicting. Some studies have shown APCs to be able to present glycolipids 
to natural killer T cells by MHC class 1-like protein CD1 (Galli et al., 2003;Liu et 
al., 2009), which can help induce B-cell proliferation and antibody production. 
Other literature has shown that CD4+ T cells have the ability to process 
polysaccharides and present them on MHC class II (Christiansen et al., 2011;Cobb 
et al., 2004). A new class of neutrophils, termed B cell helper neutrophils 
(iN
BH
s), has been shown to prime marginal zone B cells and induce non-classical 
class switching (Puga et al., 2012).  
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Figure 1.2. Postulated mechanisms of GBS pathogenesis. Bacteria such as C.jejuni 
present their LOS to B cells either directly (1), by cross-linking the B cell receptor, or 
via presentation by APCs such as B-cell helper neutrophils (iN
BH
s) (2). APCs may also 
present to T cells (3) which may then be able to present the antigen to B cells via the 
MHC class II pathway (4). The activated B cell differentiates into a plasma cell (5) which 
secretes antibodies which cross-react with gangliosides. These cross the BNB (6) and 
may bind ganglioside or related glycolipids on the peripheral nerve membranes (7). This 
may result in complement activation and MAC pore formation (see section 1.2) on glial 
(8a) or neuronal (8b) membranes, in particular, the nerve terminal and the node of 
Ranvier. Complement also attracts macrophages (9) which may be recruited to clear 
away debris from injured tissue. T cells, activated by antigen presentation by APCs, 
may also directly recruit macrophages via a Th1-type response, which results in 
pathogen clearance (10), but may also cross the BNB (11) to target myelin (12).  
 
It remains uncertain why certain members of the population lack tolerance to 
glycolipids and develop auto-reactive anti-ganglioside antibodies in response to 
antecedent infection or vaccination. It has been postulated that Toll-like 
receptor (TLR) 4, a ligand for bacterial LOS found on APS such as macrophages 
and dendritic cells, may be a host factor which determines autoimmune reaction 
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to self-gangliosides, as it is known to be a potent enhancer of DC activation. 
However, a population study of 242 GBS patients and 210 healthy controls 
showed single nucleotide polymorphisms (SNPs) in the TLR4 gene do not increase 
susceptibility to GBS (Geleijns et al., 2004). Additionally human B cells do not 
express large amount of TLR4, making it less likely to be a major influencing 
factor in GBS development.  
As an alternative to host mechanisms of susceptibility, the strain of C. jejuni 
infection may also play a role in the effectiveness of DC activation. Sialylated 
LOS, which are associated with GBS-causing C. jejuni strains, are more effective 
at promoting B cell responses than non-sialylated LOS. This enhancement has 
been shown to be due to an increase in cytokine TNFα and IFN released by 
dendritic cells in response to their activation by LOS (Huizinga et al., 2013).  
 
1.2 Complement 
One of the consequences of antibody binding is the triggering of a cascade of 
enzymatic reactions which cleave a specific collection of proteins, culminating 
in the insertion of a membranolytic pore into the cell membrane. This group of 
proteins, collectively called complement, is one of the primary means of 
humoral immunity. In the early 1890s, Hans Ernst August Buchner described an 
albuminoid substance in the blood which had bactericidal properties. He termed 
this substance alexin (Buchner, 1889). Further research by Jules Bordet showed 
that Buchner’s alexin required a heat stable “sensitising” substance to produce 
its effects (Bordet, 1898). This heat stable “sensitising” substance is the 
antibody response, which binds to the invading microorganism. In later work on 
alexin, Paul Ehrlich coined the term “complement” due to its ability to 
complement the antibody response. 
1.2.1 Classical complement pathway  
Work in the 1920s began to show that the activity of complement is dependent 
on more than one serum fraction but it was not until the 1960s that all 11 serum 
proteins of the “classical”, or antibody-dependent, complement activation 
pathway had finally been identified (Inoue and Nelson, Jr., 1965). These proteins 
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are named complement components and are termed C1-C9, with C1 being 
composed of 3 subunits, C1q, C1r and C1s. In this pathway, immune complexes 
containing complement-fixing IgG and IgM antibodies are recognised by the C1q 
portion of the C1 component which causes a conformational change, allowing 
C1r to cleave C1s. These two subunits then convert C2 to C2a and C2b and C4 to 
C4a and C4b. The C2b and C4a components combine to form C3 convertase, with 
the enzymatic capability to convert C3 into C3a and C3b. The resulting C3b joins 
the C2b/C4a complex to form C5 convertase. (Figure 1.2, red dashed box).  
1.2.2 Alternative and lectin complement pathways 
There are now 3 known pathways of complement activation, totalling around 20 
serum proteins, plus an array of endogenous complement regulatory factors. The 
lectin binding pathway is activated by mannose-binding lectin directly binding to 
pathogen oligosaccharides, but progresses similarly to the classical pathway from 
C4 cleavage onwards (Ji et al., 1993). The alternative pathway is activated by 
the spontaneous conversion of C3 to C3a and C3b by hydrolysis. The released 
C3b forms a C3 convertase complex with factor Bb, which was cleaved from 
Factor B. This alternative C3 convertase complex (C3bBb) then cleaves C5 in the 
same manner as in the classical pathway. These two pathways can provide 
positive feedback to each other as the C3b released by the classical pathway can 
increase C3bBb, which in turn increases C5 cleavage and so on. The alternative 
pathway therefore serves to enhance the complement response generated by 
the classical complement pathway (Figure 1.2, blue dashed box).    
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Figure 1.3: Classical and alternative complement activation pathways. The classical 
pathway (red dashed box) is activated by antibody-antigen interaction, in this case, 
ganglioside GD1a. The C1q protein recognises and binds the antibody-antigen complex, 
thus activating each of the C1r and C1s components. Subsequently, the activated C1 
complex cleaves C2 and C4 into C2a and b and C4a and b. C2a and C4b combine to form 
a C3 convertase which converts C3 into C3a and C3b. The resulting C3b combines with 
C4b2a to form a C5 convertase. This cleaves C5, producing C5a and C5b. C5b, C6, C7, 
C8 and multiple C9 proteins then combine to form C5b-9 complex, which inserts into the 
membrane as a pore, allowing uncontrolled influx of extracellular fluid and ions. The 
alternative activation pathway (blue dashed box) occurs when C3 is naturally hydrolysed 
into C3a and b. An alternative C3 convertase is formed by C3b in combination with Bb, 
the result of factor B (fB) cleavage into Ba and Bb. The formation of this complex is 
enhanced by C3b formed by the classical pathway (dotted arrow). The C3bBb cleaves 
C3, producing more C3b, which combines to the complex to form a C5 convertase, 
C3bBb3b. This cleaves C5 in the same manner as the classical pathway. Cleaved 
components which are not involved in the complement cascade are outlined with 
dashed lines, though these have other inflammatory roles. 
 
1.2.3 Complement-mediated injury and its role in GBS 
The C5 convertases formed by all three complement pathways serve to cleave 
C5, forming C5a and C5b. The membrane-bound C5b joins with C6-8 and 
multiple C9 proteins to form the C5b-9 complex, also called membrane attack 
complex (MAC). All three complement pathways, if left unregulated, culminate 
in the insertion of MAC into the membrane. The multiple C9 proteins form a pore 
which inserts into the plasma membrane, allowing the uncontrolled influx of 
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extracellular fluid and ions into the cell, causing swelling and cell lysis. The first 
study showing that anti-ganglioside antibodies may require complement to cause 
neuronal damage was conducted in GM2-containing neuroblastoma cells, where 
anti-GM2 antibody positive patient serum required the presence of complement 
to cause injury (Yuki et al., 1992a). In GBS patients, complement components 
have been shown to be present in patient sera, deposited on nodal structures in 
early stages of AMAN and on SC and myelin structure in AIDP (Hafer-Macko et al., 
1996a;Hafer-Macko et al., 1996b;Koski et al., 1987). In mouse models of GBS, 
many components of the classical complement cascade have been shown to 
overlap anti-ganglioside antibody deposition and to be necessary for damage to 
the nerve terminal, node of Ranvier and perisynaptic SCs (pSCs), as 
demonstrated by the reduction in injury in the presence of complement pathway 
inhibitors, or the denaturing of complement components by heat inactivation 
(Halstead et al., 2004;Halstead et al., 2005b;McGonigal et al., 2010;Fewou et 
al., 2012). The structural and mitochondrial damage which is seen in the 
neuronal structures has been shown to be due to the uncontrolled influx of 
calcium through the MAC pore, which results in release of neurotransmitter 
acetylcholine (ACh) from the synapse, injury to mitochondria, and the activation 
of the calcium-dependant protease calpain (McGonigal et al., 2010;O'Hanlon et 
al., 2003). Calpain activation results in the cleavage of many membrane bound 
receptors, cytoskeletal and nuclear proteins and cytosolic enzymes, resulting in 
a failure of the homeostatic control of cell processes, mitochondrial dysfunction, 
and failure of DNA transcription, among other neurotoxic consequences (Vosler 
et al., 2008). 
In all mouse models of anti-ganglioside antibody and complement-mediated 
injury, it is necessary to add normal human serum (NHS) to see a pathogenic 
effect. This is because, though antibody deposition is clearly seen in ex vivo 
mouse muscle preparations and in in vivo passive antibody transfer models, no 
injury is seen with endogenous mouse complement alone (Fewou et al., 
2012;Halstead et al., 2004;Rupp et al., 2012). This appears to be the case 
despite the observation that the anti-ganglioside antibodies used have the ability 
to fix mouse complement to the same degree as an anti-nicotinic ACh receptor 
(nAChR) antibody which is known to bind and induce complement-mediated 
injury at post synaptic membranes in mice (Willison et al., 2008). It was 
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considered that endogenous mouse complement regulators may be highly 
regulating complement activation at the presynaptic membrane. Despite the 
presence of CD59a, an endogenous inhibitor of mouse MAC assembly 
(Baalasubramanian et al., 2004), being detectable at nerve terminal and pSC 
membranes, CD59a deficient mice were still not able to demonstrate an anti-
ganglioside antibody-mediated injury without exogenous NHS, though some C3c 
deposits are detected (Willison et al., 2008). Another complement regulator, 
factor H (fH), works by accelerating the breakdown of the C3 convertase 
C3Bb3b, and by complementing the breakdown of C3b, thus mediating the 
activation of the alternative complement pathway (reviewed in Ferreira et al., 
2010). This complement regulator works in domains rich in sialic acid, therefore 
it is possible that at sites such as the ganglioside-rich presynaptic components of 
the NMJ, fH could prevent complement activation at “self” sites. Mouse fH has 
been demonstrated to be present at presynaptic membranes in mouse nerve-
muscle preparations, but only in the additional presence of NHS to initially 
activate the complement cascade (Willison et al., 2008). 
1.3 Gangliosides 
Ernst Klenk first discovered a new type of acidic glycolipid in 1935 and coined 
the term ganglioside 7 years later, due to its suspected localisation to ganglial 
cells in grey matter (Klenk, 1935). Since then it has become known that 
gangliosides are, in fact, ubiquitous, though are enriched in the nervous system. 
Gangliosides are amphiphilic, containing both a ceramide core, which inserts 
into the plasma membrane and an oligosaccharide domain, containing one or 
more sialic acid residues, which exists on the outer leaflet of the plasma 
membrane. 
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Figure 1.4: The biosynthesis pathway of gangliosides. From ceramide, each addition 
of oligosaccharide moiety requires a different glycosyltransferase enzyme (shown in 
italics). Complex gangliosides synthesis is initiated by the GalNAcT enzyme (red dashed 
box). Mice are available with disrupted GalNAcT. Due to the stepwise nature of 
ganglioside synthesis these mice therefore lack all complex gangliosides (see section 
1.3.4). Similarly mice are available which lack Sial-T2 (purple dashed box), also called 
GD3 synthase (GD3s). These mice lack all b and c series gangliosides.  
 
1.3.1 Nomenclature, 
Ganglioside nomenclature was defined by Svennerholm to incorporate the 
number of sialic acid residues (indicated by the initial M, D, T and Q for mono, 
di, tri and tetra), the number of sugar groups (represented by 5 minus the chain 
length e.g. GM1 has 4 sugar groups) and the number of sialic acid residues on the 
inner galactose group (0=none, a=1, b=2 or c=3) (IUPAC-IUB Commission on 
Biochemical Nomenclature, 1977).  
1.3.2 Ganglioside synthesis 
Ceramide is formed in the endoplasmic reticulum and transported to the Golgi 
complex where it is converted to glucosylceramide (GlcCer) by UDP-Glc: 
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ceramide glucosyltransferase (Glc-T1). From GlcCer, lactosylceramide (LacCer) 
is formed by the addition of a galactose group by UDP-Gal: glucosylceramide 
galactosyltransferase (Gal-T1). Simple gangliosides are formed by the sequential 
addition of the sialic acid N-acetylneuraminic acid (NeuAc), to LacCer by 
sialyltransferase enzymes Sial-T1 (also called GM3 synthase or GM3s), Sial-T2 
(GD3s) and Sial-T3. These simple gangliosides can be further converted to 
complex gangliosides of the a, b and c series, by the action of 1,4-N- 
acetylgalactosamineyltransferase (GalNAcT), Gal-T2, Sial-T4 and Sial-T5, 
resulting in the addition of N-Acetylgalactosamine (GalNAc), galactose, and 
NeuAc respectively (Daniotti and Iglesias-Bartolome, 2011). 
1.3.3 Ganglioside cycling 
After their synthesis, gangliosides are transported inside vesicles from the Golgi 
complex to the plasma membrane, where they exist in cholesterol-enriched lipid 
rafts and caveolae. Once on the plasma membrane however, they can be 
endocytosed and sorted into early endosomes. This internalisation has been 
shown by the use of both fluorescent ganglioside analogues and antibodies to be 
clathrin-independent, instead being endocytosed via caveolae, a type of lipid 
raft in the form of an invagination in the plasma membrane (Crespo et al., 
2008;Singh et al., 2003;Fewou et al., 2012). From both early and recycling 
endosomes, gangliosides may be recycled back to the plasma membrane, but 
they may also be transferred back into the Golgi complex, to undergo further 
glycosylation before returning to the plasma membrane (Chigorno et al., 
1997;Riboni et al., 1993). Endocytosed gangliosides may also be sorted into 
lysosomes, where they are enzymatically broken down (reviewed in Daniotti and 
Iglesias-Bartolome, 2011;Simons and Ikonen, 1997) (Figure 1.5). 
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Figure 1.5: Schematic showing the trafficking of gangliosides to the membrane and 
their subsequent endocytosis along with anti-ganglioside antibodies. Ceramide is 
synthesised in the ER and transported to the Golgi complex (1). Here the stepwise 
addition of oligosaccharide groups forms the finished ganglioside (2). The gangliosides 
bud off into vesicles (3) and are transported to the plasma membrane (4). In the 
membrane they may be bound by anti-ganglioside antibodies (5). As part of normal 
ganglioside turnover, the gangliosides and any attached antibody may be endocytosed in 
a clathrin-independent manner (6) and sorted to early endosomes. From here, the fate 
of the ganglioside and the antibody is either sorting to recycling endosomes and 
subsequent return to the plasma membrane (7), or sorting to late endosomes and 
degradation in lysosomes (8). 
 
1.3.4 Ganglioside function: animal models 
The generation of mice with disrupted ganglioside synthesis enzymes has 
furthered the understanding of ganglioside function. Mice lacking GD3s, and 
therefore b and c series gangliosides, were generated by Okada et al. These 
mice develop normally, the only apparent deficits being impeded regeneration 
of hypoglossal nerve (Okada et al., 2002) and an enhanced sensitivity to insulin 
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(Yamashita et al., 2003). This near-normality suggests that b and c series 
gangliosides are either non-essential for normal nervous system development 
and maintenance, or that the consequential excess of a-series gangliosides which 
results from GD3s ablation can compensate.  
Takamiya et al were the first to develop a mouse with a disrupted GalNAcT 
gene, which lack all complex gangliosides (Takamiya et al., 1996). Upon 
investigation of these GalNAcT-/- mice at 10 weeks old, the group found no 
morphological or behavioural abnormalities, with a decrease in neural 
conduction velocity being the only difference between them and their wildtype 
counterparts. Further studies have also demonstrated near-normal synaptic 
transmission (Kawai et al., 2001). It appeared therefore that complex 
gangliosides were not necessary for effective neuronal development and 
transmission. However, an age-dependent phenotype becomes clear in GalNAcT-
/- mice. From about 12 weeks they develop spontaneous degenerative features in 
their sciatic nerves and dorsal horns and central dysmyelination (Sheikh et al., 
1999;Sugiura et al., 2005;Susuki et al., 2007a) and a clinical phenotype, 
including a Parkinson-like tremor and abnormalities in hind-limb reflexes, 
balance, strength and gait (Chiavegatto et al., 2000). GalNAcT-/- mice also show 
delayed nerve regeneration following hypoglossal nerve transection compared 
with wildtype mice (Kittaka et al., 2008). However, these mice have no major 
abnormalities in neuromuscular transmission (Zitman et al., 2011a) and appear 
to regenerate motor nerve terminal and distal axons portions equally as well as 
wildtype counterparts (Rupp et al., 2013). Overall, these findings point to an 
important role for complex gangliosides in nervous system maintenance, 
however the widespread distribution of complex gangliosides, and the resulting 
over-expression of simple gangliosides, makes it difficult to pinpoint exactly 
where the expression of complex gangliosides is critical for nervous system 
integrity. 
1.3.5 Complex ganglioside rescue mice 
Recently, this lab has developed strains of transgenic mice which have restricted 
expression of the GalNAcT enzyme, and thus complex gangliosides, in neuronal 
or glial cells, two of which have been characterised in detail (Yao et al., 2014). 
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For neuronal-specific enzyme activity, the neurofilament light (NFL) promoter, 
active in mature neurons, was used while for glial-specific enzyme activity, the 
proteolipid protein (PLP) promoter, active in myelinating glia, was used. These 
mice were then backcrossed with GalNAcT-/- mice, resulting in GalNAcT-/--
Tg(neuronal) and GalNAcT-/--Tg(glial) mice, respectively. These mice only 
express the GalNAcT enzyme, and therefore complex gangliosides, on their 
neuronal and glial cells, respectively (Figure 1.6). In addition, a second neuronal 
transgenic mouse was created driven by the Thy1 promoter, which is also active 
in mature neurons.  
 
Figure 1.6: Restoration of complex ganglioside expression in GalNAcT-/--Tg(neuronal) 
and GalNAcT-/--Tg(glial)  mice. A. GalNAcT enzyme driven by NFL and PLP promoter. 
GalNAcT-/- mice lack complex gangliosides, whereas in GalNAcT-/--Tg(neuronal) and 
GalNAcT-/--Tg(glial)  mice, their expression is restored as shown by B, TLC and C, mass 
spectrometry. Modified from Yao et al., (2014). 
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These mice were created for the purpose of ganglioside immunisations, 
however, they can also tell us about the importance of complex gangliosides in 
these different nervous system cell types. When GalNAcT is “rescued” in 
neuronal cells, the age-related phenotype seen in GalNAcT-/- mice is prevented. 
These mice are almost indistinct from wildtype mice by eye and perform equally 
well in behavioural tests even when over 12 months of age. In contrast, GalNAcT-
/--Tg(glial) mice show the characteristic tremors and impaired hind-limb clasping 
seen in GalNAcT-/- mice.  GalNAcT-/--Tg(glial) mice also perform much worse 
than wildtype and GalNAcT-/--Tg(neuronal) mice in behavioural testing but are 
no different from GalNAcT-/- mice. The rescue in phenotype in GalNAcT-/--
Tg(neuronal) mice is also accompanied by a reduction in degenerate axon 
number and an increase in myelin volume, making them no different than 
wildtype mice. Nodal architecture in these mice was also similar to wildtype 
mice, with the exception of a lengthening of the paranode. The creation of 
these mice therefore demonstrated the importance of complex gangliosides in 
the neurons rather than glia. 
1.4 The peripheral nervous system 
In order to understand the effects of anti-ganglioside antibody and complement-
mediated injury in the peripheral nervous system of GBS patients, it is important 
to understand the structure and function of the various components which have 
been shown to be affected in disease. These are namely the axon, the NoR, and 
the various components of the NMJ. 
1.4.1 Axon 
Lower motor neurons in the spinal cord are responsible for all voluntary muscle 
movement. From their location in the CNS, they extend axons outwith the 
protection of the blood-brain barrier (BBB). These axons are bundled within 
peripheral nerves, protected along with its myelinating SCs, by a layer of 
connective tissue called the endoneurium. This protective sheath also envelops 
the small capillaries, whose tight-junctioned epithelial cells form the blood-
nerve barrier (BNB). The axons are also further bundled into fascicles, which 
contain variable numbers of fibres and larger blood vessels. Nerve fascicles are 
surrounded by the perineurium, a structure formed by multiple layers of 
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specialised perineurial cells and collagen. Perineurial cells form tight junctions 
with each other and work to maintain homeostatic control of the endoneurial 
environment (reviewed in Topp and Boyd, 2006). Nerves containing varying 
numbers and sizes of fascicles are surrounded by a layer of dense connective 
tissue called the epineurium, which serves to structurally protect the nerve as 
well as to adhere it to surrounding tissues (Figure 1.7). 
  
 
Figure 1.7: Structure of a peripheral nerve. The axon, surrounded by SC-derived 
myelin, is contained within protective endoneurium. Multiple axons are bundled 
together in fascicles, which in turn are surrounded by the perineurium. Fascicles are 
contained, along with blood vessels, within a layer of dense connective tissue called the 
epineurium.  
 
Within the axon itself are neurofilament proteins, heteromeric cytoskeletal 
proteins composed of a combination of three subgroups named according to 
their relative sizes: light, medium and heavy.  
1.4.2 Nodes of Ranvier 
Along the axons lie nodes of Ranvier, specialised domains which facilitate the 
saltatory conduction of action potentials along the myelinated axon. These 
domains lie in the gaps between the myelinated portions of the axon (termed 
25 
 
the internodes) and are bordered on either side by the paranode and 
juxtaparanode, two distinct domains which are defined by specific proteins 
which contribute to the structural and functional integrity of the node. 
Peripheral NoRs are protected by the BNB, allowing it moderate protection from 
blood-borne substances, though not to the same degree as the BBB. Studies have 
shown that the node of Ranvier is susceptible to anti-ganglioside antibody and 
complement-mediated attack, especially at the very distal axons and at spinal 
roots (McGonigal et al., 2010). 
1.4.3 The neuromuscular junction 
The neuromuscular junction (NMJ) is the tripartite interface between the axon 
and skeletal muscle. It comprises the terminal portion of the axon (the nerve 
terminal), the post synaptic muscle fibre and the non-myelinating pSC (Figure 
1.8). Together these components are responsible for the efficient transmission 
of the electrochemical signalling resulting in muscle contraction. The NMJ is the 
most studied of all vertebrate synapses, from the first demonstration of 
chemical synaptic transmission (Dale et al., 1936), to the demonstration of 
synapse development (Greer et al., 1999), and to the entry of neuromuscular 
toxins studied for both their pathogenic and labelling properties (Ambache et 
al., 1948;Ambache, 1948;Stoeckel et al., 1977).  
1.4.3.1 Motor nerve terminal and synaptic cleft 
When the axon of a motor neuron reaches its destination at the muscle fibre, it 
forms a “pretzel” shape which lies outwith the protection of the BNB. This is the 
motor nerve terminal, the site of neurotransmitter release. Contained within 
this structure are pools of vesicles containing the neurotransmitter ACh, which 
fuse with the membrane and release their cargo in response to nerve activity 
(see section 1.6.1). Mitochondria are also present to fuel the energy-dependent 
process of packaging ACh into vesicles. The plasma membrane of the nerve 
terminal contains many transport proteins and receptors involved in the 
effective recycling and feedback of neurotransmitter, and the extracellular 
portion which opposes the post-synaptic domain is also rich in ganglioside, as 
evidenced by the binding of many anti-ganglioside antibodies (Fewou et al., 
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2012;Goodfellow et al., 2005;Greenshields et al., 2009;Halstead et al., 
2004;Halstead et al., 2005b;O'Hanlon et al., 1996). 
Acetylcholine is released into the synaptic cleft, a space separating pre- and 
post-synaptic elements by around 50 nm (Fagerlund and Eriksson, 2009). The 
synaptic cleft contains ACh esterase (AChE), which breaks down ACh into its 
component parts following its activity on the post-synaptic membrane, thus 
terminating the neuromuscular transmission. This enzyme is tethered to an 
extracellular matrix called the basal lamina, which also has roles in maintaining 
synaptic organisation. Situated opposite the site of vesicle release, are the 
ionotropic nAChRs, which trigger muscle contraction by depolarising the post-
synaptic membrane. This depolarisation is amplified by voltage-gated sodium 
channels which are present in invaginations between nAChR clusters (Figure 
1.8). 
 
Figure 1.8: Schematic showing the gross anatomy and organisation of the NMJ. As 
the axon terminates it forms the nerve terminal which contains the machinery required 
for synaptic transmission, including mitochondria (mc) and pools of synaptic vesicles 
(sv), which fuse to the membrane, releasing ACh. Across from these release sites sit 
nAChRs, ligand-gated sodium channels, which trigger muscle fibre contraction. Within 
the synaptic cleft sits the basal lamina which holds the enzyme responsible for 
degrading ACh. Overlying the nerve terminal are pSCs, which maintain nerve terminal 
function and aid in regeneration in response to damage. Overlying both these structures 
is the kranocyte, a fibroblast-like cell which may also play important roles in NMJ 
maintenance.  
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terminal
Muscle fibre
sv
mc
nAChRsBasal lamina
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1.4.3.2 Perisynaptic Schwann cells 
Overlying the nerve terminal are the pSCs, non-myelinating SCs which extend 
processes which cap, rather than wrap, the nerve terminal. The function of 
these pSCs is manifold. Initial studies focussed on the role of these cells in 
reinnervation of damaged nerves. Upon nerve damage, pSCs enter an activated 
state and have not only been shown to remove nerve terminal debris (Miledi and 
Slater, 1970), but also to promote regeneration by extending processes which 
guide the regenerating axon back to its NMJ (Astrow et al., 1994a;Koirala et al., 
2000;Reynolds and Woolf, 1992;Son et al., 1996;Son and Thompson, 1995a;Son 
and Thompson, 1995b;Astrow et al., 1994b). These cells also have a proposed 
modulatory role in synaptic transmission; pSCs can induce decreases in synaptic 
activity (Robitaille, 1998) in response to ACh release from the synapse, detected 
by muscarinic ACh and A1 adenosine receptors expressed on the pSC membrane 
(Jahromi et al., 1992;Robitaille et al., 1997;Rochon et al., 2001). At frog NMJs, 
ablation of pSCs does not immediately cause any perturbation of nerve terminal 
function, though after a week, nerve terminals begin to retract, suggesting a 
role in long-term NMJ maintenance of the nerve terminal. The various functions 
of pSCs are reviewed in detail by Auld and Robitaille (Auld and Robitaille, 2003).  
Aside from their functions in synapse maintenance and repair, pSCs have also 
been shown to be targets of anti-ganglioside antibodies in a mouse model and 
are killed, often, but not always, in conjunction with damage to the nerve 
terminal (Halstead et al., 2004;Halstead et al., 2005b).  
1.4.3.3 Kranocytes 
Recently, a new cell type was described which closely caps the NMJ (Court et 
al., 2008). For this reason, they were termed kranocytes, meaning “helmet 
cell”. Kranocytes are positive for ganglioside GM1 and also show positive 
immunoreactivity to a variety of cell markers including ones for stem cells and 
fibroblasts. They also appear to activate in a similar manner to pSCs in response 
to denervation, by dividing and spreading from their empty endplate. This 
suggests a role for kranocytes in the maintenance and repair of the NMJ.  
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It is as yet unknown whether the kranocytes which the authors describe are, in 
fact, the same cells which had been previously noted at neuromuscular 
synapses, termed perisynaptic fibroblasts (Connor and McMahan, 
1987;Gatchalian et al., 1989;Weis et al., 1991). These cells were also shown to 
proliferate in response to denervation, though appear to be less proximal to the 
NMJ than the kranocytes, with Weis et al describing the perisynaptic fibroblasts 
being 100-200 µm from the NMJ, and Court et al showing the kranocytes to be 
within a proximity of 40 µm (Court et al., 2008;Weis et al., 1991).  
1.5 Plasma membrane 
The fluid mosaic model of the plasma membrane, first put forward by Singer and 
Nicholson (Singer and Nicolson, 1972) has become the classical model of the 
plasma membrane, where proteins and lipids float freely within a phospholipid 
bilayer. Although still generally relevant, many modifications have been made to 
the original theory. For example, Singer and Nicolson postulated that the 
membrane was uniform, with randomly distributed proteins, some of which form 
complexes in the membrane. In later modifications, it was proposed that more 
static domains may exist in the membrane, composed of ordered lipids 
(Nicolson, 1976).  
1.5.1 Lipid rafts 
The domains of ordered lipids were formally described by Karnovsky et al who 
demonstrated the heterogeneity of the membrane and the importance of 
cholesterol to lipid packing (Karnovsky et al., 1982). These lipid microdomains 
are now referred to as lipid rafts. These rafts, so called because they are akin to 
a small platform of lipids and raft-associated proteins afloat on the fluidic lipid 
sea of the plasma membrane, are tightly packed, ordered domains of lipids 
which are rich in cholesterol and sphingolipids such as sphingomyelin and 
glycosphingolipids. Initially, rafts were defined as the detergent resistant part of 
the membrane, which were made detergent soluble if cholesterol was extracted. 
This definition caused controversies, leading to the refusal by many to accept 
the existence of lipid rafts and, due to the limitations in technology at the time, 
visualising rafts in the cell membrane was difficult. Using modern techniques 
such as single-molecule spectroscopy, novel microscopy techniques and 
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fluorescently tagged lipids, advances have been made in the visualisation of the 
structure and dynamics of lipid rafts in the membrane (reviewed in Simons and 
Gerl, 2010)).  
Early work by Simons and van Meer demonstrated that following sorting in the 
Golgi complex, sphingolipids and cell surface proteins are sorted together in 
transport vesicles before movement to the apical surface of epithelial cells 
(Simons and van Meer, 1988). This led to the concept of lipid rafts as lipid and 
protein sorting and transport domains (Figure1.9). The ability of lipid rafts to 
form stable domains in the membrane and to recruit specific proteins to these 
domains, has typified rafts as compartmentalised regions of cell signalling and 
lipid trafficking, which organise receptors and signalling molecules for efficient 
signal transduction (Simons and Ikonen, 1997). 
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Figure 1.9: Organisation of lipid raft domains. Lipid rafts are cholesterol and 
sphingolipid rich domains in the plasma membrane a. Both caveolae and planar lipid 
rafts have roughly the same lipid composition, however, caveolae form flask-shaped 
invaginations in the membrane due to the association of caveolae-specific proteins 
caveolin and cavin, whereas planar lipid rafts are in line with the plasma membrane. b. 
Lipid rafts can cluster proteins to compartmentalise cell signalling cascades or c. 
prevent signalling responses by preventing interaction between signalling molecules. 
Taken with permission from Allen et al., (2007). 
 
1.5.2 Caveolae 
Caveolae, meaning “little caves”, are a subset of lipid rafts which form flask-like 
invaginations in the membrane. Caveolae are found in many mammalian cells, 
though are especially abundant in endothelial cells and adipocytes, and are 
absent in neurons (Bu et al., 2003;Trushina et al., 2006). As they are a type of 
lipid raft, these domains are also rich in sterol and sphingolipids, but are also 
associated with specialised proteins which are necessary for the formation of the 
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pit, namely caveolins and cavins (Lipardi et al., 1998;Park et al., 2002;Hill et 
al., 2008). Caveolins, of which there are three now known, were the first 
caveolae proteins to be discovered (Kurzchalia et al., 1992;Rothberg et al., 
1992). Caveolin 1 is the predominant caveolin protein in most mammalian cells 
and appears in conjunction with caveolin 2 expression. In muscle cells, caveolin 
3 appears to replace caveolin 1. Four cavin proteins have also now been 
discovered, which appear to form complexes specific to different tissue types 
(Bastiani et al., 2009), with cavin 4 having a similar tissue distribution to 
caveolin 3.  
Caveolae have been suggested to have roles in cell signalling, lipid regulation 
and, more recently, have been implicated as protecting the membrane from 
over stretching, by flattening out in an accordion-like manner (Gustavsson et al., 
1999;Siddiqui et al., 2011;Sinha et al., 2011). Caveolae also have a role in 
clathrin-independent endocytosis, where they have been shown to be involved in 
the internalisation of viruses, toxins and membrane surface lipids, including 
gangliosides (Montesano et al., 1982;Tran et al., 1987). Like clathrin-coated pits, 
caveolae are transiently associated with dynamin, which pinches off the 
caveolae from the membrane (Oh et al., 1998). It was initially thought that once 
internalised, caveolar vesicles merged with a distinct membrane organelle called 
a caveosome, which was described as a pH neutral endosome with no presence 
of clathrin proteins (Pelkmans et al., 2001). However in later years, these 
caveosomes were in fact shown to be late endosomes and lysosomes, indicating 
that the internalised caveolae can converge with clathrin-dependant endocytic 
pathways in early endosomes, (Hayer et al., 2010;Iglesias-Bartolome et al., 
2009). 
1.5.3 Ganglioside organisation in the plasma membrane 
Though also found elsewhere, gangliosides usually concentrate in lipid rafts. As a 
consequence, gangliosides are often found tightly packed alongside other 
gangliosides and smaller lipid molecules such as cholesterol and sphingomyelin. 
Recent research has uncovered that this packing in the membrane can be crucial 
to the specificity of antibodies generated to gangliosides. Gangliosides had 
previously been shown to be “masked” by surrounding glycolipids and proteins, 
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which when stripped away improved antibody binding in tissue (Gregson et al., 
1989;Kannagi et al., 1983). Crucially, Pestronk et al demonstrated that sera 
from MMN patients with no anti-GM1 IgM reactivity did show reactivity to a 
mixture of GM1, cholesterol and galactocerebroside, or GM1 cholesterol and 
sulphatide. In addition, they showed that in other GM1-lipid mixtures, even 
binding of sera with reactivity to GM1 alone was abolished, indicating that the 
lipid environment can affect antibody binding (Pestronk et al., 1997). Despite 
this observation, it was not until studies by Kaida and colleagues demonstrated 
that GBS patient sera may contain antibodies against not just a single ganglioside 
epitope, but against neoepitopes formed by complexes of GD1a/GD1b that this 
idea truly garnered support (Kaida et al., 2004). Following their initial study, the 
group screened patient serum for antibodies to combinations of GM1, GD1a, 
GD1b and GT1b, finding 17% of GBS patients with antibodies against complexes 
and that certain anti-complex antibodies were associated with more severe 
clinical outcome (Kaida et al., 2007). Greenshields et al demonstrated that 
nearby gangliosides can alter the tissue binding ability of some populations of 
antibodies. Out of two mouse monoclonal antibodies which reacted to GM1 to a 
similar degree by enzyme-linked immunosorbent assay (ELISA), only one 
successfully bound mouse NMJs in live tissue preparations. Using a newly 
developed combinatorial glycoarray, where an array of lipid and lipid complexes 
is spotted onto PVDF membrane allowing easy antibody overlay, it was shown 
that the tissue-binding antibody (DG2) could bind GM1 equally well whether it 
was alone, or in complex with other gangliosides. In contrast, the non-tissue 
binding antibody (DG1) can bind GM1 alone, but its signal is attenuated when in 
complex with other gangliosides, in particular, GD1a. When tissue GD1a is 
removed with neuraminidase treatment to remove terminal sialic acid, DG1 is 
able to bind live tissue (Greenshields et al., 2009). This demonstrated that the 
pathogenicity of antibodies against GM1, but presumably also antibodies to other 
gangliosides, may be determined by the surrounding environment. With 
confirmation in further studies, using not only antibodies, but other ganglioside-
binding ligands, the concept of three distinct types of ganglioside binding arose: 
those which bound to their target regardless of surrounding gangliosides; those 
which were inhibited by certain surrounding gangliosides and those whose 
binding to their target was enhanced by the presence of certain surrounding 
gangliosides (Rinaldi et al., 2010). These three populations of ligand binding are 
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termed complex-independent, complex-inhibited and complex-enhanced, 
respectively (Figure 1.8). 
 
Figure 1.10: Ligand binding to gangliosides can be altered by presence of 
surrounding gangliosides. Glycoarray shows gangliosides, both alone or in complex, 
spotted onto PVDF membrane and probed with different GD3-binding ligands. Arrays are 
symmetrical along the blank methanol line marked by crosses. GD3 alone is marked in 
yellow boxes and GD3 in complex with GM1 is marked in pink boxes. Tetanus toxin 
neurofragment (TeNT Hc) does not bind to GD3 alone but does bind when GD3 is in 
complex with GM1 (complex-enhanced). CGM3, a mouse anti-GD3 antibody, binds to 
GD3 alone equally as well as when in complex with GM1 (complex-independent). Siglec-
7-Fc, a sialic-acid binding lectin binds GD3 alone, but its binding is attenuated in the 
presence of GM1 (complex-inhibited). Diagrammatic representations of different types 
of cis-interactions are shown beneath each example. Modified with permission from 
Rinaldi et al., (2010). 
Recent studies have shown that ganglioside binding can also be altered by cis-
interactions by other surrounding lipids and glycolipids, confirming the data put 
forward by Pestronk in 1988, with particular interest in complexes of GM1 with 
galactocerebroside in MMN patient sera (Galban-Horcajo et al., 2012). The 
emergence of this data on antibodies against ganglioside-lipid complexes, and 
the effect that the plasma membrane microenvironment  has  on antibody 
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binding, has spurred new hope in identifying better biomarkers for disease and 
in finding the all-elusive AIDP antigen (Rinaldi et al., 2013). 
1.6 Endocytosis at the motor nerve terminal 
1.6.1 Trafficking of vesicles 
The motor nerve terminal is the site responsible for the release of 
neurotransmitter in response to the action potentials which are propagated 
along the axon from the motor neuron body. Within the motor nerve terminal lie 
pools of ACh-containing vesicles. Each vesicle contains around 10,000 ACh 
molecules, otherwise termed a quantum. When filled with neurotransmitter, the 
vesicles remain in a reserve pool until they are activated for release. In 
preparation for vesicle release, vesicles migrate to the “active zone” and form a 
releasable pool of vesicles. Around 20% of all motor nerve terminal vesicles are 
in the releasable pool at a given time, while 80% make up the reserve pool 
(Richards et al., 2003). At the active zone, vesicles dock to the presynaptic 
membrane by the interaction of the vesicle-associated synaptobrevin (also called 
vesicle associated membrane protein or VAMP) with the nerve terminal-
associated SNAP-25 and syntaxin (Figure 1.11, inset). When an action potential 
reaches the synapse, the membrane becomes depolarised, causing the opening 
of voltage-gated calcium channels at the presynaptic membrane and the 
subsequent influx of extracellular calcium. Another vesicle-associated protein, 
synaptotagmin, is calcium-sensitive and allows the fusion of the synaptic vesicle 
to the nerve terminal membrane (Figure 1.10). Once the neurotransmitter has 
been released, the vesicle is endocytosed and recycled, however the 
mechanisms by which this recycling occurs are plastic and are dependent on the 
type of initial stimulus. It is generally accepted that vesicle recycling via 
clathrin-mediated endocytosis is one of the major methods of vesicle retrieval, 
especially during moderate stimulation (Granseth et al., 2007), where the 
retrieved vesicles are acidified and either recycle immediately, or via 
endosomes. Other methods include a direct recycling at the active zone, where 
the vesicles are immediately refilled and remain docked at the active zone and 
the “kiss and run” method, by which the vesicles are endocytosed in a clathrin 
independent manner and are acidified and recycled to the reserve pool (Figure 
1.11). 
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Figure 1.11: Schematic of synaptic vesicle exo-and endocytosis at the motor nerve 
terminal. Exocytic processes are shown by the dark green arrows, while the various 
endocytic pathways are displayed in other colours. ACh is synthesised locally in the 
nerve terminal and then transported into the synaptic vesicle (1). Filled vesicles abide 
in the reserve pool (2) or in the readily releasable pool at the active zone (3). Calcium 
influx via voltage gated calcium channels causes vesicle fusion (4) – insert shows the 
docking of vesicles to the membrane by interaction of vesicle-bound synaptobrevin and 
nerve terminal-bound syntaxin and SNAP-25. Calcium interacts with vesicle-bound 
synaptotagmin, causing vesicle fusion with the membrane and ACh release into the 
synapse. When vesicles have fused they may: (5) refill directly and remain bound to 
active zone, shown by light green arrow; (6) be endocytosed in a clathrin independent 
manner and undergo re-acidification and recycling to the reserve pool as shown by light 
blue arrow; (7) be endocytosed via clathrin-coated pits and either recycled directly or 
via endosomes; (8) be bulk endocytosed if membrane activity was strong, resulting in 
large vacuoles which are recycled via endosomes, shown by purple arrow.  
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1.6.2 Bacterial toxins targeting gangliosides 
As gangliosides can be endocytosed from the plasma membrane, it follows that 
any cargo which these gangliosides carry may also be internalised. The classic 
examples of this are bacterial toxins, many of which use gangliosides as a means 
of entering the cell in order to carry out their pathological effects. Examples of 
these toxins include the AB toxins pertussis and cholera which bind complex a-
series gangliosides GD1a and GM1 respectively (Hausman and Burns, 
1993;Holmgren et al., 1975). In contrast, clostridium toxins tetanus and 
botulinum both prefer complex b-series gangliosides. For instance botulinum 
toxin has a preference for GT1b and GD1b (Schiavo et al., 2000) and in GalNAcT-
/-
, mice which lack complex ganglioside, its toxicity is greatly reduced (Peng et 
al., 2011). In addition, increased membrane activity and recycling increases 
botulinum toxin entry into cells implying that there is a high amount of 
endocytic recycling ongoing at the presynaptic membrane of the motor nerve 
terminal. 
The endocytosis of toxins does not necessarily reflect the normal recycling of 
gangliosides however. The uptake of botulinum toxin is increased in response to 
membrane activity as it hijacks the synaptic vesicle recycling system by binding 
SNARE-proteins in addition to ganglioside ligand (Dong et al., 2003). Similarly, 
tetanus toxin has been shown to be internalised via clathrin-coated pits, 
independent of synaptic vesicle recycling. Its target ganglioside GD1b was not 
shown to be endocytosed along with it (Deinhardt et al., 2006). In addition, 
cholera toxin has been shown to be internalised by both clathrin-dependent and 
clathrin-independent pathways in different cell types and can switch between 
these methods if the cellular machinery required is low (Singh et al., 2003). In 
contrast to all of the above toxin entry, use of fluorescent glycosphingolipid 
analogues has shown that gangliosides are primarily internalised by clathrin-
independent endocytosis (Iglesias-Bartolome et al., 2009;Singh et al., 2003). The 
use of antibodies against gangliosides as a means of labelling the gangliosides 
has also demonstrated their internalisation by clathrin-independent routes 
(Crespo et al., 2008;Iglesias-Bartolome et al., 2006;Iglesias-Bartolome et al., 
2009). This is of interest in the context of GBS as these antibodies are 
pathogenic in this disease and their uptake opens a new perspective in which 
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disease may be mediated. The fact that they appear to be able to mark the 
normal trafficking of gangliosides logically implies that the antibodies may be 
able to undergo the same possible fates as endocytosed gangliosides (see Section 
1.3.3.), i.e. recycling back to the plasma membrane, broken down in the into 
component parts to be used in new ganglioside synthesis, or degradation.  
1.6.3 Uptake of anti-ganglioside antibody 
In cell work, antibodies against GD3, GM1, GD1a and GD1b have been shown to 
be endocytosed via clathrin-independent pathways and sorted into early 
endosomes (Fewou et al., 2012;Iglesias-Bartolome et al., 2009). This uptake 
could be dramatically reduced by the reduction or ablation of caveolin-1 
protein. Using a variety of cells, an antibody against GM1 was shown to be 
recycled back to the plasma membrane (Iglesias-Bartolome et al., 2009), while 
in CHO-K1 cells, anti-GD3 antibody was also shown to be recycled, rather than 
targeted to lysosomes. A separate GM1 antibody, along with antibodies against 
GD1b and GD1a showed co-localisation with recycling endosomes and also 
lysosomes in PC12 cells, indicating the possibility for both recycling and 
degradation (Fewou et al., 2012).  
Having established that the antibodies associated with autoimmune attack of 
peripheral nerve membranes can be endocytosed, it became of interest to this 
laboratory to define whether this was relevant to the disease-specific sites and 
what effect this would have in the context of GBS. It was found that the motor 
nerve terminal, which is highly susceptible to attack by anti-ganglioside antibody 
in mouse nerve-muscle preparations (Goodyear et al., 1999;Greenshields et al., 
2009;Halstead et al., 2004;Halstead et al., 2005b;Rupp et al., 2012;Rupp et al., 
2013), can endocytose surface-bound anti-ganglioside antibody at physiological 
temperatures. This phenomenon protected the nerve terminals from 
complement-mediated damage and its prevention, by depletion of cholesterol, 
resulted in increased MAC deposition and nerve terminal injury (Fewou et al., 
2012). The NoR, another site which is vulnerable to anti-ganglioside antibody 
attack (Hafer-Macko et al., 1996a;McGonigal et al., 2010;Susuki et al., 
2007b;Susuki et al., 2012;Takigawa et al., 1995), was found not to share the 
same ability to internalise anti-ganglioside antibody, leaving it more vulnerable 
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to injury (Fewou et al., 2012). Mature nodes of Ranvier have been shown to be 
relatively stable, with slow turnover of membrane components (Zhang et al., 
2012). This difference between membrane activity between the nerve terminal 
and the node of Ranvier may explain why nerve terminal damage has been 
difficult to show in patient tissue. The mechanism of internalisation at the 
motor nerve terminal is as of yet unknown. The normal caveolae-dependent 
route of uptake is less likely here as, although they can express caveolin 
proteins, neurons do not contain caveolae (Bu et al., 2003;Trushina et al., 
2006). 
 
Figure 1.12: The motor nerve terminal, but not the node of Ranvier has the ability 
to internalise antibody within 60 minutes at physiological temperatures. (A) When 
mouse skeletal muscle is incubated ex vivo with anti-ganglioside antibody at 4oC before 
immediate fixation, strong binding is seen at the NMJ. If, before fixation, the antibody 
is washed and the tissue kept at physiological temperature for 30 or 60 minutes, the 
amount of surface-bound antibody at the nerve terminal is significantly reduced. Upon 
permeabilisation this antibody can be seen within the nerve terminal, leaving no 
significant difference between the antibody overlying the nerve terminal at any 
timepoint. (B) When the NoR is looked at under the same conditions, surface-bound 
antibody remains statistically similar after 30 and 60 minutes at physiological 
temperatures to that of 0 minutes. Modified with permission from Fewou et al., (2012). 
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1.6.4 Retrograde trafficking of immunoglobulins 
The fate of anti-ganglioside antibody which has been endocytosed at the nerve 
terminal is unknown, though it is possible that the antibody may be trafficked to 
the spinal cord, in a similar manner to some ganglioside-binding toxins. Though 
endocytosed in a different manner, cholera toxin and anti-ganglioside antibody 
have been shown to converge in early endosomes (Iglesias-Bartolome et al., 
2009) and, while the toxic effects of cholera toxin are local, the B subunit 
responsible for docking to ganglioside on the plasma membrane, is retrogradely 
transported to the spinal cord (Angelucci et al., 1996). Tetanus toxin, also 
enters a retrograde transport pathway, resulting in its presence in the soma of 
motor neurons, from where it spreads trans-synaptically to inhibitory 
interneurons, preventing their action. These toxins are widely used as neuronal 
tracers, but it has also been known for some time that immunoglobulins which 
bind synaptic membrane components can be internalised by motor neurons and 
retrogradely transported to cell bodies in the spinal cord (Fabian and Ritchie, 
1986;Fabian and Petroff, 1987;Fabian, 1988;Fabian, 1990;Ritchie et al., 
1985;Ritchie et al., 1986;Wenthold et al., 1984). Although many papers 
described the phenomenon of intra-neuronal IgG and even IgM, no further work 
has been done to dissect the implications of this event. In one study, Ritchie et 
al found the apparent trans-synaptic spread of monoclonal antibodies following 
intramuscular injection and retrograde transport (Ritchie et al., 1986). In 
general, most studies have found that anti-sera and mono- or polyclonal 
antibodies which target synaptosome or nerve terminal membrane components 
were retrogradely transported, while control sera was not (Ritchie et al., 
1985;Wenthold et al., 1984) (Figure 1.13). This implies that the uptake of these 
antibodies was at the nerve-terminal and was dependent on the binding of 
antibody to the nerve terminal membrane. In the context of GBS and the new 
concept of anti-ganglioside antibody internalisation, this implies that following 
its uptake into the nerve terminal, anti-ganglioside antibody may enter into a 
retrograde transport pathway and subsequently be present in the spinal cord. If 
this phenomenon occurs in patients it is unknown what kind of effect it may 
have within the motor neurons. 
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Figure 1.13: Antisera against nerve terminal glycoproteins are retrogradely 
transported to the spinal cord. This example show the facial nucleus from rats injected 
with (A) guinea pig antisera against synaptic membrane glycoproteins and (B) 
unimmunised guinea pig serum. Immunoglobulins are detected in the facial nucleus of 
rats injected with antisera, but not in those who were injected with normal serum. 
Modified with permission from Wenthold et al., (1984). 
 
1.6.5 The neonatal Fc receptor 
The major method of antibody clearance from the serum is via non-specific 
pinocytosis. When internalised, the immunoglobulin is sorted into endosomes 
which are acidified and targeted to lysosomes for degradation (Mould and 
Sweeney, 2007). However, the expression of the neonatal Fc receptor (FcRn) can 
extend serum half-life of the IgG subclass by scavenging the endocytosed 
antibodies and return it to the cell surface (Lobo et al., 2004). This protein, 
originally named for its role in transportation of maternal antibodies to the 
foetal circulation, binds IgG molecules in acidified endosomes and protects the 
IgG from degradation by lysosomes. Instead, the IgG is sorted into recycling 
endosomes, returned to the cell surface and released back into the circulation. 
The effects of FcRn are demonstrated by the prolonged presence of IgG in the 
circulation. While in mice, IgM, IgA and IgE have a half-life of between 1 and 4 
days, the various IgG subclasses can remain in the serum for between 3 and 10 
days (Zuckier et al., 1989). In humans the effect is even more dramatic, with 
IgM, IgA, IgD and IgE half-lives ranging from 2-6 days, while IgG can remain in 
the serum for 23 days (Mould and Sweeney, 2007). Although expressed in other 
cell types, including immune cells (Zhu et al., 2001), FcRn is expressed to a high 
degree in the highly endocytically active cells of the vascular endothelium 
(Mould and Sweeney, 2007).  The importance of the vascular endothelial FcRn’s 
role in IgG homeostasis was shown by Montoyo et al in 2009 by its conditional 
A B
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deletion in vascular endothelial cells. These mice showed a reduced serum half-
life of IgG compared to het or wildtype controls, and levels of IgA were not 
affected (Montoyo et al., 2009). 
1.7 Animal models of Guillain-Barré syndrome 
1.7.1 Experimental Allergic Neuritis 
Animal models are important in gaining an integrated view of disease. The 
traditional model resembling GBS, experimental allergic neuritis (EAN) was 
described almost 60 years ago (Waksman and Adams, 1955). This rabbit model is 
characterised by a demyelinating pathology caused by an immune response 
against a sciatic nerve homogenate, and can be recreated using inoculation with 
p0 or p2 myelin protein in rabbits and rats. The immunised animals develop a 
nerve disease characterised by abnormal gait and posture and motor 
abnormalities (Waksman and Adams, 1955). These symptomatic changes are 
accompanied by the appearance of lesions in the dorsal and ventral roots, the 
dorsal root ganglion and the spinal nerve itself. The pathology of EAN is thought 
to be mainly driven by the actions of macrophages, though the appearance of 
other inflammatory cells such as neutrophils, mononuclear cells and lymphocytes 
is also observed. In the original paper, macrophages were seen to be involved in 
the disintegration of myelin, with remnant of fatty deposits observed inside 
these cells. This has led EAN to be a characteristic model of AIDP, the 
demyelinating form of GBS. Rat immunisations with p2 or PNS myelin by Hughes 
et al demonstrated that an anti-p2 antibody response is generated, but that this 
response did not appear to coincide with the development of neurological 
symptoms. In addition, the transfer of antisera to naïve animals failed to induce 
disease, whereas the transfer of lymph nodes from immunised animals did 
induce neurological symptoms (Hughes et al., 1981). This, plus evidence that 
elimination of T cells in rats frequently prevents development of EAN, led to the 
hypothesis that the pathology seen in EAN is cell-mediated (Brosnan et al., 
1987). While EAN mimics AIDP symptoms and pathology, the induction 
mechanism of myelin attack does not translate to AIDP patients (Asbury and 
McKhann, 1997;Willison, 2012). 
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1.7.2 Rabbit model of AMAN 
With the emerging association of antibodies against gangliosides in GBS, 
particularly with the association of anti-GM1 antibodies in AMAN (Kuwabara et 
al., 1998;Vriesendorp et al., 1993;Yuki et al., 1990;Yuki et al., 1999), there 
came a study lending great credence to the concept that these antibodies may 
be pathological in nature. Japanese white rabbits were inoculated with a 
mixture of bovine brain gangliosides or GM1 alone along with complete Freud’s 
adjuvant and keyhole limpet hemocyanin to act as a carrier protein. Immunised 
rabbits began to develop limb weakness or flaccid paralysis, accompanied by an 
increase in serum-reactivity to GM1 ganglioside (Yuki et al., 2001). Upon 
sacrifice, rabbits were shown to have invasion of macrophages into the 
periaxonal space and Wallerian degeneration of nerve fibres, with only rare 
demyelination.  A follow up study where rabbits were injected with GM1-
mimicking LOS from C. jejuni, resulted in similar outcomes, thus demonstrating 
that the anti-GM1 antibodies may be generated as a result of molecular mimicry 
from an antecedent infection (Yuki et al., 2004). 
1.7.3 Mouse models of Guillain-Barré syndrome 
Currently there is no mouse model equivalent of EAN, or as eloquent a model of 
active immunisation as seen in the rabbit AMAN model. Creating animal models 
for GBS and related conditions has proven difficult due to the poorly understood 
mechanisms of lipid tolerance and the poor immunogenicity of glycolipid 
structures. To model disease in mice, which bestow the benefit of potential 
genetic manipulation, investigations have thus far focused on generating 
antibodies in glycosyltransferase knock-out (KO) mice. Unlike wildtype mice, 
GalNAcT-/- and GD3s-/- mice lack the tolerance to those gangliosides which they 
fail to synthesise (Bowes et al., 2002;Gong et al., 2002;Goodyear et al., 
1999;Lunn et al., 2000;Townson et al., 2007). More recent immunisations in this 
laboratory have utilised liposomes as a method of antigen introduction, whereby 
the ganglioside or LOS antigens are displayed in a multilamellar membrane with 
other lipid raft proteins, to emulate a physiologically similar environment to 
naturally occurring gangliosides. Using this method alone however, these 
liposomes yield very little/no immune response in wildtype mice and so 
liposomes were created which encapsulated the non-self-protein ovalbumin 
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(OVA), found in chick egg white. This hapten-carrier style approach recruits T-
cell help and induces a high increase in anti-ganglioside antibody specific IgM 
and IgG by ELISA, though in wildtype mice this response is still far lower than in 
mice which lack the target antigen (Bowes et al., 2002) (Figure 1.14).  
 
Figure 1.14: Immunisation with ganglioside and OVA-containing liposomes induces 
anti-ganglioside antibodies more effectively in mice which lack endogenous antigen. 
A. Anti-ganglioside IgM and IgG responses in wildtype and GalNAcT-/- mice immunised 
with GD1a liposomes. Immune response to GD1b is specific to this ganglioside and only 
occurs to a significant degree in GalNAcT-/- mice. B. Similarly, mice immunised with 
GQ1b liposomes also show a GQ1b-specific response which is only significant in GalNAcT-
/- mice. Modified with permission from Bowes et al., (2002). 
 
The antibodies produced in these mice can be purified and cloned and 
subsequently used to model anti-ganglioside-mediated injury both in vivo and ex 
vivo in studies designed both to understand disease pathogenesis and ultimately 
to test the effectiveness of therapeutics. These antibodies have been used to 
demonstrate the role of complement activation in AMAN and MFS, the 
effectiveness of complement inhibitors in preventing damage caused by MAC 
formation, and the role of complement and calpain in the injury of the node of 
Ranvier (Goodfellow et al., 2005;Greenshields et al., 2009;Halstead et al., 
2004;Halstead et al., 2005a;Halstead et al., 2005b;Halstead et al., 
2008;McGonigal et al., 2010). However the ultimate goal would be to create a 
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GBS model in which the antibodies are both generated and cause disease in the 
same animal. Due to the wildtype mice’s inability to produce an effective 
response to ganglioside immunisation and the GalNAcT-/- mice’s lack of target, 
this has thus far proved very difficult. The GalNAcT-/--Tg(neuronal) and GalNAcT-
/--Tg(glial) mice described earlier were created for the purpose of active 
immunisations, where it was hoped that the restricted expression of complex 
gangliosides to neurons and glia would allow for a break in tolerance. This topic 
will be addressed as part of this thesis. 
1.8 Aims of thesis 
Generation of an active immunisation model of GBS in the mouse remains one of 
the major challenges in understanding the pathophysiology of GBS and for pre-
clinical testing of novel therapies. One major historical hurdle to overcome is 
that the serum levels of antibody in wildtype mice immunised with ganglioside 
are low. This can be bypassed by immunising ganglioside deficient mice 
(GalNAcT-/- mice) as they lack immunological tolerance, seeing gangliosides as 
foreign; however they cannot themselves be injured as they lack the neural 
target for antibody attack. Consequently, in wildtype mice anti-ganglioside 
antibody levels are so low that injury does not occur, even with the addition of 
an exogenous source of complement. The generation of complex-ganglioside 
“rescue mice”, which express GalNAcT (and therefore complex gangliosides) in 
only neurons or glia, may allow for such a model to be developed. In these mice, 
the restricted nature of ganglioside expression is anticipated to overcome the 
tolerance to ganglioside immunisation which is seen in wildtype mice. The 
creation of these mouse strains also affords the ability to investigate the 
importance of ganglioside expression and dynamics in these different 
membranes. The emergence of the novel concept of anti-ganglioside antibody 
internalisation at the motor nerve terminal, also allows these mice to be used 
for assessing the uptake of different anti-ganglioside antibodies at different 
membrane sites. 
On this background, the aims of my thesis were to: 
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 Characterise the ganglioside expression in GalNAcT-/--Tg(neuronal) mice 
and GalNAcT-/--Tg(glial) rescue mice in comparison with wildtype and 
GalNAcT-/- mice. 
 Determine whether the rescued expression of gangliosides could correct 
morphological and behavioural defects seen in GalNAcT-/- mice, thus 
investigating the importance of neuronal (and glial) ganglioside expression 
 Optimise the conditions for achieving an active immunisation model of 
mouse GBS using neuronal and glial rescue mice. 
The results of the active immunisation model led the project in a different 
direction by bringing up the issue of antibody internalisation. Therefore the 
aims of the thesis were expanded to: 
 Investigate the uptake of anti-ganglioside antibody at the neuromuscular 
junction, exploiting the differences in ganglioside expression in the 
different mouse genotypes 
 Determine how the uptake of anti-ganglioside antibody may affect its 
availability to bind and cause injury to neural membranes using in and ex 
vivo models of nerve injury. 
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2 Methods 
2.1 Materials 
2.1.1 Antibodies and tissue stains 
Commonly used antibodies, manufacturers, stock concentrations (where 
applicable) and dilutions used are shown in Table 2.1. Controls are indicated 
throughout the thesis but were generally either secondary antibody alone, or a 
mouse lacking the receptor for the antibody. 
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Table 2.1: Primary antibodies used throughout this thesis. 
Labelling reagent Monoclonal 
/polyclonal 
Manufacturer Stock 
Concentrat
ion 
Dilution  
Rabbit anti-cow s100 Polyclonal Dako, 
(Glostrup, 
Denmark) 
4 mg/ml 1/200 
Goat anti-mouse 
secondary antibodies: IgG, 
IgM, IgG2a, IgG2b, IgG3, 
IgG1 (TRITC, FITC and Cy5 
conjugates) 
Polyclonal Southern 
Biotech, 
(Birmingham, 
AL, USA) 
1 mg/ml 1/300 
sections, 
1/200 whole 
mount 
Goat anti-rat IgG-Cy5 Polyclonal Southern 
Biotech, 
(Birmingham, 
AL, USA) 
1 mg/ml 1/300 sections 
Goat anti-rabbit secondary 
antibodies: IgG, IgG1 
(Alexa Fluor 555 and 647 
conjugates) 
Polyclonal Molecular 
Probes, 
(Eugene, 
OR,USA) 
2 mg/ml 1/500 sections 
1/300 whole 
mount 
Goat anti-mouse IgG, IgM 
(HRP conjugate) 
Polyclonal Southern 
Biotech, 
(Birmingham, 
AL, USA) 
n/a 1/3000 
Mouse anti-human C5b-9 Monoclonal Dako, 
(Glostrup, 
Denmark) 
50  µl /ml 1/50 
Rabbit anti-human C3c-
FITC 
Polyclonal Dako, 
(Glostrup, 
Denmark) 
3 mg/ml 1/300 sections 
Rabbit anti-mouse NeuN Monoclonal Millipore, 
(Billerica, MA, 
USA) 
1 mg/ml 1/750 sections 
Rabbit anti-mouse MAP-2 Polyclonal Cell Signalling 
Technology, 
(Danvers, MA, 
USA) 
n/a 1/100 sections 
Rabbit 1211 (NF-H) Polyclonal Enzo Life 
Sciences 
(Exeter, UK) 
n/a 1/200 whole 
mount 
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2.1.2 Commonly used lipids 
The gangliosides and lipids used for immunisations and glycoarray were 
purchased from Sigma Aldrich (St Louis, MO, USA), with the exception of 
sphingomyelin which was purchased from Carbosynth (Newbury, UK). For 
ELISpots, GD1b was also purchased from Carbosynth. 
2.1.3 Commonly Used reagents 
Reagents, abbreviations, suppliers (and stock concentrations if required). 
 Alpha-bungarotoxin (BTx) - Alexa Fluor 488, 555 and 647 conjugates, 
(Molecular Probes, Eugene, OR,USA) 
 Bovine serum albumin (BSA), (Sigma-Aldrich, St Louis, MO, USA) 
 Citifluor antifade (Citifluor, Canterbury, UK) 
 Normal goat serum (NGS), (Sigma-Aldrich, St Louis, MO, USA) 
 Normal human serum (NHS) (blood taken from one donor and serum 
removed and stored at -80oC) 
 Tissue Tek Optical cutting temperature compound (OCT) (Sakura Finetek, 
Alphen aan den Rijn, Netherlands) 
 Triton X-100, (Sigma-Aldrich, St Louis, MO, USA) 
 TWEEN-20, (Sigma-Aldrich, St Louis, MO, USA) 
 Vectashield (with DAPI), (Vector Laboratories, Burlington, Canada) 
2.1.4 Preparation of commonly used buffers 
All solutions were used at a pH of 7.3. 
2.1.4.1 Ringer’s Solutions  
Ringer’s was prepared to a final concentration of 116 mM NaCl, 4.5 mM KCl, 23 
mM NaHCO
3
, 1 mM NaH
2
PO
4
, 11 mM glucose, 1 mM MgCl
2 
and 2 mM CaCl
2 in 
distilled water. Ringer’s was bubbled with oxygen for 10 minutes prior to use. 
For activity dependent internalisation experiments, a high potassium Ringer’s 
solution was used. For this, KCl concentration was increased to 56 mM and NaCl 
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was reduced to 65 mM. For experiments inhibiting vesicle acidification, in some 
experiments, NaCl was replaced with NH4Cl. 
2.1.4.2 Phosphate buffered saline (PBS) 
Phosphate buffered saline (PBS) was used at a final concentration of 140 mM 
NaCl, 1.5mM KH
2
PO
4
, 2.7 mM KCl and 77 mM Na
2
HPO
4. 
2.2 Animals 
Male and female mice aged 4-12 weeks were used for all in vivo experiments. 
For ex vivo work, male and female mice ranged from 4-16 weeks. All mice were 
housed in the University central research facility under a 12 hour light/12 hour 
dark cycle and given food and water ad libitum. All animals were killed with a 
rising concentration of CO2 as per Home Office regulation with either cardiac 
puncture or cervical dislocation to confirm death. 
2.2.1 Genotypes 
The mice used throughout this thesis are referred to as wildtype, GalNAcT-/-, 
GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial). All of these mice are on a 
C57Bl/6 background (specifically C57Bl/6JOlaHsd from Harlan Laboratories).   
GalNAcT-/- mice, generated by the group of Koichi Furakawa, have disrupted 
GalNAcT synthesis (Takamiya et al., 1996), meaning they do not express complex 
gangliosides. Male GalNAcT-/- mice are sterile and therefore heterozygous male 
mice were bred with homozygous females. Subsequently, litters required 
genotyping.  
GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mice were created by crossing 
GalNAcT-/- mice with mice which carried a transgene expressing GalNAcT driven 
by either the NFL or PLP promoter respectively (Yao et al., 2014). The resulting 
GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mice should have GalNAcT 
expression solely on their neurons and glia respectively. Like GalNAcT-/- mice, 
males were sterile and therefore heterozygous males were bred with 
homozygous females. The GalNAcT KO and the transgene insertion were 
confirmed by PCR (section 2.2.3). 
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2.2.2 Fluorescent mice 
In some ex vivo experiments, B6.Cg-Tg(Thy1-CFP/S100B-GFP) transgenic mice, 
expressing green fluorescent protein (GFP) driven by the s100 promoter and cyan 
fluorescent protein (CFP) driven by the Thy1 promoter were used, allowing easy 
identification of Schwann cells and axons respectively (Feng et al., 2000;Zuo et 
al., 2004). These mice were gifted to the lab by Wesley Thompson but are now 
available commercially through Jackson laboratories. To make fluorescent 
varieties of all of the above transgenic mice in section 2.2.1, these mice were 
crossbred with B6.Cg-Tg(Thy1-CFP/S100B-GFP), making GalNAcT-/- x B6.Cg-
Tg(Thy1-CFP/S100B-GFP), GalNAcT-/--Tg(neuronal) x B6.Cg-Tg(Thy1-CFP/S100B-
GFP) and GalNAcT-/--Tg(glial) x  B6.Cg-Tg(Thy1-CFP/S100B-GFP). However, for 
simplicity, throughout this thesis all fluorescent mice will be referred to as 
either wildtype, GalNAcT-/-, GalNAcT-/--Tg(neuronal) or GalNAcT-/--Tg(glial), and 
fluorescence will be indicated where appropriate. 
2.2.3 Genotyping 
2.2.3.1 Polymerase chain reaction 
Genotyping was done by polymerase chain reaction (PCR) to confirm in mice on a 
GalNAcT-/- background, the KO of the GalNAcT enzyme and, where appropriate, 
the incorporation of the transgene indicating restoration of GalNAcT synthesis 
tagged onto Thy1, PLP or NFL promoters. Genotyping of non-fluorescent 
GalNAcT-/- mice, GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mice was 
carried out by Dr Denggao Yao. 
DNA extraction was performed on ear or tail samples taken from mice. Briefly, 
the samples were incubated in 75 µl lysis buffer (25 mM NaOH, 0.2 mM EDTA, pH 
12) for 1 hour at 95oC to extract DNA. The solution was neutralised with 75 µl 
neutralising buffer (40 mM TRIS, pH 5) and kept at 4oC.  
The primers for GalNAcT KO used were: 
PAG3:  5’-GCC TGC TTG CCG AAT ATC ATG GTG GAA AAT-3’ 
PES4: 5’-GAA GAA TTC AAG ACT GTC TGT GAA ATT CTG-3’ 
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AK5: 5’-TCC CCC GTG AGA GTC ACT CCT GTT ACT TCC-3’ 
Flag primer was used to confirm GalNAcT transgene insertion: 
P1: 5’-ACTTGGTTTCCTTCGTGTTG-3’ 
P59: 5’-CTTATCGTCGTCATCCTTGTAATC-3’ 
In autoclaved sample tubes the following volumes of reagents were added on 
ice: 
DNA – 5 µl 
dH2O – 13.5 µl 
5X Green GoTaq® Reaction Buffer (Promega, Madison, WI, USA) -5 µl  
Primer (each) 0.5 µl 
dNTPs – 0.25 µl 
GoTaq® G2 DNA Polymerase (Promega, Madison, WI, USA) – 0.25 µl 
Samples were transferred immediately to a Veriti Thermal cycler (Life 
Technologies, Thermo Fisher Scientific, MA, USA). For confirmation of GalNAcT 
KO the following program was run:  
 3 minutes at 95oC 
 1 minute at 60oC. 
 2 minutes at 72oC 
 35 cycles of 1 minute at 90oC, 30s at 57oC, 1 minute at 72oC 
 10 minutes at 72oC, 
For confirmation of the incorporation of the transgene, the program was as 
follows: 
 5 minutes at 95oC. 
 30 cycles of 30 s at 95oC, 30 s at 55oC, 1 minute 30 s at 72oC. 
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 10 minutes at 72oC. 
2.2.3.2 Gel electrophoresis 
The DNA samples (20 µl) were run on an agarose gel (1.5% agarose in 1x Tris-
acetate-EDTA buffer) containing ethidium bromide and DNA was imaged under 
UV light. A 1kb DNA marker was run alongside samples. GalNAcT-/- was confirmed 
by a 500bp band, wildtype a 350bp band and flag a 229bp band. 
2.2.4 Fluorescent Phenotyping 
The skin from mouse ear samples was peeled apart, mounted in Citifluor  and 
coverslipped. Samples were then viewed under a Zeiss Axio Imager Z1 
fluorescent microscope (Carl Zeiss AG, Oberkochen, Germany) to confirm 
presence of CFP in ear axons and GFP in S100 positive cells. 
2.3 Production of monoclonal antibodies from hybridoma cell 
lines. 
Antibody-producing hybridoma cell lines (Table 2.2) were generated previously 
by immunisation of GalNAcT-/- mice or GD3s-/- mice with either liposomes 
containing ganglioside or with ganglioside-mimicking LPS using previously 
described immunisation protocols and hybridoma techniques (Bowes et al., 
2002;Goodyear et al., 1999;Townson et al., 2007). Frozen stocks of previously 
purified antibodies were used where available but on occasion cell lines had to 
be grown and antibodies purified from hybridoma supernatant.  
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Table 2.2: Mouse monoclonal anti-ganglioside antibodies used throughout this thesis, 
their predominant targets by ELISA and their immunoglobulin subtype. 
Mouse monoclonal 
antibody 
Predominant targets Immunoglobulin 
subtype 
MOG1 GD1b IgG3 
MOG3 GD1b IgG3 
MOG16 GD1b IgG3 
MOG35 GD1a IgG2b 
DG1 GM1 IgG2b 
DG2 GM1 IgG3 
 
Non-adherent cells were grown in flasks suspended in RPMI supplemented with 
10% foetal calf serum (FCS) at 37oC in 5% CO2. Once per week, cells were 
centrifuged at 1500rpm for 5 minutes and supernatant was collected and stored 
at -20oC. Cells were then resuspended in fresh media and split into 2 flasks. 
When >5 flasks were highly confluent, cells could be transferred to an Integra 
CELLine flask (Integra Biosciences, MA, USA), which are more efficient for 
antibody production than usual tissue culture flasks. To do this, firstly 10 ml of 
RPMI (20% FCS) was added to the cell compartment for 5 minutes. In this time, 
cells from 6 T175 flasks were spun down as above and resuspended in 15ml of 
RPMI (20% FCS). This was added to the cell compartment. The cells were grown 
in the cell compartment in RPMI (20% FCS), whereas the medium compartment 
still contained RPMI with the usual 10% FCS. Half the volume of medium from 
these cells were removed weekly and stored at -20oC until purification, and 
fresh media was applied. Similarly, 50% of the cell volume was removed each 
week and replaced with fresh 20% FCS. 
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2.4 Purification of monoclonal antibody supernatant 
To purify IgG monoclonal antibodies, supernatant was spun down in Sorval 
centrifuge bottles (Thermo Fisher Scientific, Waltham, MA, USA) at 150000g for 
30 minutes at 4oC. Supernatant was then dialysed overnight in 10x volume of 
binding buffer (0.2 M Na
2
H
2
PO
4
.2H
2
O, 0.2 M Na
2
HPO
4
). The supernatant was then 
collected, filtered through a 0.22 µm membrane and kept at 4oC. Binding buffer 
and 0.1 M glycine were also filtered before use. Binding buffer 10x column 
volume was run through a HiTrap Protein G HP column (GE Healthcare, Little 
Chalfont, UK) before the supernatant. Flow through was collected and stored at 
4oC until antibody purification was confirmed. Binding buffer was run through 
the column and 10x 1 ml wash samples were collected. To remove the bound IgG 
from the column, 0.1 M glycine was run through the column and 10x 1 ml 
elutions were collected in centrifuge tubes containing 40 µl of 1 M Tris-HCl to 
neutralise the glycine. The IgG concentration in mg/ml of wash samples and 
elutions were measured using a NanoDrop 1000 spectrophotometer at an 
absorption wavelength of 280 nm (Thermo Fisher Scientific, Waltham, MA, USA). 
2.5 Labelling of monoclonal antibody 
To label anti-ganglioside antibodies, an Alexa Fluor 488 Protein labelling kit 
(Molecular Probes, Eugene, OR, USA) was used as per manufacturer’s 
instructions. Briefly, purified monoclonal antibody from section 2.4, was 
prepared at 2 mg/ml (or as close as possible) and 0.5 ml of the antibody solution 
was added to 50 µl of 1 M sodium bicarbonate solution. The resulting solution 
was added to a vial of room temperature Alexa Fluor 488 reactive dye which 
contained a tiny stir bar. The solution was inverted to ensure all the dye was 
dissolved, and then reaction mixture was stirred for at least 1 hour at room 
temperature. While the mixture was stirring, the purification column was set up.  
The column was positioned upright using a retort stand, using the provided foam 
holder to prevent the column being damaged. The provided purification resin 
(Bio-Rad BioGel P-30 Fine size exclusion purification resin, packaged in PBS) was 
stirred thoroughly before adding to the column, and allowing it to migrate 
downwards, with any excess PBS being collected in a small bijous. The dye 
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reaction mixture was added to the column and allowed to enter into the resin.  
The provided PBS elution buffer 10x stock (0.1 M potassium phosphate, 1.5 M 
NaCl, 2 mM sodium azide) was diluted 1 in 10 and added to the column slowly, 
until the labelled antibody had been eluted. The eluted fractions were collected 
and retained and included buffer, dye-conjugated antibody, and unincorporated 
dye.  
The final concentration of labelled antibody was once again calculated using a 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, 
USA). In addition to the concentration in mg/ml, the following equation was 
used to determine the molar concentration, accounting for dye absorption at 280 
nm: 
protein concentraion (M) =
[A280 − (A494 x 0.11)] 
203,000
 
where A280 is the absorption at 280 nm and 203,000 cm
-1M-1 is the molar 
extinction coefficient of an average IgG. The results were used to determine the 
degree of labelling using the following equation: 
moles dye per mole protein =
A494 
71,000 x protein concentration (M)
 
where A494 is the absorption at 494 nm and 71,000cm
-1M-1 is the approximate 
extinction coefficient of the dye at 494 nm.  
Protein labelling was attempted using various dye incubation lengths. To test the 
binding and fluorescent intensity of the labelled antibodies following different 
incubation lengths, antibodies were tested by glycoarray first (see section 2.19), 
then, if successful binding was seen, in tissue (section 2.10.2). 
2.6 In vivo procedures 
All in vivo procedures were carried out in accordance with Home Office 
regulations and in accordance with both project (60/4493) and personal 
(60/12266) licences.  
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2.6.1 Nerve crush 
The sciatic nerve crush model is a well-established procedure for the study of 
peripheral nerve injury in rodents and is ideal for monitoring the regenerative 
capacity of the injured nerve (Bauder and Ferguson, 2012;Lehmann et al., 
2007;Magill et al., 2007). To perform the nerve crush, anaesthesia was induced 
using an oxygen/isoflurane mixture (4%), and the hind leg on the crush side was 
shaved. The mice were transferred to a face mask and anaesthesia maintained 
at 1‐2%. The notch of the pelvis was identified and the sciatic nerve was exposed 
by blunt dissection. Perpendicular to the notch of the pelvis, the sciatic nerve 
was crushed for 30 seconds with jeweller’s forceps (size 5). Crush was confirmed 
immediately by the separation of proximal and distal parts of the nerve, and 
then post-recovery by identifying absence of toe stretching in mice held by their 
tails. The wound was closed using suture clips which were removed 1 week later. 
Due to the likelihood of autotomy in mice, whereby their affected limb is bitten 
and chewed, measures were taken to prevent this behaviour. To provide a 
stimulating environment to distract and improve the mood of the mice, a tunnel, 
a wooden chew block and a pineapple-flavoured mineral block were provided in 
each cage. Additionally, to prevent swelling of the limb and provide low dose 
pain relief, carprofen was added to the animal’s water (5ml in 250ml water). 
Mice were recovered for 8 weeks before sacrifice. Upon sacrifice, the legs of the 
mice were removed for lumbrical dissection (section 2.7.4), and the mice were 
perfusion fixed (perfused transcardially with saline, followed by 4% 
paraformaldehyde) and the sciatic and tibial nerves removed (section 2.7.3). 
2.6.2 Gait analysis 
Information on gait differences between aged wildtype mice, GalNAcT-/-, 
GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mice was obtained using the 
Digigait™ imaging system (Mouse Specifics Inc., Boston, MA). This technology can 
automatically quantify gait dynamics of mice, rats and guinea pigs and consists 
of a motorized transparent treadmill with a high speed camera below to video 
capture the mice from the ventral side. The captured videos can then be 
analysed using the Digigait™ software which identifies the rodents’ feet by and 
measures many parameters involved in the animals’ gait including stride length, 
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stance width, stance duration, swing duration, braking duration, propulsion 
duration, stride frequency and paw angle (Table2.3). 
Wildtype, GalNAcT-/-, GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mice all 
between 12 and 18 months were given training on the Digigait™ prior to 
commencement of the study. This involved building up from placement in the 
testing chamber on a stopped treadmill to trial runs on the treadmill. This also 
allowed an optimal speed to be chosen where mice with the most severe 
phenotypes could still run while not being too slow for non-affected mice. Mice 
were placed in the Digigait™ and allowed to settle. The treadmill was started at 
6cm/sec and increased to 16cm/sec as soon as the mouse began to walk. The 
treadmill was kept at this speed for approximately 10 seconds, unless the mouse 
stopped running. The videos captured were approximately 3 seconds long and 
roughly 10 videos were captured per animal.  
Captured videos were analysed using Digigait™ software, which outputs the area 
of paw contact on the treadmill into graph form. The software allows manual 
correction of the calculated waveforms where the user can watch the videos in 
slow motion and ensure that for each limb, the software has interpreted the paw 
placement correctly. Videos with too many errors or errors which could not be 
resolved using the software were discarded. Animals were excluded if, when all 
corrections were done, they had fewer than 5 videos remaining. This left 
wildtype (n=4), GalNAcT-/- (n=4), GalNAcT-/--Tg(glial) (n=3), GalNAcT-/--
Tg(neuronal) (n=7). The software then calculates 38 parameters associated with 
gait based on the paw area graphs, examples of which are shown in Table 2.3. 
Analysis for the runs was averaged per animal and the mean values for each 
genotype were plotted. 
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Table 2.3: Examples of gait parameters generated by the Digigait™ which can be used 
to assess function after injury (Taken from Berryman et al., 2009) 
Gait Indices Description 
1. Swing Time (sec) The forward portion of the stride during which the paw is 
not in contact with the belt 
2. Stance/Swing (ratio) The ratio of Stance time to Swing time 
3. Braking Time (sec) The time between initial paw contact with the belt to the 
maximal paw contact 
4. Stance Time (sec) The portion of the stride in which the paw remains in 
contact with the belt 
5. % Stance/Stride The percent of time that the Stance Time contributes to 
one complete Stride cycle 
6. Stride Length (cm) The distance between initial contacts of the same paw in 
one complete stride 
7. Stride Time (sec) The amount of time to complete one complete stride for 
one limb 
8. % Swing/Stride The percent of time that the Swing Time contributes to one 
complete Stride cycle 
9. % Propulsion/Stride The percent of time that the Propulsion Time contributes to 
one complete Stride cycle 
10. Paw Area at peak 
stance (cm2) 
The maximal paw area in contact with the treadmill during 
the stance phase of the step cycle 
11. Stance Width (cm) The distance between the two front feet or the two hind 
feet as measured from the middle of the paw area 
 
2.6.3 Passive Immunisation of anti-ganglioside antibody for injury 
2.6.3.1 Protocol 
Mice were injected with 1 mg monoclonal anti-GD1b antibody MOG1 via the 
intraperitoneal (i.p.) route. After 16 hours the mice were injected i.p. with 0.5 
ml neat NHS. Mice were sacrificed following post-NHS plethysmography and 
behavioural analysis 3-4 hours later. 
2.6.3.2 Rotarod testing  
Prior to injection of antibody, mice underwent baseline rotarod analysis to 
assess their motor skills. The rotarod (Ugo Basile, Gemonio, Italy) is a rotating 
cylinder, 3 cm in diameter and forces motor movement in the mice, who need to 
move forward to stay on. Following 3 practice runs a day prior to baseline 
testing, mice were placed on a stopped rod which began rotating at 4.5 rpm and 
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increased at a rate of 0.12 rpm per second, up to 300 seconds, culminating in a 
speed of 40 rpm. Mice were given three trials on the rotarod with a 5 minute 
rest period in between. The latency to fall was recorded for each animal and 
each trial and the average of the three trials was calculated per mouse. This 
protocol was repeated 2 hours after NHS injection.  
2.6.3.3 Whole body plethysmography 
Mice underwent whole body plethysmography (Electro-Medical Measurement 
systems, Hampshire, UK) to indicate changes in tidal volume and respiratory rate 
as a means of determining diaphragm function. Mice were acclimatised to the 
whole body chambers for 1 hour 1 day prior to baseline measurements. 
Chambers were calibrated according to the manufacturer’s instructions. Before 
recording started, the mice were given a period of at least 20 minutes to 
acclimatise and longer if required. Breathing was recorded for 30 minutes at 
baseline before NHS injection, and for 2 hours after. The provided eDaq 
software outputs data averaged from 25 accepted breaths. An accepted breath 
was one which was over 0.01 ml tidal volume. At each timepoint, the first 25 
outputs were averaged to provide a timepoint measurement. Some animals had 
such shallow breathing after injury that the software did not recognise any 
breaths in the entire 30 minute period between timepoints. The tidal volume of 
these animals was therefore marked as the minimum accepted tidal volume, 
0.01 ml. 
2.6.4 Active immunisation of mice with GD1b liposomes 
2.6.4.1 Liposome preparation 
GD1b, cholesterol, sphingomyelin (SM) and dicetylphosphate (DCP) were 
dissolved in chloroform-methanol (1:1) and stored at -20oC. For liposomes, lipids 
were combined at a molar ratio of 1:5:4:1 with the optional addition of 200 
µg/ml monophosphoryl lipid A (MPLA). Chloroform-methanol was removed by 
drying the suspension with nitrogen gas before resuspending lipids in PBS 5x the 
final volume and kept at 37oC. To encapsulate OVA within the liposomes, 
thereby promoting T-cell help in the immune response, PBS also contained OVA 
at 5 mg/ml. The mixture was vortexed briefly, then sonicated for 15 minutes at 
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room temperature before undergoing 5x freeze-thaw cycles in liquid nitrogen 
and a 37oC water bath. The solution was then centrifuged at 510 g for 20 
minutes at room temperature. Following this, the supernatant was kept at 37oC 
and extruded 11X through a 0.4 µm polycarbonate filter using a mini extruder 
(Avanti Polar Lipids Inc., AL, USA). Liposomes were centrifuged at 109000 g for 1 
hour at 16oC, supernatant discarded and the resulting pellet resuspended in PBS. 
Liposomes were stored at 4oC until used and kept for no longer than 5 days. 
2.6.4.2 Protocol 
Initial immunisations were carried out using previously a described protocol 
(Bowes et al., 2002) (Figure 2.1A). Briefly, on day 0, animals were given 100 µl 
OVA-alum (0.6 mg OVA per 1 ml aluminium hydroxide) i.p. to prime the immune 
response. On day 7, 14, 21 and 28, animals received a 100 µl i.p. injection of 1 
mg/ml GD1b liposomes which did not contain MPLA (as per (Bowes et al., 2002)). 
On days 33, 34 and 35 animals received 50 µl of 200 µg /ml of these liposomes 
intravenously (i.v.) into the tail vein. In groups of 4 per day, mice were injected 
i.p. with 1 ml neat NHS on day 40, 41 or 42 and following behavioural analysis, 
were sacrificed. Blood samples were taken via tail vein venesection prior to 
injections on days 0, 7 and 14, 21, 28, 36 and upon sacrifice.  
A modified protocol was employed to attempt to gain a similar immune response 
in a shorter period of time (Figure 2.1B). In this protocol, on day 0 animals were 
given 100 µl OVA-alum (0.6 mg OVA per 1 ml aluminium hydroxide) i.p. to prime 
the immune response. On day 7, 8, 11 and 12, animals received a 100 µl i.p. 
injection of 1 mg/ml GD1b liposomes containing the addition of MPLA. On days 
19, 20 and 21 animals received 50 µl of 200 µg /ml GD1b liposomes intravenously 
(i.v.) into the tail vein. Blood samples were taken via tail vein venesection prior 
to injections on days 0, 19 and 22 and upon sacrifice. On the day of sacrifice, 
animals were given 1 ml of NHS i.p. to induce injury.  
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Figure 2.1: Protocols used for active immunisations. A. Initial immunisations were 
carried out using the protocol A. B. A modified protocol was employed for later 
immunisations.  
 
Behavioural testing and plethysmography were carried out as in section 2.6.2.2 
and 2.6.2.3, with the addition of the following behavioural tests: 
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2.6.4.3 Latency to Platform 
To assess the mice’s balance they were placed on a wooden beam 2 cm in 
diameter which was suspended 60 cm above a foam pillow. At either end of the 
beam was an enclosed platform. The time taken for the mice to reach this 
platform was recorded up to 60 seconds. If the mice failed to reach the platform 
they scored the maximum of 60 seconds. This was repeated 3 times per animal. 
2.6.4.4 Grip strength 
Both forelimb and total grip strength was scored using a Chatillon-Ametek digital 
Force Gauge model DFIS 2 (Columbus Instruments, OH, USA) as per 
manufacturer’s instructions. Each animal was scored 6 times for both types of 
grip assessment. 
2.6.4.5 Blood samples 
Blood samples taken from mice were left to clot for 1 hour at room 
temperature, then centrifuged at 20000 g for 20 minutes at 4oC. Serum was 
removed and frozen in aliquots at -80oC. 
2.6.4.6 Splenocyte isolation 
Splenocytes from actively immunised mice were isolated under sterile conditions 
by homogenising mouse spleens with a tissue grinder in RPMI and passing through 
a 70 µm filter. Splenocytes were centrifuged for 10 minutes at 525 g, 
supernatant discarded and cells were resuspended in fresh RPMI. Cells were 
diluted 1 in 2 in Trypan blue to identify dead cells and counted using a 
haemocytometer. Cells were once again centrifuged for 10 minutes at 525 g and 
resuspended at 1 x 106 cells/ml. Cells were either added to ELISpot plates 
immediately (see section 2.17), or kept in T25 tissue culture flasks for 7 days 
and supernatant removed and stored at 4oC. 
2.6.5 Serum clearance of monoclonal antibody 
A baseline blood sample was taken from mice 1 day before antibody injection. 
Mice were given 250 µg of monoclonal antibody i.p. on day 0 and further blood 
samples were taken by tail vein venesection on day 1, 3 and 6, with a terminal 
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blood sample taken on day 7 upon sacrifice. Spinal cord and diaphragm were 
harvested from these mice (section 1.7.2) 
2.7 Dissections 
2.7.1 Triangularis sterni preparation 
The triangularis sterni (TS) is a thin muscle sheet, densely innervated by 
branches of the third, fourth and fifth intercostal nerves and found on the inner 
surface of the ribcage. It is ideal for ex vivo imaging of distal motor axons and 
NMJs as it is easy to dissect, fewer than 5 muscle fibres thick, and has NMJs 
which lie parallel with the muscle. It can therefore be easily imaged whole 
mount giving clear images, and can be kept alive in a oxygenated physiological 
solution for several hours following dissection (McArdle et al., 1981). 
The TS was isolated from the mice as described previously (Kerschensteiner et 
al., 2008). Briefly, the body cavity was opened and the rib cage isolated from all 
surrounding organs and connective tissue, dissected out and pinned flat, with 
the ventral surface of the ribs facing upwards, in an organ dish coated with 
Sylgard (Dow-Corning, MI, USA), in oxygenated Ringer’s solution. The 
intercostalis internus muscles were removed carefully, revealing the TS below. A 
“window” of TS muscle with an external border of tissue was excised and pinned 
in a smaller Sylgard-coated organ dish filled with Ringer’s solution. 
For stimulation of the intercostal nerves which supply the TS, extra care was 
taken to ensure nerves were not damaged during dissection. The three nerves 
were carefully released from the surrounding muscle at the point they enter the 
ribcage.  
2.7.2 Diaphragm dissection 
Mice were pinned out on their backs and the ribcage exposed. The peritoneum 
was opened and the viscera moved downwards, exposing the diaphragm. For 
diaphragm sectioning, the diaphragm was cut out and snap frozen before cutting 
sections of 8 μm using a cryostat (Bright instruments, Cambridgeshire, UK) and 
collecting onto Tissue Tek Adhesion slides (Sakura Finetek, Alphen aan den Rijn, 
Netherlands).  
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2.7.3 Sciatic and tibial nerve dissection 
Sciatic and tibial nerves were exposed and removed by cutting through the skin 
overlying the pelvis and blunt dissecting through the overlying muscle. These 
nerves were pinned onto wax and stored in strong fix (4% PFA/5% 
glutaraldehyde) until resin processed (see section 2.8)  
2.7.4 Lumbrical dissection 
The legs were removed before perfusion fixation and the skin peeled back over 
the toes revealing the muscles below. The Achilles tendon was cut below the 
knee and carefully pulled back and removed along with the flexor digitorum 
brevis muscle and its associated tendons. The tendons of the flexor digitorum 
longus and the lumbrical muscles which arise in between these tendons were 
carefully removed. The tendons, with lumbricals still attached, were pinned 
down in Sylgard-coated dishes in oxygenated Ringer’s solution. Lumbricals were 
stained and analysed as per section 2.9. 
2.7.5 Spinal cord dissection 
The skin along the spine was opened and the vertebrae exposed. Forceps were 
slipped between vertebra and cord and used to perform a laminectomy by simply 
breaking and peeling back the bones, exposing the spinal cord. Meninges were 
removed carefully and the cord was cut between the desired segments (as 
identified by the dorsal roots) and removed. Cord was fixed by storing in 4% PFA 
overnight then in 30% sucrose overnight. Cord was then embedded in OCT and 
stored at -80oC. 
2.8 Resin processing and staining for light microscopy 
Sciatic and tibial nerves from animals that had undergone a sciatic nerve crush 
were removed from strong fix and washed in sodium cacodylate for 30 minutes 
in a fume hood. Cacodylate buffer was removed and replaced with 1% osmium 
tetroxide for two hours at room temperature. Nerves were washed again with 
sodium cacodylate for 30 minutes. Nerves were then incubated in increasing 
volumes of ethanol for 20 minutes each (50%, 70%, 80%, 90%, and 100%), 
followed by a final additional 30 minute incubation in 100% ethanol. Nerves were 
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then incubated with propylene oxide for 2x 20 minutes, and then left overnight 
in a 1:1 mixture of araldite:propylene oxide. The following day, this was 
replaced with a 3:1 mixture of araldite:propylene oxide overnight. Nerves were 
then oriented in araldite filled moulds and heated at 60oC for 4 days. The 
remainder of the protocol was kindly carried out in full by Jennifer Barrie: Once 
the araldite resin had hardened, tissue sections of 1 µm thickness were cut onto 
microscope slides and dried at 60oC. To stain sections for examination by light 
microscopy, a methylene blue/azur II stain (1% methylene blue, 1% azure II, 1% 
disodium tetraborate in dH
2
O) was added to the sections for 30-60 seconds then 
rinsed off with dH
2
O. Slides were mounted in DPX mounting media then 
coverslipped. 
2.9 Lumbrical analysis 
Lumbricals from mice which had undergone nerve crush were incubated with 
BTx-647, 2 μg/ml) in Ringer’s for 30 minutes. The muscles were then rinsed with 
Ringer’s and immersion fixed in 4% paraformaldehyde for 30 minutes at 4oC 
before sequential 10 minute rinses with PBS, 0.1M glycine then PBS. Tissue was 
then incubated in the anti-NFil antibody 1211, at a dilution of 1/200, overnight 
at 4oC with 1% Triton X-100. Following this, the tissue was rinsed 3x with PBS and 
incubated in TRITC-conjugated anti-rabbit IgG (5 μg/ml) for 3 hours at room 
temperature then rinsed with PBS, mounted and coverslipped. Lumbricals were 
viewed using a Zeiss AxioImager Z1 microscope. A total of 100 NMJs were 
counted and scored as vacant, polyinnervated or monoinnervated. Innervation 
was determined by the presence or absence of NFil staining overlaying BTx signal 
and whether or not this staining entered the junction from one or more than one 
axonal branch. 
2.10 Antiganglioside antibody studies 
2.10.1 Muscle sections 
For antiganglioside antibody binding studies in various muscles, the tissues to be 
investigated (sternomastoid, diaphragm, sternohyoid, lumbricals or triangularis 
sterni) were snap frozen before cutting sections of 8 μm using a cryostat (Bright 
instruments, Cambridgeshire, UK) and collecting onto Tissue Tek Adhesion slides 
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(Sakura Finetek, Alphen aan den Rijn, Netherlands). Monoclonal antiganglioside 
antibody was applied to slides at 40 µg/ml for 3 hours at 4oC. Appropriate 
secondary antibody (FITC conjugated) was applied at 3.3 µg/ml along with 1.33 
μg/ml BTx-555. Sections were then washed 3x in PBS before coverslipping with 
Citifluor, sealing with clear nail varnish and storing at -20oC until imaged. 
2.10.2 Whole mount, live triangularis sterni staining 
To determine the binding profile of monoclonal anti-ganglioside antibodies in 
live TS, the TS was incubated in 100 µg/ml of the desired antibody with BTx 
(488, 555 or 647 conjugate, 2 μg/ml) in Ringer’s at 4oC for 30 minutes. Tissue 
was rinsed 3x with Ringer’s then fixed in 4% PFA in PBS for 20 minutes at 4oC and 
rinsed with PBS, 0.1M glycine (dissolved in PBS) and PBS alone again for 10 
minutes each. The TS was subsequently dissected away from any remaining 
excess tissue and then incubated with a subtype-specific FITC (or TRITC) 
conjugated secondary Ab (5 μg/ml) and 1% normal goat serum (NGS) in PBS 
overnight at 4oC. The muscle was then mounted on a glass slide, coverslipped 
with Citifluor, sealed with clear nail varnish and stored at ‐20oC until imaging. 
2.10.3 Uptake of antibody at the NMJ 
To look at the uptake of anti-ganglioside antibody at the motor nerve terminal, 
the TS was incubated with antibody as per section 2.10.2. Following the 30 
minute primary incubation and 3x Ringer’s wash steps, tissue was either fixed as 
normal (0 minutes timepoint), or moved to 37oC for 30 or 60 minutes in Ringer’s 
before fixation and secondary incubation. When TS had been imaged and 
quantified (see section 2.16.3), the coverslip was carefully removed, and the 
tissue then washed 3x in PBS, incubated in 0.5% Triton X-100 for 30 minutes at 
4oC, washed again and incubated in secondary antibody as previously. The 
permeabilised tissue was then reimaged and requantified. 
For some experiments, to determine the fate of antibody following 
internalisation, a labelled monoclonal antibody was used. For these experiments 
the labelled antibody was incubated for 30 minutes at 4oC. Preparations were 
washed and, as above, either left for 30 or 60 minutes in Ringer’s at 37oC, or 
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fixed immediately. These preparations did not require permeabilisation and 
reimaging. 
2.11 Anti-ganglioside antibody-mediated injury 
To demonstrate anti-ganglioside-mediated injury to the NT, TS muscle was 
incubated in a solution of anti-ganglioside antibody as above (see section 
2.10.2), followed by a 3x rinse with Ringer’s then a 30 minute incubation with 
40% NHS in Ringer’s at room temperature. The tissue was rinsed 3x with 
Ringer’s. For MAC detection the tissue was incubated in anti‐C5b‐9 antibody 
(2.375 μg/ml in Ringers) for 1 hour at room temperature before fixing and 
rinsing as above. The fixed tissue was incubated again in anti‐C5b‐9 antibody 
(2.375 μg/ml in PBS) overnight at 4oC then rinsed 3x with PBS before applying 
the secondary antibody (5 μg/ml in PBS with 1% NGS) for 3 hours at 4oC. The 
tissue was then rinsed, coverslipped in Citifluor and stored as above. 
2.12 Activity dependent uptake experiments 
2.12.1 High potassium stimulation in TS 
To look at the effect of nerve terminal activity on the internalisation of 
antibodies, following the primary anti-ganglioside antibody incubation and wash 
steps (section 2.10.2), TS tissue was incubated for 10 minutes at room 
temperature in either standard Ringer’s or high potassium Ringer’s solution, then 
rinsed 3x with standard Ringer’s solution. Tissue was then either fixed and 
incubated with secondary antibody as in section 2.10.2 to look for antibody 
presence, or incubated with 40% NHS in Ringer’s at 37oC for 30 minutes, rinsed 
3x with Ringer’s then probed for MAC deposition as per section 2.11. 
2.12.2 Stimulation of intercostal nerves 
Again following the primary antibody incubation and wash steps (section 2.10.2), 
intercostal nerves were stimulated with a Grass SD9 square pulse stimulator 
(Natus medical Inc., CA, USA) using platinum electrodes. Live, whole mount TS 
preparations were stretched out so that successful muscle contraction would be 
evident. The intercostal nerves which innervate the TS were stimulated for 5 
seconds at 10Hz, 30 Volts with a pulse duration of 0.3 ms. Stimulation was 
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confirmed by muscle twitching evoked by the nerves as opposed to direct muscle 
stimulation. For comparison of antibody binding, tissue was then fixed and 
incubated with secondary antibody as in section 2.10.2. For comparison of MAC 
deposition, TS muscle was incubated with 40% NHS in Ringer’s at 37oC for 30 
minutes, rinsed 3x with Ringer’s then probed for MAC deposition as per section 
2.11. 
2.13 Staining of diaphragm sections from immunised mice 
Diaphragm sections which were previously exposed to antibody plus NHS in vivo 
were stained for presence of IgG or IgM, C3, MAC and NFil as follows. For C3 and 
IgG/IgM, tissue was incubated in mouse α-human C3c-FITC (10 µg/ml in PBS) or 
α-mouse IgG or IgM-FITC (3.33 µg/ml in PBS) for 3 hour at 4oC. MAC deposition 
was stained for by incubating tissue in mouse α-human C5b-9 (2.375 μg/ml in 
PBS) for 1 hour at 4oC then following 3x rinses in PBS, for 1 hour in α-mouse 
IgG2a-FITC (3.33 μg/ml in PBS) at 4oC. Each solution contained BTx-555 (1.33 
μg/ml). For NFil staining, tissue was incubated with BTx-555 for 1 hour at 4oC, 
then rinsed and incubated in 1/200 rabbit polyclonal 1211 overnight in 1% Triton 
and 1% NGS. Tissue was then rinsed and incubated in goat anti-rabbit-488 (4 
µg/ml in PBS) for 2 hours at 4oC. All tissue was rinsed in PBS before being 
mounted in Citifluor then coverslipped. 
2.14 Spinal cord staining 
Transverse sections of spinal cord were cut at 15 µm, air dried then stored at -
20oC. Sections were first washed 3x with 0.5% Triton X-100/PBS then blocked for 
1h at room temperature in 3% NGS/PBS. Primary antibodies were applied 
overnight at 4oC in 3% NGS/PBS at the dilutions or concentrations stated in Table 
2.1. The following day, relevant secondary antibodies were applied for 3 hours 
at 4oC. 
2.15 Topical complement assay 
Diaphragms from naïve wildtype mice were removed, snap frozen and stored at -
80oC before being cut into 8 μm sections. Serum from actively immunised mice 
was heat inactivated at 56oC for 30 minutes to inactivate complement proteins, 
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before adding neat to tissue sections for 2 hours at 4oC. Monoclonal antibody (20 
µg/ml) was added as a positive control. Following a 3x rinse in PBS, sections 
were incubated with 4% NHS in Ringer’s solution for 1 hour at 37oC. After 
another 3x PBS rinse, sections were incubated with anti-human C5b-9 (2.375 
μg/ml) and BTx-555 (1.33 µg/ml) in PBS for 2 hours at 4oC. Tissue was rinsed 3x 
in PBS then incubated with anti-mouse IgG2a-Cy5 (3.33 µg/ml in PBS) for 1 hour 
at room temperature before rinsing and coverslipping. 
2.16 Microscopy 
2.16.1 Light microscopy 
Images of stained sciatic and tibial nerves were captured using a light 
microscope and the resulting images were analysed for presence of myelinated 
fibres in a 200 µm ROI. One image was taken per animal using a 20x objective.  
2.16.2 Fluorescent microscopy 
Images for analysis of fluorescent intensity (section 2.16.3) or percentage of NFil 
at the nerve terminal (section 2.16.4) were captured as single slices using an 
LSM 5 Pascal or LSM 510 microscope. The LSM 5 Pascal was used for tissue which 
had been stained with Rhodamine/555 conjugates and FITC/488 conjugates, 
whereas the LSM 510 allowed quantitative imaging of tissues which had been 
stained using cy5-conjugates or DAPI. For experiments where comparisons were 
being made between genotypes, tissue was coded and analysed blinded. 
Pinhole size and amplifier gain were set at the beginning and kept consistent 
throughout each experiment. For analysis of diaphragm sections, each 
mouse/antibody to be analysed was imaged in triplicate using a 40x objective, 
with 15 images taken of each section of tissue with several NMJs in each image, 
so as to total over 100 NMJs imaged per animal/antibody. 
For whole mount TS, at least 15 images were taken of each tissue, again with 
several NMJs per image. Although a thin muscle, TS is nonetheless thicker than 
sectioned tissue and therefore has superficial and deep NMJs. As any antibody 
was more likely to be uniformly present on the topmost layers, images were 
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taken of the superficial NMJs. This normally totalled around 50 NMJs imaged per 
animal. 
Illustrative images of whole mount tissue were taken using a Zeiss AxioImager Z1 
microscope with ApoTome attachment, which uses structured illumination to 
capture high resolution images. Images were captured as stacks and displayed as 
maximum intensity projections (MIPs). These are 2D renderings of the 3D image 
which are constructed using AxioVision 4.7.2 software.  
2.16.3 Fluorescent intensity at the nerve terminal 
To quantify the fluorescent intensity at the nerve terminal, the fluorescent 
intensity overlying the BTx signal was measured using ImageJ software (NIH, MD, 
USA). To do this, the BTx signal was thresholded between 50 and 255 pixels. 
Each area of BTx was then selected as a region of interest (ROI), and overlaid 
onto the channel of the antibody being measured. The mean intensity grey value 
was then measured in this ROI, generating a pixel value between 0 and 255 
(Figure 2.2). 
 
Figure 2.2: Measurement of fluorescent intensity overlying the endplate. The first 
image shows the merged signal from BTx (red) and antibody (green). Throughout the 
thesis this antibody may be against mouse anti-ganglioside antibodies, human C3 or 
human MAC. In the next image the BTx has been thresholded and one junction has been 
selected as a ROI (selection bordered by yellow line). This ROI is overlaid onto the 
antibody channel as shown in the third image and the mean pixel intensity is measured 
within the ROI. The process is repeated for all NMJs in the image. 
2.16.4 Percentage coverage of NFil at the nerve terminal 
To measure the extent damage to the nerve terminal structure, the percentage 
coverage of nerve terminal by NFil was calculated. Using ImageJ, both BTx and 
the NFil signals, were thresholded. Again the BTx was selected as a ROI and 
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overlaid onto the NFil channel. The % area coverage within this ROI was then 
measured (Figure 2.3).  
 
Figure 2.3: Measurement of percentage NFil coverage. The first image shows the 
merged signal from BTx (red) and NFil (green). In the next image the BTx has been 
thresholded and one junction has been selected as a ROI (selection bordered by yellow 
line). The third image shows the NFil channel which has also been thresholded (now 
shown in red). The ROI from the BTx channel is then overlaid onto the thresholded NFil 
channel and the % area of NFil within the ROI is measured. 
 
Both of the above methods of quantification were performed using macros 
modified from ones originally generated by former lab member, Peter 
Humphries.  
2.16.5 CFP counts 
As an alternative to using percentage NFil coverage, in fluorescent mice, 
damage to nerve terminals could also be measured by manually assessing 
percentage of NMJs which contained CFP. A NMJ was scored as having CFP if CFP 
was present in a normal distribution overlying the BTx, regardless of intensity 
(Figure 2.4). One hundred NMJs were assessed per animal per condition. 
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Figure 2.4: Illustrative examples of CFP presence at the NMJ. A: CFP in an 
undamaged nerve terminal. CFP follows the line of the BTx. B: CFP at a slightly injured 
nerve terminal. The CFP is less bright than in A, but is still present in a normal 
distribution overlying the BTx signal. C: A damaged nerve terminal with CFP present in 
the distal axon but not in the nerve terminal overlying the BTx. A and B are examples of 
nerve terminals which would be scored at “CFP present”, whereas C would be scored as 
“CFP absent”. 
 
2.17 ELISpots 
To quantitatively determine antigen-specific responses in mice which were 
immunised with ganglioside-containing liposomes, ELISpots were performed. 
MultiScreen-IP Filter Plates (Merk Millipore, Billerica, MA, USA) were activated 
with 35 µl 35% ethanol for 30 seconds. Ethanol was discarded and plates coated 
with 100 µl of 50 µg/ml GD1b in 100% ethanol, or ethanol only for blank wells. 
When ethanol had evaporated, plates were blocked with RPMI with 10% FCS for 1 
hour in a CO2 incubator at 37
oC. Block was discarded and 100 µl previously 
isolated splenocytes (see section 2.6.3.6) were added at 106 cells per well, 
overnight in a CO2 incubator at 37
oC. The following day cells were discarded and 
plates washed 4x in PBS before incubating with secondary antibody (HRP 
conjugated goat anti-mouse IgG or IgM) for 1 hour at 4oC. Secondary was 
discarded and plates washed a further 4x in PBS. Plates were developed by 
A B C
B
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C
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incubation with 3-Amino-9-ethylcarbazole (AEC) substrate. Solution was 
prepared by adding 1 AEC tablet (Sigma-Aldrich, St Louis, MO, USA) to 2.5 ml of 
N,N-dimethylformamide (DMF) in a fume hood. When tablet was fully dissolved, 
the 2.5 ml solution was added to 47.5 ml of 50 mM acetate buffer (14.8 mM 
C
2
H
4
O
2
, 35.3 nM C
2
H
3
NaO
2
) and 25 µl of 30% H
2
O
2
 added immediately prior to 
use. The AEC substrate solution (100 µl) was added to wells for around 20 
minutes, or until spots began to develop. Reaction was stopped by washing wells 
with dH
2
O. Wells were imaged using an AID ELISpot reader (Autoimmun 
Diagnostika GmbH, Strassberg, Germany) and spots were counted either 
manually or using the provided AID software. 
2.18 ELISAs  
To test for anti-ganglioside antibody reactivities, lipid ELISAs were performed.  
Immulon-2HB 96 well plates (Thermo Fisher Scientific, MA, USA), were coated 
with 200 ng of GD1b in methanol, or methanol only for blank wells. Plates were 
left to dry overnight at room temperature in a fume hood, then blocked with 200 
µl 2% bovine serum albumin (BSA)/PBS solution per well for 1 hour at 4oC. Block 
was discarded and mouse serum (1/100 in 0.1% BSA solution) or neat splenocyte 
supernatant (concentrated 5x) was added to both positive and negative wells. 
Monoclonal antibodies were used as positive controls and were used at 50 µg/ml 
in 0.1% BSA and, if used as a standard, serial diluted 1 in 2. Each sample was run 
in triplicate. Plates were left overnight at 4oC then primary solution discarded. 
Plates were washed 3x in PBS then secondary antibody (goat anti-mouse IgG or 
IgM-HRP) was added at 30 ng/ml, in 0.1% BSA solution for 1 hour at 4oC. Plate 
was washed in PBS 3x then 100 µl OPD substrate solution (30ml dH
2
O, 16ml 0.2M 
Na
2
HP0
4
, 14ml 0.IM C
6
HgO
7
, 1 OPD tablet and 20 µl 30% H
2
O
2 
added immediately 
prior to use) was added to each well. Plates were left to develop for 20 minutes 
at room temperature in the dark before addition of 50 µl stop solution (4M 
H
2
SO
4
) to each well. Plates were read at 492 nm on a Tecan Sunrise™ automated 
microplate reader (Tecan Group Ltd, Männedorf, Switzerland) using the 
provided Magellan™ software.  
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2.19 Glycoarray 
Using combinatorial glycoarray (Rinaldi et al., 2009), serum and monoclonal 
antibodies were tested against single lipids and lipids complexes. Slides were 
pre-prepared by applying Immobilon-FL PVDF membrane (Merk Millipore, 
Billerica, MA, USA) to glass slides using photomount glue (3M, MN, USA). Once 
glue was dry, 0.1 µl of each lipid or premixed lipid complex (100 µg/ml for single 
lipid, 50 µg /ml for each of the lipids in complex) was spotted using an 
automatic TLC sampler (CAMAG, Muttenz, Switzerland), onto the slides. Once 
spotted, slides were left overnight at 4oC then blocked with 2% BSA for 1 hour at 
room temperature. Serum (1/100 in 1% BSA) or monoclonal antibody (10 µg/ml in 
1% BSA) was applied to slides for 1 hour at 4oC. Following 2x 15 minute washes in 
1% BSA, goat anti-mouse IgG or IgM 555 or 647-conjugated antibody was applied 
(2 µg/ml in 1% BSA) for 1 hour at 4oC. Slides were washed 2x 30 minutes in 1% 
BSA, followed by 1x 5 minutes wash with PBS and 1X 5 minute wash with dH
2
O. 
Slides were left to dry overnight at 4oC then scanned using a ScanArray express 
microarray scanner (Perkin-Elmer, Waltham, MA, USA). Images from labelled 
DG2 antibody were taken on a Typhoon 8600 Variable Mode Imager (GE 
Healthcare Life Sciences, Little Chalfont, UK) as the ScanArray did not have a 
laser of the correct wavelength. 
2.20 Statistics and display of data 
All graphs were composed in GraphPad Prism 6 and all statistical tests were 
calculated using this software, using p<0.05 as the value of significance.  
Immunohistological data on antibody intensity or NFil coverage (section 2.16.3 
and 2.16.4) are considered to be nonparametric and as such, results from each 
NMJ are displayed as Tukey box and whisker plots. The horizontal line displays 
the median of the data, with the top and bottom of the box representing the 
75th and 25th percentile respectively. Top whiskers denote the 75th percentile 
plus 1.5x the interquartile range (IQR). Bottom whiskers denote the 25th 
percentile minus 1.5x the IQR and any values outwith this range are plotted as 
individual points. Unless stated otherwise, ROUT analysis was conducted in 
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GraphPad Prism 6 to remove outliers caused by high background signal 
(maximum desired false discovery rate of 1%).  
Bar graphs shown in this thesis show error bars representing the standard error 
of the mean from results from each animal tested. Statistical tests used for each 
figure are shown in the figure legends. 
3 Rescue of complex ganglioside in neuronal and glial 
membranes 
3.1 Introduction 
The generation of complex ganglioside rescue mice driven by GalNAcT expression 
in neurons and glia is an important step in the generation of an animal model of 
GBS (Yao et al., 2014). This lab has developed three strains of mouse which have 
neuronal rescue of GalNAcT expression and one which has glial rescue. The three 
neuronal rescue strains have GalNAcT expression driven by the NFL promotor in 
one mouse strain and by the Thy1 promoter in the other two. Before using these 
mice as part of experimental paradigms, they needed to be characterised. 
Therefore this chapter focuses on the demonstration and localisation of 
ganglioside expression in these mice, which was also the basis for the selection 
of mouse strains, antibodies and antigens for future work. Additionally, this 
chapter includes some preliminary work characterising the phenotypic 
consequences of ganglioside rescue, including gait analysis differences and 
comparison of nerve regeneration. Wildtype mice have been shown to perform 
better than GalNAcT-/- mice in various behavioural tests from 4 months of age 
(Chiavegatto et al., 2000). This difference in behavioural phenotype is 
accompanied by neuronal degeneration as discussed in chapter 1, therefore it 
was expected that a neuronal reintroduction of complex ganglioside expression 
may result in an improvement in phenotype.  
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3.2 Comparison of binding profiles of different antibodies in mice 
with restored neuronal complex ganglioside expression 
To demonstrate that the rescue mice generated had restored ganglioside 
expression, the nerve terminal antibody staining profile of 4 antibodies was 
compared in a number of different muscle sections from three different 
“neuronal rescue” mouse strains. The results were subsequently used to 
determine which antigen to concentrate on in future experiments. One such 
rescue mouse has GalNAcT enzyme expression driven by the NFL promoter and 
the other two driven by the Thy1 promoter. For this chapter only these mice will 
be referred to as NFLTg, Thy1Tg(112) and Thy1Tg(115) mice. The results of this 
section will also determine which of these three strains of “neuronal rescue” 
mouse to bring forward for use in future experiments. Nerve terminal antibody 
staining was calculated by measuring the antibody intensity overlying the BTx, 
representing the nerve terminal. Data were analysed by Kruskal-Wallis with 
Dunn’s multiple comparison test against wildtype mice, with GalNAcT-/- shown as 
negative controls. Three animals from each strain were analysed. 
3.2.1 MOG3 staining 
The anti-GD1b antibody MOG3 bound with high intensity to the nerve terminals 
of all muscle groups in each mouse strain, with the exception of the GalNAcT-/- 
mouse which lacks GD1b (Figure 3.1). This antibody binds strongly to wildtype 
nerve terminals in all muscles and staining is abolished in the GalNAcT-/- mice. In 
NFLTg mice, staining is rescued to levels akin to that of the wildtype in 
lumbricals and shows intensity levels higher than that of the wildtype in all other 
muscles. Similarly, the Thy1Tg(112) mouse had statistically similar staining to 
wildtype mice in lumbricals and significantly higher staining in all other tissues. 
Thy1Tg(115) mice, however, had significantly lower staining intensity than 
wildtype mice in all muscles, with the exception of the sternomastoid. 
Additionally, these mice had a much larger IQR than the other genotypes with 
MOG3. Using sternomastoid muscle as an example, wildtype mice had a median 
staining intensity of 167 AU, with an IQR of 131 AU. Thy1Tg(115) mice showed a 
much more wide spread of data with a median of 130.0 AU and an IQR of 245.5 
AU. Upon examination of the images, this large IQR appeared to be due to 
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inconsistencies between NMJ staining in the same muscle, with only some NMJs 
having positive staining. In contrast, wildtype, NFLTg and Thy1Tg(112) had much 
more consistent staining between NMJs in the same muscle. 
 
Figure 3.1: Anti-GD1b staining at the nerve terminal in various muscles in wildtype, 
GalNAcT-/-, NFLTg and Thy1Tg (line 112 and 115) mice (n=3 per group). Sections of 
muscle were stained with MOG3, a monoclonal anti-GD1b antibody followed by anti-
mouse IgG3-TRITC secondary antibody. NMJs were identified with the addition of BTx-
488. Staining was quantified by the intensity of antibody overlying BTx staining. Staining 
was observed in wildtype mice and abolished in GalNAcT-/- mice. NFLTg and Thy1Tg(112) 
showed either comparable staining to wildtype or higher staining than wildtype mice. 
Staining in Thy1Tg(115) was consistently lower than wildtype mice except in 
sternomastoid. Kruskal-Wallis with Dunn’s multiple comparisons test vs wildtype mice. 
*=p<0.05, ***=p<0.001, ****=p<0.0001. Non-parametric data displayed as Tukey box plot 
(see section 2.20). 
3.2.2 DG2 staining 
In mice tested against anti-GM1 antibody DG2, all rescue strains showed some 
degree of staining in sternomastoid and diaphragm (Figure 3.2). In sternomastoid 
muscle, this staining was consistently lower than wildtype mice but in diaphragm 
NFLTg mice show significantly higher staining intensity than wildtype mice, 
whereas both Thy1Tg strains were statistically similar to wildtype. In sternohyoid 
muscle NFLTg and Thy1Tg(112) again showed a restoration of staining intensity 
but not to levels akin to wildtype mice. In contrast, staining in Thy1Tg(115) mice 
was not restored. In the lumbricals and TS muscle, staining was also very low or 
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negative in all rescue strains, indicating a much lower restoration of GM1 in 
these tissues.  
 
Figure 3.2: DG2 staining at the nerve terminal in various muscles in wildtype, 
GalNAcT-/-, NFLTg and Thy1Tg (line 112 and 115) mice (n=3 per group).. Sections of 
muscle were stained with DG2, a monoclonal anti-GM1 antibody, followed by anti-
mouse IgG3-TRITC secondary antibody. NMJs were identified with the addition of BTx-
488. Staining was quantified by the intensity of antibody overlying BTx staining. Staining 
was observed in wildtype mice and abolished in GalNAcT-/- mice. NFLTg, Thy1Tg(112) 
and Thy1Tg(115) showed a degree of restored antibody staining but this was consistently 
lower to wildtype except NFL Tg diaphragm. Kruskal-Wallis with Dunn’s multiple 
comparisons test vs. wildtype mice. ***=p<0.001, ****=p<0.0001. Non-parametric data 
displayed as Tukey box plot (see section 2.20) 
 
3.2.3 DG1 staining 
DG1 is an antibody which binds to GM1 in ELISA but not in live wildtype mice 
tissue. This has been shown to be due to the inhibition of its binding to GM1 by 
nearby GD1a (Greenshields et al., 2009). This antibody was included in this panel 
screening to test whether the rescue of GalNAcT expression in neurons resulted 
in similar ganglioside distribution on the membrane. If the restored gangliosides 
were similarly distributed to wildtype mice, it would be expected that the DG1 
would not bind. 
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As was the case in wildtype mice, DG1 showed very little/no staining in most 
tissues (Figure 3.3). Diaphragm appears to have high staining in all rescue strains 
but this was due to high background fluorescence in this tissue, though all rescue 
strains were higher than wildtype mice. However diaphragm was the only muscle 
where this was the case as all other muscles showed either statistically similar 
or lower staining than in wildtype mice.  
 
Figure 3.3: DG1 staining at the nerve terminal in various muscles in wildtype, 
GalNAcT-/-, NFLTg and Thy1Tg (line 112 and 115) mice (n=3 per group). Sections of 
muscle were stained with DG1, a monoclonal anti-GM1 antibody which has previously 
been shown not to bind live wildtype tissue, followed by anti-mouse IgG2b-TRITC 
secondary antibody. NMJs were identified with the addition of BTx-488. Staining was 
quantified by the intensity of antibody overlying BTx staining. Staining was not observed 
in wildtype mice and NFLTg, Thy1Tg(112) and Thy1Tg(115) showed staining similar or 
lower than wildtype mice in all muscles except diaphragm, where they had significantly 
higher staining. Kruskal-Wallis with Dunn’s multiple comparisons test vs wildtype mice. 
*=p<0.05, ***=p<0.001, ****=p<0.0001. Non-parametric data displayed as Tukey box plot 
(see section 2.20) 
 
3.2.4 MOG35 staining 
This anti-GD1a antibody has also been shown to bind poorly in wildtype mouse 
tissue, instead optimal binding being shown previously in GD3s-/- which over-
express GD1a (Goodfellow et al., 2005).  
W
T
G
M
2
s
K
O
N
F
L
T
h
y
1
 (
1
1
2
)
T
h
y
1
 (
1
1
5
)
0
1 0 0
2 0 0
3 0 0
C le a n e d  d a ta :  Id e n tify  o u tlie rs  o f D G 1  -  S te rn o m a s to id
A
n
ti
b
o
d
y
 I
n
te
n
s
it
y
 T
R
IT
C
W
T
G
M
2
s
K
O
N
F
L
T
h
y
1
 (
1
1
2
)
T
h
y
1
 (
1
1
5
)
0
1 0 0
2 0 0
3 0 0
C le a n e d  d a ta : Id e n tify  o u tl ie r s  o f D G 1 - D ia p h ra g m
A
n
ti
b
o
d
y
 I
n
te
n
s
it
y
 T
R
IT
C
W
T
G
M
2
s
K
O
N
F
L
T
h
y
1
 (
1
1
2
)
T
h
y
1
 (
1
1
5
)
0
1 0 0
2 0 0
3 0 0
C le a n e d  d a ta :  Id e n tify  o u tlie r s  o f D G 1  -  S te rn o h y o id
A
n
ti
b
o
d
y
 I
n
te
n
s
it
y
 T
R
IT
C
W
T
G
M
2
s
K
O
N
F
L
T
h
y
1
 (
1
1
2
)
T
h
y
1
 (
1
1
5
)
0
1 0 0
2 0 0
3 0 0
C le a n e d  d a ta : Id e n tify  o u t lie rs  o f  D G 1 - L u m b r ic a ls
A
n
ti
b
o
d
y
 I
n
te
n
s
it
y
 T
R
IT
C
W
T
G
M
2
s
K
O
N
F
L
T
h
y
1
 (
1
1
2
)
T
h
y
1
 (
1
1
5
)
0
1 0 0
2 0 0
3 0 0
C le a n e d  d a ta : Id e n tify  o u tl ie r s  o f  D G 1 -  T S
A
n
ti
b
o
d
y
 I
n
te
n
s
it
y
 T
R
IT
C
Sternomastoid Diaphragm Sterno oid
Lumbricals Triangularis Sterni
A
n
ti
b
o
d
y 
In
te
n
si
ty
 (
A
U
)
A
n
ti
b
o
d
y 
In
te
n
si
ty
 (
A
U
)
M O G 3  -  T S
In
te
n
s
it
y
 (
u
n
it
s
)
W
T
G
M
2
s
K
O
N
F
L
 T
g
T
h
y
1
(1
1
2
)
T
h
y
1
(1
1
5
)
0
1 0 0
2 0 0
3 0 0
W T
G M 2sK O
N F L  T g
T h y 1 (1 1 2 )
T h y 1 (1 1 5 )
Wildtype
GalNAcT-/-
NFL
Thy1Tg(112)
Thy1Tg(115)
*
****
**** **** ****
**** *** ****
**** **** **** ****
****
80 
 
As expected, MOG35 showed poor staining in all wildtype muscle (Figure 3.4). 
This poor staining was reflected in rescue lines with each muscle being negative 
for MOG35 presence at the nerve terminal. 
 
Figure 3.4: MOG35 staining at nerve terminals in various muscles in wildtype, 
GalNAcT-/-, NFLTg and Thy1Tg (line 112 and 115) mice (n=3 per group). Sections of 
muscle were stained with MOG35, a monoclonal anti-GD1a antibody which has 
previously been shown not to bind well in wildtype tissue, followed by anti-mouse 
IgG2b-TRITC secondary antibody. NMJs were identified with the addition of BTx-488. 
Staining was quantified by the intensity of antibody overlying BTx staining. Staining was 
not observed in either wildtype mice or any of the rescue strains Kruskal-Wallis with 
Dunn’s multiple comparisons test vs. wildtype mice. *=p<0.05, ***=p<0.001, 
****=p<0.0001. Non-parametric data displayed as Tukey box plot (see section 2.20) 
 
3.2.5 Summary 
As Thy1Tg(115) appeared to show inconsistent expression of GalNAcT-driven 
GD1b, this line was immediately ruled out to be carried forward for future 
experiments. Differences between Thy1Tg(112) and NFLTg were minor and often 
when staining was statistically different to wildtype mice, there was no 
statistical difference between the two neuronal rescue strains. For this reason, 
and due to the ongoing characterisation of this mouse by other members of the 
lab, the NFLTg was used as data generated by both myself and other lab 
members could be mutually beneficial.  
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3.3 Illustrative binding profiles of GalNAcT-/--Tg(neuronal) and 
GalNAcT-/--Tg(glial) mice 
Having selected mice with NFL-driven GalNAcT expression, these mice will now 
be known throughout this thesis as GalNAcT-/--Tg(neuronal) mice. As quantitative 
staining intensity data does not fully show the nuances of antibody binding, 
whole mount illustrative images were taken of those antibodies which had 
produced the best binding in the various muscle sections. Additionally, another 
GD1b antibody which also binds to GT1b, MOG16, was used. In addition to the 
previously investigated GalNAcT-/--Tg(neuronal) mouse, GalNAcT-/--Tg(glial) mice 
were incorporated to investigate binding differences between mice with 
neuronal and glial directed expression of GalNAcT and thus complex 
gangliosides.  For this study live TS muscle was used.  
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(Figure on previous page) 
Figure 3.5: Binding pattern in TS muscles of mouse monoclonal antibodies in four 
mouse strains. Staining with antibodies against complex gangliosides is absent in 
GalNAcT-/- mice but restored in neuronal and glial structures in GalNAcT-/--Tg(neuronal) 
and GalNAcT-/--Tg(glial) mice respectively. MOG16 (A) binds clearly to neuronal 
structures in wildtype and GalNAcT-/--Tg(neuronal) mice. In GalNAcT-/--Tg(glial) mice, 
pSC body staining is seen weakly, as well as more strongly to processes overlying the 
NMJ. This is also the case for DG2 (B) and MOG1 (C), though some additional glial 
staining is seen in GalNAcT-/--Tg(neuronal) mice (indicated by arrows). DG2 also binds 
kranocytes in wildtype mice which partially obscure the neuronal staining seen at the 
NMJ.  
As was the case for sectioned muscle, all antibodies bound well in wildtype mice 
and were absent in GalNAcT-/- mice. Once again, staining was reinstated in both 
rescue strains. However, slight differences were seen in the specific NMJ 
structures being bound in the different rescue mice strains. MOG16 staining 
shows a neuronal binding pattern in wildtype mice, with no apparent pSC 
staining (Figure 3.5A). This neuronal pattern of staining is rescued in GalNAcT-/--
Tg(neuronal) mice, where gangliosides should be available on the axonal 
membrane. In GalNAcT-/--Tg(glial) mice, staining is also present but is on glial, 
rather than neuronal structures (pSC body indicated by white arrowhead). A 
similar staining pattern is found with MOG1 (Figure 3.5B), with neuronal binding 
seen in wildtype and GalNAcT-/--Tg(neuronal) mouse. Interestingly however, 
pSCs also appear to be bound by MOG1 in GalNAcT-/--Tg(neuronal) mice, though 
this does not occur in wildtype mice. In the GalNAcT-/--Tg(glial) mouse, MOG1 
staining is seemingly only on the pSC cell bodies and the processes it extends 
over the NMJ. In wildtype mice, DG2 binds to GM1-positive kranocytes which can 
be seen capping the NMJ (Figure 3.5C), when no kranocyte staining was present, 
clear nerve terminal binding could be seen. Neuronal and again also glial 
structures show positive DG2 staining in GalNAcT-/--Tg(neuronal) mice, whereas 
in the GalNAcT-/--Tg(glial) mouse, binding appears to be present only on glial 
structures, though not on processes over every NMJ (example image shows one 
NMJ with DG2 staining over processes and one without). However, it is important 
to note that in both rescue strains, no kranocyte staining is present with DG2, 
confirming the KO of GalNAcT in other cell types.  
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3.4 Comparison of gait parameters between wildtype, GalNAcT-/- 
and rescue mouse strains 
Observationally, GalNAcT-/--Tg(neuronal) mice lack the age-dependant 
phenotype seen with GalNAcT-/- mice. Contrastingly, the phenotype of GalNAcT-
/--Tg(glial) appears equal to, or worse than, GalNAcT-/- mice, with an apparent 
exaggeration of the Parkinson-like tremor. It has already been demonstrated 
that this degenerative phenotype is accompanied by alterations in gait 
parameters in GalNAcT-/- mice when compared to wildtype mice (Chiavegatto et 
al., 2000). Specifically, GalNAcT-/- mice were shown to have a reduced stride 
length, stride width and hind-paw print length. Therefore, to see if the 
observational differences in phenotype of the rescue mice could be quantified, 
mice were trained on a Digigait™ treadmill and gait parameters were measured. 
As some animals do not run well on the treadmill, even following training, the 
groups were as follows: wildtype n=4, GalNAcT-/- n=4, GalNAcT-/--Tg(neuronal) 
n=7, GalNAcT-/--Tg(glial) n=3.  
Of the parameters measured by the Digigait™ software, 6 are shown (Figure 3.6). 
These include the equivalent measurements which were previously shown to be 
altered in GalNAcT-/- mice, with stance width substituting for stride width and 
paw area for paw print length. No significant differences were observed in 
stance width, stride length and paw area between wildtype mice and GalNAcT-/-, 
GalNAcT-/--Tg(neuronal) or GalNAcT-/--Tg(glial) (Figure 3.6 A, C, E). Hind limbs 
have an increased stance width variability in GalNAcT-/- (p<0.05) and GalNAcT-/--
Tg(glial) mice compared to wildtype, though this does not reach significance in 
the GalNAcT-/--Tg(glial) mice (Figure 3.6B). Similarly, stride length variability is 
significantly higher in both left and right forelimbs in GalNAcT-/- (p<0.05) and 
GalNAcT-/--Tg(glial) (p<0.001 for left forelimb, p<0.05 for right forelimb) mice 
compared with the normal fluctuations in stride length (about 1cm in wildtype 
mice). The GalNAcT-/--Tg(neuronal) mice do not show any differences from 
wildtype mice. Finally, paw area variability is increased in GalNAcT-/--Tg(glial) 
hind limbs (p<0.001) and left forelimb (p<0.001). GalNAcT-/- mice show similar 
paw area variability to wildtype in hind limbs but a slight increase in both 
forelimbs, reaching significance in the left forelimb (p<0.05).  
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Figure 3.6: Comparison of gait parameters between 4 mouse strains. No changes 
were observed in stance width (A), stride length (C) or paw area at peak stance (E). 
Increases in stance width variability (B) were observed between the hind limbs of 
GalNAcT-/- and wildtype mice. Similarly, increased stride length variability (D) was seen 
between forelimbs of GalNAcT-/- and GalNAcT-/--Tg(glial) mice vs. wildtype mice. Paw 
area variability (F) was increased in GalNAcT-/--Tg(glial) mice hind limbs but not 
GalNAcT-/- forelimbs. Two way ANOVA with Dunnett’s multiple comparisons test vs. 
wildtype mice. *=p<0.05, ***=p<0.001, ****=p<0.0001.  
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3.5 Comparison of axon regeneration in wildtype, GalNAcT-/- and 
GalNAcT-/--Tg(neuronal) mice 
GalNAcT-/- mice have previously been shown to have delayed nerve regeneration 
following hypoglossal nerve transection compared with wildtype mice (Kittaka et 
al., 2008). To determine whether the neuronal rescue of complex ganglioside 
expression, which is sufficient to rescue the degenerative phenotype seen in 
these GalNAcT-/- mice, can also restore the delay in regeneration in GalNAcT-/- 
mice, mice underwent a sciatic nerve crush followed by 8 weeks of 
regeneration. This period of regeneration was chosen based on previous studies 
in wildtype mice which took 10 weeks to have fully mono-innervated lumbrical 
NMJs. 
3.5.1 Lumbrical re-innervation 
Lumbricals were scored manually as being either vacant, polyinnervated or 
monoinnervated. One hundred NMJs were scored per mouse. Chi-squared 
analysis was performed on the contingency table to determine whether there 
were differences in the NMJ innervations state of the three genotypes after 8 
weeks. No significant difference was observed in the state of NMJ innervation 
among the groups (Figure 3.7). 
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Figure 3.7: Comparison of axon regeneration in wildtype, GalNAcT-/- and GalNAcT-/--
Tg(neuronal) mice (n=3 per group). Innervation of lumbrical muscles 8 weeks following 
sciatic nerve crush. A. Counts of NMJs which were vacant, polyinnervated or 
monoinnervated. No significant differences existed between these groups (p=0.1086, 
Chi squared test). B. Example image from wildtype mouse showing a vacant NMJ 
(asterisk), a polyinnervated NMJ (arrowhead) and monoinnervated NMJs.  
 
3.5.2 Sciatic and tibial nerve light morphometry 
Transverse sections of sciatic and tibial nerves taken 1 and 2 cm distal from the 
crush site respectively, were analysed by light microscopy for myelinated fibres 
(Figure 3.8). As with the lumbrical innervation, there was no significant 
difference between the presences of myelinated fibres in sciatic or tibial nerve 
among any of the genotypes. Compared with control nerves from the 
contralateral leg, the myelinated fibres of crushed sciatic and tibial nerves were 
smaller in caliber, consistent with regenerating fibres. 
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Figure 3.8: Comparison of myelinated fibre presence among wildtype, GalNAcT-/- and 
GalNAcT-/--Tg(neuronal) mice 8 weeks following sciatic nerve crush. Sciatic and tibial 
nerves from each genotype (n=3) were examined by light morphometry for the presence 
of myelinated fibres. Graphs displayed as percentage of control nerve from 
contralateral leg of each animal. No significant differences exist in the number of 
myelinated fibres present among any of the genotypes. One way ANOVA with Tukey’s 
multiple comparison test. 
 
3.6 Discussion 
To confirm that complex gangliosides were not only re-instated but comparable 
to wildtype by immuno-fluorescence, various tissues were screened against a 
panel of antibodies whose binding patterns were known in wildtype tissue. The 
results of this analysis confirmed the expected wildtype binding pattern, with 
strong anti-GD1b antibody staining in all tissues, strong anti-GM1 staining with 
DG2 in all tissues, no anti-GM1 staining with DG1 and no GD1a staining with 
MOG35. Neuronal rescue of GalNAcT and therefore complex ganglioside 
expression, resulted in restored antibody staining in most cases, though to 
varying degrees. NFLTg, and Thy1(112) mice, appeared to have similar or 
increased GD1b expression, as evidenced by the significantly higher binding 
presence of MOG3 staining in most tissues. However, the Thy1(115) mouse 
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appeared to have an uneven GalNAcT expression, with some junctions showing 
positive staining and some showing very little within the same piece of tissue. 
DG2 staining appeared to show lower intensity staining in both neuronal rescue 
lines, indicating that GM1 expression in these mice is lower at the terminal than 
wildtype mice. This is unsurprising considering the lower GalNAcT enzyme 
expression levels in these mice as compared to wildtype mice (Yao et al., 2014). 
However, staining was still present, indicating GM1 was still at the terminal. The 
lack of DG1 antibody binding in these rescue mice provides some degree of 
support that GM1 and GD1a, are presented in the membrane in a similar manner 
to wildtype mice, where GD1a inhibits DG1 binding to GM1 (Greenshields et al., 
2009). The lack of binding of MOG35 in rescue lines also confirmed this 
hypothesis, as, although it has been shown to bind well when GD1a is 
overexpressed (Goodfellow et al., 2005), wildtype binding has never been easy 
to show. Glycoarray analysis of MOG35 (data not shown) showed that this 
antibody is inhibited by GT1b, which is absent in GD3s-/- mice, presumably 
lending to the increased binding in these mice. Therefore with the relative 
similarity in ganglioside expression and membrane placement, it was clear that 
both NFLTg and Thy1(112) mice could be used in future experiments to compare 
to wildtype mice. NFLTg mice were used in all experiments from this point 
onwards and are referred to as GalNAcT-/--Tg(neuronal) mice.   
Despite having confirmed that anti-ganglioside antibody binding is roughly 
similar in intensity between wildtype and GalNAcT-/--Tg(neuronal) mice, the 
nuances of binding are not able to be distinguished in tissue sections, therefore 
whole mount TS was used. The GalNAcT-/--Tg(glial) mouse was included, which 
allowed the visualisation of staining in mice which should have complex 
gangliosides only on glial cells. As expected for the two different rescue strains, 
each showed staining on the structures where GalNAcT had been re-expressed. 
Staining was seen for all antibodies on the neuronal structures in GalNAcT-/--
Tg(neuronal) mice and on the glial structures in GalNAcT-/--Tg(glial)  mice. 
However, in GalNAcT-/--Tg(neuronal) mice, the pSCs also appeared to be stained 
in some cases. The NFL promoter used to drive GalNAcT expression can be found 
to be active in pSCs. Work in this lab has confirmed that SCs from GalNAcT-/--
Tg(neuronal) mice co-cultured along with DRG neurons from GalNAcT-/- mice 
show activation of NFL promoter by NFL mRNA expression, despite no protein 
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expression (G. Meehan, unpublished data). However, when cultured alone, no 
mRNA expression was present. This is not the first time that neurofilament 
promoter activity has been detected in SCs (Sotelo-Silveira et al., 2000), but 
previously the expression has been shown to be transient and only in response to 
axonal injury or demyelination (Fabrizi et al., 1997). Despite this potential for 
additional pSC expression, neuronal reintroduction is clear and previous 
evidence of glial expression of NFL mRNA has been shown to only be in immature 
SCs or SCs which are responding to injury (Haynes et al., 1999;Fabrizi et al., 
1997), therefore the use of this mouse strain is still justified.  
As well as the restored ganglioside synthesis, GalNAcT-/--Tg(neuronal) mice also 
appear phenotypically like wildtype mice, lacking the Parkinson-like tremor 
associated with aged GalNAcT-/- mice (Chiavegatto et al., 2000). A series of 
behavioural tests confirmed that even aged GalNAcT-/--Tg(neuronal) mice 
performed as well as wildtype mice in grip strength, Rotarod and grid walking in 
a recent publication (Yao et al., 2014). Conversely, restoration of complex 
gangliosides in the glia does not prevent the degenerative phenotype seen in 
GalNAcT-/- mice. As previous deficits in gait were also seen in GalNAcT-/- mice 
(Chiavegatto et al., 2000), Digigait™ was used to analyse differences in gait 
parameters between the four genotypes. In this study, mice were between 12 
and 18 months of age; equal to or greater than the age where gait deficits had 
been seen in GalNAcT-/- mice previously (Chiavegatto et al., 2000). GalNAcT-/- 
mice in this previous study were shown to have a reduced stride length, stance 
width and hind paw print length but using the Digigait™, there were no 
significant differences in the equivalent parameters in our mice. However, 
larger variability was seen in each of these parameters between GalNAcT-/- and 
wildtype mice. This means that although the mean values were not different, 
the normal fluctuations seen with these measurements are increased, implying 
movement control is impaired. Interestingly, increases in gait variability were 
seen most often in GalNAcT-/--Tg(glial) mice when compared to wildtype, 
indicating a more severe phenotype than GalNAcT-/- mice. This correlates with 
other behavioural data on these mice where they scored equal to or worse than 
GalNAcT-/- mice (Yao et al., 2014). Morphological characterisation has shown 
that these mice have similar numbers of degenerative axons to GalNAcT-/- mice 
in both peripheral and central nervous system sites, and that these mice have a 
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more pronounced lengthening of Nav1.6 clusters in PNS nodes of Ranvier (Yao et 
al., 2014).  
Due to the apparent rescue of the behavioural phenotype in GalNAcT-/--
Tg(neuronal) mice, it was proposed that the inhibition in nerve regeneration 
observed previously in GalNAcT-/- mice (Kittaka et al., 2008) may also be rescued 
in GalNAcT-/--Tg(neuronal) mice. Previous, unpublished data in this lab has 
shown that 6 weeks following a nerve crush in wildtype mice, approximately 50% 
of lumbrical NMJs are monoinnervated and by 10 weeks, 100% are 
monoinnervated (K. Greenshields, unpublished data). Therefore, to observe 
differences between wildtype, GalNAcT-/- and GalNAcT-/--Tg(neuronal) strains, 
an intermediate 8 week timepoint was chosen. However, by lumbrical analysis 
alone, there was no difference in the stage of regeneration between strains. 
This indicated there was no initial difference between wildtype and GalNAcT-/- 
mice at this time point and therefore nothing to be “rescued” in GalNAcT-/--
Tg(neuronal) mice. The initial study showing impaired regeneration in GalNAcT-/- 
mice had shown inhibited regeneration in the hypoglossal nerve. Regeneration 
was scored by the number of HRP positive neurons following injection of HRP in 
the tongue (Kittaka et al., 2008). There is a possibility that by simply scoring the 
lumbricals as “monoinnervated”, we have not taken into consideration earlier 
branching of the axon, therefore one motor axon may for instance be 
innervating more than one NMJ, until appropriate pruning takes place, meaning 
retrograde HRP transport may be directed to a smaller number of neurons. 
Therefore had we analysed it in the same fashion as Kittaka et al, there may 
have been more of an indication of inhibited regeneration. However, the animals 
appeared to have regained function of their legs by this timepoint indicating 
that if there was any impaired regeneration in GalNAcT-/- mice, it was subtle. In 
addition, the similar numbers of myelinated fibres in the sciatic and tibial nerves 
provide further evidence that no major regeneration differences exist among 
these genotypes. The results of this study do appear to correlate with a previous 
study in this laboratory whereby GalNAcT-/- mice also regenerated at the same 
rate as wildtype mice following a very site-specific distal injury of the motor 
nerve terminal (Rupp et al., 2013). Gangliosides have been proposed to have a 
role in regeneration due to the enhanced nerve regeneration seen following 
exogenous ganglioside injection (Itoh et al., 1999;Kittaka et al., 2008). In 
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GalNAcT-/- mice, the over-expression of simple gangliosides GM3, GD3 and GT3 
may compensate for the lack of complex gangliosides, meaning the overall 
effect on regeneration is not large enough to be seen in the paradigm described 
here.  
This chapter has delivered some information on the binding profiles of GalNAcT-
/--Tg(neuronal) and GalNAcT-/--Tg(glial)  mice in comparison to GalNAcT-/- and 
wildtype mice using various antibodies, as well as providing some basic 
characterisation of gait and regeneration in these newly developed mice.  
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4 Development of an active immunisation model of GBS 
4.1 Introduction 
Inherent self-tolerance to gangliosides prevents wildtype mice from mounting an 
antibody response when immunised with gangliosides. Therefore, in order to 
model the effects of anti-ganglioside antibodies in vivo, wildtype mice 
containing the target ganglioside on their peripheral nerve membranes must be 
injected with monoclonal antibodies produced from GalNAcT-/- or GD3s-/- mice 
which lack the intended target antigen. This has proven to be a successful way 
of modelling the anti-ganglioside antibody mediated injury of peripheral nerves 
in vivo (Halstead et al., 2004;Halstead et al., 2008). However, this does not 
mimic the induction of disease in patients, where antibodies are produced by 
individuals who lack tolerance to gangliosides and therefore produce an antibody 
reaction. The GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mouse strains 
were created as a means to overcome tolerance in wildtype mice while still 
retaining target on disease-relevant sites. Indeed, in an earlier pilot study in this 
laboratory, GalNAcT-/--Tg(neuronal) mice were shown to produce an immune 
response when immunised with GT1b-containing liposomes (S. Rinaldi, 
unpublished data). When these mice were injected with NHS to induce an injury, 
there was no difference in motor control or co-ordination by behavioural testing 
methods. Plethysmography data did show a reduction in tidal volume at later 
timepoints, indicating diaphragm injury. Weak presence of complement pathway 
components overlying the diaphragm NMJs was also seen. In this chapter, 
GalNAcT-/- mice serve as a negative control for all behavioural and 
immunohistological tests as their lack of GD1b target ganglioside means no 
antibody binding and injury should occur. 
4.2 Passive immunisation of mice with anti-GD1b antibody 
Based on the high binding of anti-GD1b antibodies MOG3 and MOG1 in wildtype 
mice and both strains of rescue mice (Chapter 3), GD1b was the antigen of 
choice for trialling an active immunisation in the transgenic mouse lines. A 
preliminary passive immunisation model was used to demonstrate the ability of 
antibodies targeting GD1b to injure the membrane in vivo, as measured by 
behavioural testing and plethysmography, and ex vivo, by immunofluorescent 
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analysis of the diaphragm. The injection of antibody was accompanied 16 hours 
later by the injection of NHS to induce complement-mediated injury. This 
protocol has been used previously to demonstrate anti-GQ1b antibody’s ability 
to cause damage to motor nerve terminals in vivo (Halstead et al., 
2004;Halstead et al., 2008). The diaphragm is used as a site of interest as it has 
rich motor innervation from the phrenic nerve and is a muscle which lies in close 
proximity to the injection sites of antibody and NHS. It is therefore a muscle 
which is likely to be measurably injured. The antibody used to passively 
immunise the mice was MOG1. Three animals (4-6 weeks old) were used per 
genotype, however due to an unsuccessful NHS injection (subcutaneous injection 
rather than i.p.) in one GalNAcT-/--Tg(neuronal) mouse, this mouse was excluded 
from all injury analysis, but was included when assessing antibody deposition at 
the diaphragm NMJs. 
4.2.1 Behaviour and plethysmography 
Mice did not appear to be affected by antibody injection alone, with the 
exception of one wildtype mouse which seemed to be less active than its two 
counterparts. Following injection of NHS, all wildtype mice appeared very ill, 
with pinched abdomens (example best displayed in image of GalNAcT-/--
Tg(neuronal) mouse, Figure 4.1A), and laboured breathing. They also had 
difficulty moving (wildtype mouse seen in Figure 4.1A shown with splayed hind-
limbs) but this may have been as a consequence of their breathing difficulties 
rather than direct muscle impairment. Rotarod testing performed 2 hours post 
NHS injection indicated a very sharp, significant decrease in their latency to fall 
(one-way ANOVA, p<0.01 vs baseline), as mice were unable to maintain their 
normal running speed or grip onto the Rotarod (Figure 4.1B). In contrast, 
GalNAcT-/- mice appeared normal following NHS injection with no change in 
Rotarod testing score (Figure 4.1B). GalNAcT-/--Tg(neuronal) mice also appeared 
ill, though not as severely as wildtype mice. Performance on Rotarod was 
significantly decreased versus baseline (one-way ANOVA, p<0.01 vs baseline) 
(Figure 4.1B). Although GalNAcT-/--Tg(glial) mice appeared more lethargic than 
GalNAcT-/- mice, they did not appear to have any breathing difficulties and 
lacked the pinched waist seen in wildtype and GalNAcT-/--Tg(neuronal) mice. 
Despite this, Rotarod performance was significantly decreased in GalNAcT-/--
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Tg(glial) mice post-NHS compared to baseline (one-way ANOVA, p<0.05 vs 
baseline).  
Whole body plethysmography was performed to indicate deficits in diaphragm 
function, as measured by tidal volume. Wildtype mice showed a decrease in tidal 
volume, reaching significance compared to baseline from 90 minutes post-NHS 
injection (two-way ANOVA, p<0.05), and continuing to decrease at 120 minutes 
(two-way ANOVA, p<0.01). Similarly, GalNAcT-/--Tg(neuronal) mice showed a 
decrease in tidal volume, reaching significance at 120 minutes (two-way ANOVA, 
p<0.05). No significant decrease was seen in either GalNAcT-/- or GalNAcT-/--
Tg(glial) mice, though GalNAcT-/--Tg(glial) mice did trend towards a decrease in 
tidal volume over time (Figure 4.1C). Respiratory rate did not appear to be 
affected by NHS injection as no significant changes from baseline were observed 
in any mouse strain following NHS (Figure 4.1D). 
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Figure 4.1: In vivo analysis of injury in wildtype, GalNAcT-/-, GalNAcT-/--Tg(neuronal) 
and GalNAcT-/--Tg(glial) mice following MOG1 + NHS mediated injury. A: Wildtype 
mice (n=3) appeared very sick, were unable to support weight and had pinched waists 
whereas GalNAcT-/- mice (n=3) appeared normal. GalNAcT-/--Tg(neuronal) mice (n=2 for 
this analysis) also had pinched waists. GalNAcT-/--Tg(glial) mice (n=3) appeared 
lethargic but were otherwise normal. B: Rotarod analysis showed a vast decrease in 
latency to fall in wildtype mice post-NHS vs pre NHS. GalNAcT-/--Tg(neuronal) and 
GalNAcT-/--Tg(glial) also showed significantly lower scores post-NHS. GalNAcT-/- mice 
scored no differently. *=p<0.05, **=p<0.01, ****=p<0.0001, two-way ANOVA with Sidak’s 
multiple comparison’s test.  C: Tidal volume was significantly lower than baseline from 
90 minutes onwards in wildtype mice. The same occurred in GalNAcT-/--Tg(neuronal) 
mice after 120 minutes. No significant differences were observed in GalNAcT-/- or 
GalNAcT-/--Tg(glial) mice. D: No difference was seen in respiratory rate with the 
exception of an increase between baseline and pre-NHS in GalNAcT-/--Tg(glial) mice. 
*=p<0.05, **=p<0.01, two-way ANOVA with Dunnett’s multiple comparison’s test. E: 
Example breath traces from the four mouse strains at baseline and 60 minutes post-
NHS.  
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4.2.2 Tissue analysis 
Diaphragms taken from the mice at sacrifice 3-4 hours post NHS were sectioned 
at 8 µm and analysed for presence of IgG3, C3, MAC and NFil as described in 
section 2.16. Both wildtype and GalNAcT-/--Tg(neuronal) mice showed deposition 
of IgG3 at the NMJ, indicating MOG1 antibody had bound there following 
injection (Figure 4.2A). GalNAcT-/- mice were negative for IgG3. Although some 
antibody was present in GalNAcT-/--Tg(glial) mice, it was often not found 
directly over the BTx signal, instead appearing to be on pSC cell bodies, but not 
on the processes covering the NMJ. Corresponding to the deposition of IgG3, 
wildtype and GalNAcT-/--Tg(neuronal) mice also showed C3 deposition whereas 
GalNAcT-/- mice were negative for C3 staining. The GalNAcT-/--Tg(glial) mice 
which had showed little IgG3 deposition directly overlying the BTx signal, 
showed strong C3 deposition, both overlying BTx and again on pSC cell bodies. 
Deposition of MAC was also present in wildtype, GalNAcT-/--Tg(neuronal) and 
GalNAcT-/--Tg(glial) mice and absent in GalNAcT-/- mice, indicating culmination 
of the complement cascade following C3 deposition. The presence of NFil was 
significantly reduced in wildtype, GalNAcT-/--Tg(neuronal) and GalNAcT-/--
Tg(glial) mice compared to GalNAcT-/-. The GalNAcT-/- mice also did appear to 
have a lower than expected NFil presence, however this was similar to PBS 
control (PBS control data not shown).  
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(Figure on previous page) 
Figure 4.2: Ex vivo analysis of diaphragm injury in wildtype, GalNAcT-/-, GalNAcT-/--
Tg(neuronal) and GalNAcT-/--Tg(glial) mice following MOG1 + NHS mediated injury. 
A: IgG3 was deposited over nerve terminals of wildtype and GalNAcT-/--Tg(neuronal) 
endplates. Little was present directly over the BTx signal of GalNAcT-/--Tg(glial) mice 
endplates, though staining was seen on what appeared to be pSC cell bodies. Negligible 
amounts were present on the nerve terminals of GalNAcT-/- mice. B: C3 was deposited 
over the nerve terminals of wildtype, GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) 
mice with GalNAcT-/--Tg(neuronal) mice showing significantly higher deposition than 
wildtype and GalNAcT-/--Tg(glial). Negligible amounts of C3 were present on GalNAcT-/- 
mice endplates. C: MAC deposits were also seen in wildtype, GalNAcT-/--Tg(neuronal) 
and GalNAcT-/--Tg(glial) mice and were absent in GalNAcT-/- mice. D: NFil overlying the 
BTx signal was reduced in wildtype, GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) 
mice compared with GalNAcT-/-, with wildtype mice showing the lowest NFil presence. 
*=p<0.05, **=p<0.01, ****=p<0.0001, Kruskal-Wallis with Dunn’s multiple comparison 
test. A minimum of 228 NMJs were analysed per group. Non-parametric data displayed 
as Tukey box plot (see section 2.20). 
 
4.3 Active immunisation of mice with GD1b-containing liposomes 
Initial immunisations were performed as per a previously used immunisation 
protocol in GalNAcT-/- and wildtype mice (Bowes et al., 2002). These 
immunisations (protocol A) resulted in a successful immune response in all mice 
but no injury was detectable by behavioural tests, plethysmography or tissue 
analysis (data not shown). To attempt to gain a larger immune response in a 
shorter period of time, immunisations were performed using a slightly modified 
protocol which combined the hapten-carrier-like effect of ova-containing 
liposomes used in protocol A, with the adjuvant effect of monophosphoryl lipid a 
(MPLA) into a short series of immunisations spaced closer together (protocol B). 
Lipid A is a derivative of endotoxin lipopolysaccharide (LPS) found on the coats 
of gram negative bacteria such as C. jejuni. It is often used as an adjuvant due 
to its ability to bind to TLR4 on antigen presenting cells, enhancing the antigen-
specific antibody response (Alving et al., 2012). 
4.3.1 Immune response 
Blood samples were taken on day 0, 19 and 22 with terminal samples taken on 
day 25-27 (mice were culled in batches of 4 over these days). Serum was tested 
by ELISA against GD1b and analysed by two-way ANOVA with Tukey’s multiple 
comparison’s test.  
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4.3.1.1 IgM response 
All groups showed a rise in serum OD values over the immunisation period, with 
wildtype mice being consistently lower than all other groups (Figure 4.3), though 
only significantly lower than GalNAcT-/- mice sera values at the day 22 timepoint 
(p<0.05). Serum analysis by glycoarray was performed at day 22 to indicate the 
pattern of immune response to liposome components plus two structurally 
similar gangliosides, GM1 and GT1b. Despite some small cross reactivity with 
GT1b and its complexes in some mice (regardless of genotype, examples shown 
in Figure 4.3B) the immune response seemed to be specific to GD1b and its 
complexes. Sphingomyelin and GM1 appeared to consistently inhibit binding to 
GD1b. Reflecting the day 22 ELISA data, GalNAcT-/- mice sera showed the 
strongest glycoarray binding signals against GD1b, wildtype the weakest and 
rescue mice lay somewhere in the middle. Some mice, regardless of genotype, 
also showed responses to DCP alone and all mice showed responses to 
cholesterol alone, though cholesterol reactivity is commonly found in naïve mice 
also (G. Meehan, unpublished data). 
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Figure 4.3: IgM reactivity in GD1b-immunised mice. A: Serum IgM response to GD1b by 
ELISA. All groups had a baseline IgM response which rose over time. Wildtype mice 
showed lower OD values than other groups at day 19, 22 and terminal, though was only 
significantly lower than GalNAcT-/- at day 22. B: Glycoarray analysis showing illustrative 
IgM responses at day 22 to GD1b and other liposome components both alone and in 
complex. A weak signal against GD1b is present in the wildtype mouse, whereas the 
GalNAcT-/- mouse shows strong reactivity to GD1b. GalNAcT-/--Tg(neuronal) and 
GalNAcT-/--Tg(glial) mice show very similar GD1b signals. All mice do also show 
reactivity to some other liposome components. Arrays are read by reading along both 
axes to find the resulting combination of lipids, with a line of symmetry marked by 
white crosses. The GD1b columns are highlighted by a red box. *=p<0.05 vs wildtype, 
two-way ANOVA with Tukey’s multiple comparison test. 
 
4.3.1.2 IgG response 
No IgG response was detectable by ELISA until the day 22 timepoint, following 
the 3 i.v. booster injections (Figure 4.4). At this timepoint, wildtype mice sera 
showed significantly lower IgG reactivity than GalNAcT-/- sera and GalNAcT-/--
Tg(glial) sera (p<0.0001 vs. GalNAcT-/- and p<0.01 vs. GalNAcT-/--Tg(glial). 
Optical density values of GalNAcT-/--Tg(neuronal) mice sera were not 
significantly different  from wildtype sera at day 22 and were significantly lower 
than GalNAcT-/- mice sera at this timepoint (p<0.01). GalNAcT-/- mice sera show 
a further increase in OD at the terminal timepoint, with OD values remaining 
significantly higher than wildtype and GalNAcT-/--Tg(neuronal) mice sera and 
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being also now significantly higher than GalNAcT-/--Tg(glial) mice sera (p<0.0001 
vs wildtype, p<0.01 vs. GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial)). Both 
GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mice sera showed significantly 
higher OD values than wildtype mice at the terminal timepoint (Figure 4.4A). 
Glycoarrays of IgG responses showed similar patterns to IgM responses with GD1b 
and its complexes showing up in the sera from all genotypes. GD1b signal again 
showed similar patterns to that seen by ELISA at day 22 with GalNAcT-/- sera 
showing the strongest signal, followed by GalNAcT-/--Tg(glial),  GalNAcT-/--
Tg(neuronal) then wildtype mice sera. Sphingomyelin again appeared to inhibit 
the signal of GD1b alone and whereas only some mice showed reactivity to other 
liposome components, all mice sera showed cholesterol reactivity. 
 
 
Figure 4.4: IgG reactivity in GD1b-immunised mice. A: Serum IgG response to GD1b by 
ELISA. No significant difference was present among groups until day 22 when wildtype 
mice showed significantly lower OD values than GalNAcT-/- and GalNAcT-/--Tg(glial) 
mice. By the terminal timepoint wildtype mice had significantly lower OD values than 
all other groups. B: Glycoarray analysis showing illustrative IgG responses at day 22 to 
GD1b and other liposome components both alone and in complex. A weak GD1b signal is 
present in the wildtype and GalNAcT-/--Tg(neuronal) mouse whereas the GalNAcT-/- and 
GalNAcT-/--Tg(glial) mouse show stronger reactivity to GD1b. As with IgM, all mice also 
show reactivity to other some other liposome components. * denotes significance vs. 
wildtype, # denotes significance vs. GalNAcT-/-, two-way ANOVA with Tukey’s multiple 
comparison test. The GD1b column is highlighted by a red box. 
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4.3.2 Behavioural testing and plethysmography 
Following injection of NHS, no significant changes were seen in Rotarod 
performance in any of the groups (Figure 4.5). Tidal volume did not show major 
differences among groups over time (Figure 4.5A). The only differences were 
seen between wildtype and GalNAcT-/--Tg(glial) 60 minutes post NHS (p<0.05). 
Similarly, though most groups showed a decline in respiratory rate from pre-NHS, 
no significant differences were observed among groups, indicating that these 
changes were not due to anti-GD1b related immune injury and may instead be 
due to the higher volume of NHS injected (Figure 4.5B). Some additional 
behavioural tests were employed to try and detect injury in the active 
immunisation paradigm (Figure 4.5E). No significant differences were observed 
in the mouse’s latency to walk from an open balance beam to an enclosed 
platform, nor in either forelimb or total grip strength.  
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Figure 4.5: Rotarod and plethysmography data from immunised mice both before 
and after NHS injection. A: Rotarod data (n=3 per group) no significant difference was 
observed following NHS injection in any group (two-way ANOVA with Sidak’s multiple 
comparison’s test). B: Tidal volume shown as a percentage of baseline values (before 
NHS was given). Following NHS injection little change was seen. The only significant 
difference among groups was between wildtype and GalNAcT-/--Tg(glial) at 60 minutes 
(p<0.05). C: Respiratory rate shown as a percentage of baseline values. All groups 
showed a slight reduction in respiratory rate however no significant change was 
observable among groups at any timepoint. D: Example breath traces from genotypes 
both pre-NHS and 90 minutes post-NHS. E: Additional behavioural tests showing no 
significant difference between pre and post NHS. *=p<0.05, two-way ANOVA with 
Dunnett’s multiple comparison’s test. 
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4.3.3 Tissue analysis 
Diaphragms taken from mice 3-4 hours post-NHS injection were sectioned at 8 
µm and analysed for presence of IgG, IgM C3, MAC and NFil as described in 
section 2.16 (Figure 4.6, IgG data not shown). Neither IgM (Figure 4.6A) nor IgG 
(data not shown) was present on the nerve terminals of any mouse strain at 
detectable levels (median of 0.00 for all groups) even though circulating 
antibodies were found in the serum. In spite of this, some C3 activation 
appeared to have occurred. Despite some high background, C3 activation was 
lower in GalNAcT-/- mice in comparison to wildtype, GalNAcT-/--Tg(neuronal) and 
GalNAcT-/--Tg(glial) mice (median of 12.00 AU vs. 39.00, 71.00 and 94.00 
respectively). Despite the deposition of C3, no MAC deposition was seen in any 
mouse group and as a result, no injury was seen to the NFil. In fact wildtype and 
GalNAcT-/--Tg(neuronal) mice had a higher percentage of NFil presence at the 
endplate than GalNAcT-/- mice.  
Tissue was also analysed for presence of immune cells using CD11b as a pan-
immune cell marker, though all diaphragms were found to be negative (sciatic 
nerve taken 7 days post crush was used as positive control). This work was 
carried out by Su Yan, as part of her project for the degree of Master of 
Research. 
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(Figure on previous page) 
Figure 4.6: Analysis of diaphragm from actively immunised mice following NHS 
injection. A: IgM was not detectable at the nerve terminals of mice from any group 
(n=3 per group). B: C3 was deposited over the nerve terminals of wildtype, GalNAcT-/--
Tg(neuronal) and GalNAcT-/--Tg(glial) mice with little to none present in GalNAcT-/- 
mice. C: MAC was not deposited over the nerve terminals of mice in any group despite 
C3 activation. D: NFil was present overlying the BTx signal but was lower in GalNAcT-/- 
and GalNAcT-/--Tg(glial) mice compared with wildtype and GalNAcT-/--Tg(neuronal). 
*=p<0.05, ***=p<0.001, ****=p<0.0001, Kruskal-Wallis with Dunn’s multiple comparison 
test. A minimum of 246 NMJs were analysed per group. Non-parametric data displayed 
as Tukey box plot (see section 2.20). 
 
4.3.4 Topical complement assay 
To assess whether the serum from the actively immunised mice was able to 
exert pathogenic effects ex vivo, a topical complement assay was performed 
with serum taken from these mice (n=3 per genotype). Serum was applied to 
fresh frozen sections of naïve wildtype diaphragm, followed by incubation with 
4% NHS to induce complement activation. Sera from all genotypes failed to 
induce MAC deposition (Figure 4.7.A). Diaphragm incubated with 10 µg/ml MOG1 
antibody served as a positive control. 
108 
 
 
Figure 4.7: Serum from actively immunised mice does not result in MAC deposition 
in wildtype diaphragm. A: Serum from GD1b-immunised wildtype, GalNAcT-/-, GalNAcT-
/--Tg(neuronal) and GalNAcT-/--Tg(glial) failed to produce MAC following incubation with 
NHS  in wildtype diaphragm sections. Incubation with MOG1 monoclonal antibody as a 
positive control did.  B: Illustrative images showing absence of MAC deposition overlying 
BTx signal following treatment with actively immunised mouse serum followed by NHS. 
MOG1 incubation followed by NHS results in MAC presence at the endplate. A minimum 
of 261 NMJs were analysed per group. Non-parametric data displayed as Tukey box plot 
(see section 2.20). 
 
4.3.5 ELISpots 
To confirm that the differences in immune responses to GD1b seen in the serum 
of actively immunised mice was due to differential activation of B cells, ELISpots 
were performed using splenocytes taken from actively immunised mice upon 
sacrifice (Figure 4.8, n=3 per group). IgM reactive spot numbers were higher 
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than IgG. Though no significant difference existed among any of the genotypes, 
spots were most numerous from splenocytes from GalNAcT-/- mice probed for 
both IgM and IgG (4.28±1.14 spots/106 cells and 1.67±1.20 spots/106 cells, 
respectively). As a secondary measure of GD1b-specific B-cell activity, 
splenocytes were kept alive in RPMI with 20% FCS for 7 days and supernatant 
collected on day 7, concentrated 5x and tested by ELISA. Again no significant 
difference existed among the genotypes but GalNAcT-/- mice showed the highest 
OD value in the IgG ELISA (0.65±0.45 OD).  Due to the high background in the 
negative wells of the IgM plate, values appeared low all around, with wildtype 
mice showing the highest OD values (0.20±0.12 OD). 
This result implied that the anti-GD1b response between wildtype and GalNAcT-/- 
was similar, despite a significant difference being observed in serum antibody 
levels by ELISA. The immunisation was repeated using only wildtype and 
GalNAcT-/- mice to confirm this result. In this instance cells were plated at 3x105 
cells/well. Once again no significant difference was observed between the 
wildtype and GalNAcT-/- anti-GD1b specific immune response for either IgM 
(6.75±3.65 vs. 5.33±1.054 spots/3x105 cells respectively) or IgG (0.25±0.16 vs. 
1.167±0.726 spots/3x105 cells respectively). Once again IgM values were higher 
than IgG (Figure 4.9).  
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Figure 4.8: Immune reactivity of various mouse strains to GD1b liposomes. 
Splenocytes from immunised mice were cultured from spleens taken upon sacrifice and 
maintained in T25 flasks for 7 days. On day 2 ELISpot analyses was performed by 
applying 106 cells/well to a GD1b coated plate. A: Representative ELISpot wells probed 
for IgG or IgM. B: GD1b-specific IgM and IgG spot production from immunised mice and 
control naïve mice. No significant differences existed among groups (one-way ANOVA 
with Tukey’s multiple comparison test) C: Supernatant from splenocytes was removed 
after 7 days and analysed for GD1b-specific IgM and IgG production. No significant 
differences existed among groups (one-way ANOVA with Tukey’s multiple comparison 
test). 
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Figure 4.9: ELISpot analysis of spleen B cell reactivity to GD1b liposome. Splenocytes 
from GD1b-immunised wildtype and GalNAcT-/- mice (n=4 per group) mice were applied 
to a GD1b-coated plate at 3x105 cells/well. A: No significant difference was observed 
between the spot number of wildtype and GalNAcT-/- mice (one-way ANOVA). Control 
mouse was unimmunised (n=1) and showed no GD1b-specific response. B: 
Representative ELISpot wells probed for GD1b-specific or total IgG or IgM. 
 
4.4 Discussion 
The passive immunisation protocol used in this study has been used before to 
demonstrate anti-ganglioside antibody mediated injury to wildtype diaphragm in 
a MFS mouse model (Halstead et al., 2004;Halstead et al., 2005a;Halstead et al., 
2008). Passive immunisation of wildtype, GalNAcT-/--Tg(neuronal) and GalNAcT-/-
-Tg(glial) mice did result in a detectable injury in vivo, with wildtype and 
GalNAcT-/--Tg(neuronal) mice showing reduced tidal volumes indicating 
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diaphragm injury. These mice, and the GalNAcT-/--Tg(glial) mice also showed 
reduced ability to stay on the Rotarod. This is most likely due to diaphragm 
injury resulting in breathing difficulties rather than functional deficits in the 
limb muscles, as the NHS is unlikely to be systemically distributed at this 
timepoint (Halstead et al., 2008). GalNAcT-/--Tg(glial) mice were less severely ill 
and diaphragms showed lower IgG3 deposits over the endplate, but there was 
some loss of neurofilament. In ex vivo TS preparations, GalNAcT-/--Tg(glial) mice 
show MOG1 binding on pSC cell bodies and the processes they extend over the 
nerve terminal. IgG3 deposits in the diaphragms of passively immunised mice 
appeared to show strongest staining on the cell bodies and not the processes. 
Therefore, it is unclear whether the loss of NFil seen in these mice is due to 
direct complement activation on the processes (antibody may be present but 
much lower than staining on cell bodies), resulting in a secondary loss of NFil 
from lack of pSC support, or if the nerve terminal itself is subjected to bystander 
injury due to its close proximity to the pSCs. A previous study using ex vivo 
hemidiaphragms has shown that pSC injury without nerve terminal damage is 
possible, therefore the former assumption is the most likely in this instance 
(Halstead et al., 2005b). This also may explain why the GalNAcT-/--Tg(glial) mice 
did not appear to be as severely affected as wildtype and GalNAcT-/--
Tg(neuronal) mice at the earlier stages of behavioural testing, but GalNAcT-/--
Tg(glial) mice did trend towards lower tidal volume by the 120 minute timepoint 
and showed a reduced Rotarod performance which again was 2-3 hours post NHS 
treatment.  
As the passive immunisation with MOG1 showed a quantifiable injury in wildtype 
and both rescue strains, an attempt was made to actively immunise these mice 
then to use NHS to induce an injury. This followed on from a previous 
unpublished study by Dr S. Rinaldi, where GalNAcT-/--Tg(neuronal) mice were 
successfully immunised with GT1b-containing liposomes to produce anti-GT1b 
antibodies. Using GD1b-containing liposomes, this study has shown that these 
mice and additionally the GalNAcT -/--Tg(glial) mice can be successfully 
immunised with GD1b-containing liposomes, producing both IgM and IgG 
antibodies against GD1b at intermediate levels compared to GalNAcT-/- and 
wildtype mice, which produce higher and lower responses respectfully. The low 
serum presence of antibodies in wildtype mice compared with GalNAcT-/- mice 
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corresponded with previous immunisation studies using these mice in active 
immunisation studies (Bowes et al., 2002;Lunn et al., 2000). Since GalNAcT-/--
Tg(neuronal) and GalNAcT-/--Tg(glial) mice are able to produce antibodies 
against a target ganglioside, they clearly do not possess the same level of 
tolerance as wildtype mice. It is unknown precisely why these mice lack 
tolerance to a self-lipid. It may be that the lower levels of enzyme expression 
result in levels of target antigen production which are below the critical 
threshold for induction of tolerance. B cells which are autoreactive can avoid 
deletion if antigen levels are low enough. These cells are termed to be clonally 
ignorant (Thomas, 2001). Alternatively, the global KO of the B4galnt1 gene in 
these mice may result in the developing B cells being unexposed to the presence 
of GD1b which is only re-introduced in neurons and glia of GalNAcT-/--
Tg(neuronal) and GalNAcT-/--Tg(glial) mice, respectively. In the thymus, T cells 
are presented with tissue-specific antigens by means of the autoimmune 
regulator gene Aire, which promotes expression of genes which are only present 
in specialised peripheral tissues. This process allows any self-reactive T-cells to 
be deleted (Liston et al., 2003). The bone marrow, on the other hand, does not 
have an equivalent regulatory mechanism for tissue-specific antigen 
presentation. B cells may therefore not be presented with GD1b in GalNAcT-/--
Tg(neuronal) and GalNAcT-/--Tg(glial) mice, allowing them to react with target 
upon immunisation. 
Based on the wildtype mice’s apparent tolerance to GD1b resulting in the low 
presence of antibody in the serum, it was unsurprising that no injury was 
detectable by in vivo testing or ex vivo diaphragm analysis. Similarly, with 
GalNAcT-/- mice, injury to NMJs would not be expected as these mice do not 
contain the target antigen. Despite a detectable level of both IgG and IgM 
antibody in the serum of GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mice 
and the known expression of the target antigen, these mice also did not show 
any behavioural or functional changes and negligible immunoglobulin was 
detectable at the endplate. C3 was however present at the nerve terminals of 
all mice groups which express GD1b (wildtype, GalNAcT-/--Tg(neuronal) and 
GalNAcT-/--Tg(glial)). Despite this, no MAC deposition occurred and 
subsequently, differences in NFil at the endplate are not likely due to antibody 
and complement-mediated injury. Unexpectedly, NFil presence was lower in 
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GalNAcT-/- and GalNAcT-/--Tg(glial) mice. Although these mice are approximately 
3 months old at time of sacrifice, they may already be showing some of the 
degenerative phenotype associated with aged GalNAcT-/- and GalNAcT-/--Tg(glial) 
mice (Yao et al., 2014). 
As it has proven difficult to show any injury at mouse endplates using anti-
ganglioside antibody alone, NHS is administered to induce injury. This is thought 
to overcome the endogenous mouse complement regulators which prevent 
cascade activation as these regulators do not affect human complement. It is 
possible that levels of antibody were so low that only low levels of human C3 
were activated. This may allow endogenous soluble complement regulating 
factors present in the administered NHS to prevent the activation of the 
terminal pathway. S protein is one soluble factor which acts on the C5b-9 
complex, preventing it from inserting into the membrane (Podack et al., 1978). 
If this was present in sufficient amount in the NHS injected into the mice, it may 
have inhibited MAC deposition thereby preventing injury to the NFil at the nerve 
terminal. This effect may only be apparent when antibody levels are relatively 
low. Alternatively, the antibodies seen in the serum of these mice may not be 
pathogenic antibodies. Instead these antibodies may be cis-inhibited by 
surrounding glycolipids, preventing binding to GD1b when it is in complex with 
other gangliosides or lipids. This effect has been demonstrated before with many 
ganglioside-binding ligands (Greenshields et al., 2009;Rinaldi et al., 2009;Rinaldi 
et al., 2013). Glycoarray analysis of serum at day 22 showed inhibition by GM1 
fairly consistently in all mouse strains which could result in decreased binding at 
the nerve terminal, where GM1 is known to be expressed (Hansson et al., 
1977;Ganser et al., 1983). Results from the topical application of the sera from 
the actively immunised mice followed by 4% NHS were consistent with results 
from the in vivo work with no MAC deposition occurring. 
As GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mice showed intermediate 
serum levels of antibody compared with the low values seen in wildtype and the 
higher values seen in GalNAcT-/- mice, ELISpots were performed to measure 
differences in the immune response more directly than serum analysis. No 
significant difference was observed in the GD1b-specific IgG and IgM production 
among the mice groups, indicating that the levels of antibody seen in the serum 
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were not reflective of the antibody being produced at a plasma cell level. 
However, the trend was towards a higher production in GalNAcT-/- mice.  
The successful immunisation of these mice but inability for the antibodies 
produced to cause injury could have been caused by a number of factors. Firstly, 
the antibodies may not have been produced at high enough concentrations; spot 
numbers were low in ELISpots. Secondly, the antibodies may not have been 
pathogenic. Antibodies can be prevented from binding their target epitope by 
surrounding structures, rendering them non-pathogenic (Greenshields et al., 
2009). However the activation of C3 at the endplates, suggest that at least some 
of the antibodies produced have the ability to bind. In reality it is likely that a 
combination of these factors is preventing sufficient complement activation and 
MAC deposition to result in a measurable injury, with only a portion of the 
already low-level of antibodies produced being pathogenic. Further 
improvements to the immunisation protocol may result in an increased antibody 
production and thus increase the likelihood of producing a measurable injury.  
The necessity of NHS administration is in some ways beneficial, as it means we 
can control when injury is introduced in these mice. However, one single NHS 
injection may not be the optimal way of inducing injury in a long-term 
immunisation model, where mice have constant, low levels of circulating 
antibodies. Indeed, it was unsurprising that no infiltration of immune cells were 
seen at the diaphragm so soon after a single NHS injection. A protocol involving 
regular, small injections of NHS, may be more likely to produce a successful 
active immunisation model which more keenly reflects the clinical situation. 
The most intriguing factor of these results was that despite no significant 
differences in antibody production at a plasma cell level, there were significant 
differences in the serum of the four different mouse groups. In particular it 
appeared that wildtype mice, despite having a very low serum presence of anti-
GD1b antibodies, showed almost equal IgM production to GalNAcT-/--
Tg(neuronal) mice by ELISpot and splenocyte supernatant ELISA, and only 
slightly lower production of IgG by the same methods. It was hypothesised that 
the difference between the serum levels and the actual antibody production may 
be caused by the previously demonstrated ability of cells, particularly the motor 
nerve terminal, to internalise antibody (Fewou et al., 2012;Iglesias-Bartolome et 
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al., 2006;Iglesias-Bartolome et al., 2009). This possibility was therefore 
addressed in the remainder of this thesis. 
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5 Ability of the NMJ to clear anti-GD1b antibody 
5.1 Introduction 
As described in the previous chapter, circulating anti-GD1b antibody was present 
in the sera of GalNAcT-/--Tg(neuronal) and GalNAcT -/--Tg(glial) mice after active 
immunisation with GD1b liposomes. These levels were somewhat intermediate 
compared to levels in wildtype mice and GalNAcT-/- mice, which showed lower 
and higher OD values by ELISA respectively. These intermediate levels of 
circulating antibody were not able to induce any functional deficits in these 
mice when NHS was given i.p., though they did induce some minor evidence of 
complement activation at the NMJ itself. Despite the differences seen in serum 
levels of antibody, ELISpots performed on splenocytes from immunised mice 
showed that no statistically significant difference in antibody production existed 
between the responses of any of the genotypes. Taking into account these 
findings, along with the knowledge that antibodies against gangliosides can be 
taken up at wildtype and GD3s
-/- mouse motor nerve terminals (Fewou et al., 
2012), it was hypothesised that antibodies are produced to a similar degree in all 
genotypes, but levels of antibody in the serum may be being affected by this 
internalisation.  
The aim of this chapter is to investigate the phenomenon of anti-ganglioside 
antibody internalisation, especially at the NMJ, utilising GalNAcT-/--Tg(neuronal) 
and GalNAcT-/--Tg(glial) mice to look at membrane-specific uptake, and to 
determine whether the internalisation here is enough to affect the circulating 
levels of anti-ganglioside antibody in vivo. As this chapter followed on from 
investigations performed in mice which were immunised with GD1b, the anti-
GD1b antibody MOG1 was used in all studies in this chapter. 
5.2 Ex vivo uptake of anti-GD1b antibody 
Whole mount TS preparations were used to investigate the internalisation of 
MOG1 ex vivo. This has been done before previously in wildtype mice, but the 
present study has included GalNAcT-/--Tg(neuronal), GalNAcT-/--Tg(glial) mice 
and GalNAcT-/- mice. Where possible, the same endplate was imaged pre and 
post-permeabilisation. For full methods please refer to Chapter 2 section 2.10.3. 
118 
 
Wildtype mice showed strong neuronal presence of antibody immediately after 
incubation with MOG1 (0 minutes timepoint, median 85.00 AU), with no apparent 
staining of pSCs (Figure 5.1A, B). Following incubation at 37oC for 30 minutes, a 
reduction in the levels of antibody intensity at the nerve terminal was seen 
(Figure 5.1A), leaving reduced staining (median 57.00 AU), however this 
reduction was not significant. After 60 minutes at 37oC, there were similar levels 
of staining intensity overlying the NMJ (median 61.00 AU, Figure 5.1B). These 
decreases were not statistically significant compared with 0 minutes, however 
some NMJs completely lacked in antibody staining at the 60 minutes timepoint 
(Figure 5.1A). Tissue was then permeabilised and reprobed with secondary 
antibody, revealing presence of anti-GD1b antibody in junctions which previously 
were antibody negative or had very weak staining (Figure 5.1A). Despite this 
clear visual difference, following permeabilisation, the 30 and 60 minute 
timepoints were statistically lower than 0 minutes with medians of 173.00 AU 
and 155.00 AU respectively compared with 223.00 AU (Figure 5.1C). The staining 
following permeabilisation was punctate and appeared to be within the nerve 
terminal, with no discernible presence in pSCs.  Although not directly 
comparable due to the further addition of secondary antibody and the potential 
internalisation which may have occurred even during the 4oC antibody incubation 
step, the 0 minutes timepoint was also compared directly with 60 minutes 
before and after Triton. Still no significant difference is observed vs. 60 minutes 
before permeabilisation; however an increase is seen in staining at 60 minutes + 
Triton when compared to 0 minutes – Triton.  
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Figure 5.1: Internalisation of anti-GD1b antibody occurs at the nerve terminal after 
30 minutes at 37oC in wildtype mice. Wildtype mice (n=3) TS muscle was labelled with 
anti-GD1b antibody for 30 minutes at 4oC then rinsed and either fixed immediately (0 
minutes) or moved to 37oC for 30 minutes or 60 minutes. Junctions were analysed for 
presence of antibody. The preparations were then permeabilised, reprobed with 
secondary antibody and re-analysed. A: Illustrative images show the wildtype motor 
endplates were labelled at 0 minutes with anti-GD1b antibody, but upon incubation at 
37OC for 60 minutes, labelling is reduced. Permeabilisation of the membrane with Triton 
X-100 reveals presence of antibody within the motor nerve terminal. B: Quantification 
of antibody binding shows that after 30 and 60 minutes at 37oC there was a decrease in 
presence of anti-GD1b antibody compared with 0 minutes though not significant. C: 
Following permeabilisation, a difference still existed between 30 and 60 minute 
timepoints and 0 minutes. D: When 0 minutes is compared with 60 minutes ± Triton, 
still no significant difference is observed when compared with – Triton and a significant 
increase is seen compared with + Triton. Scale Bar = 20 µm. **** = p<0.0001 vs. 0 
minutes, Kruskal-Wallis with Dunn’s multiple comparisons test. Controls are secondary 
antibody only. A minimum of 107 NMJs were analysed per group. Non-parametric data 
displayed as Tukey box plot (see section 2.20). 
 
0
 m
in
s
3
0
 m
in
s
6
0
 m
in
s
C
o
n
tr
o
l
0
1 0 0
2 0 0
3 0 0
C le a n e d  d a ta : Id e n tify  o u tlie rs  o f e x  v iv o  M O G 1  W T  -  T R IT O N  X
t  (m in )
M
O
G
1
 i
n
te
n
s
it
y
 (
A
U
)
0
 m
in
s
3
0
 m
in
s
6
0
 m
in
s
C
o
n
tr
o
l
0
1 0 0
2 0 0
3 0 0
C le a n e d  d a ta : Id e n tify  o u tlie rs  o f  e x  v iv o  M O G 1  W T  +  T R IT O N  X
t  (m in )
M
O
G
1
 i
n
te
n
s
it
y
 (
A
U
)
B
TX
/p
SC
/A
xo
n
/α
-G
D
1
b
0 min 60 min
60 min
+ Triton-X100
α
-G
D
1
b
0 30 60 Control
0 30 60 Control
t(min)
t(min)
α
-G
D
1
b
 A
b
 
in
te
n
si
ty
 (A
U
)
α
-G
D
1
b
 A
b
 
in
te
n
si
ty
 (A
U
)
300
200
00
300
200
100
0
A B
C
- Triton X-100
+ Triton X-100
****
********
****
0
 m
in
s
6
0
 m
in
s
6
0
 m
in
s
 +
 T
r i
to
n
C
o
n
tr
o
l 
+
T
r i
to
n
0
1 0 0
2 0 0
3 0 0
C le a n e d  d a ta : Id e n tify  o u tlie rs  o f  e x  v iv o  M O G 1  W T  +  T R IT O N  X
t  (m in )
M
O
G
1
 i
n
te
n
s
it
y
 (
A
U
)
Co trol
****
****
D
0 60
t(min)
α
-G
D
1
b
 A
b
 
in
te
n
si
ty
 (
A
U
)
300
200
0
0
60 
+ Triton
120 
 
In GalNAcT-/--Tg(neuronal) tissue, a similar, but more clear cut phenomenon is 
observed. Immediately after incubation at 4°C, anti-GD1b antibody presence is 
apparent at the NMJ, including staining of pSCs (Figure 5.2A). This staining was 
reduced following 30 or 60 minutes at 37oC (median 68.50 and 75.00 AU 
respectively vs. 0 minutes median of 240.00 AU). Neuromuscular junctions which 
had previously shown little or no staining after 30 or 60 minutes at 37oC did show 
presence of antibody following permeabilisation and re-probing with secondary 
antibody. Compared with the 0 minute timepoint there appeared to be little 
difference between medians of 30 and 60 minute timepoint (median of 255.00 
AU vs. 233.00 and 244.00 AU respectively), though this difference was significant 
in both cases (p<0.0001).
 
Figure 5.2: Internalisation of anti-GD1b antibody occurs at the nerve terminal after 
30 minutes at 37oC in GalNAcT-/--Tg(neuronal) mice. GalNAcT-/--Tg(neuronal) mice 
(n=3) TS muscle was labelled with anti-GD1b antibody for 30 minutes at 4oC then rinsed 
and either fixed immediately (0 minutes) or moved to 37oC for 30 minutes or 60 
minutes. Junctions were analysed for presence of antibody. The preparations were then 
permeabilised, reprobed with secondary antibody and re-analysed. A: Illustrative 
images show the NMJs were labelled at 0 minutes with anti-GD1b antibody, but upon 
incubation at 37OC, labelling is no longer present. Permeabilisation of the membrane 
with Triton X-100 reveals presence of antibody within the motor nerve terminal. B: 
Quantification of antibody binding shows that after 30 and 60 minutes at 37oC there was 
a significant decrease in presence of anti-GD1b antibody compared with 0 minutes. C: 
Following permeabilisation, a significant difference still existed between 30 and 60 
minute timepoints and 0 minutes, however there was a large reduction in the 
differences. Scale Bar = 20 µm. **** = p<0.0001 vs. 0 minutes, Kruskal-Wallis with Dunn’s 
multiple comparisons test. Controls are secondary antibody only. A minimum of 197 
NMJs were analysed per group. Non-parametric data displayed as Tukey box plot (see 
section 2.20). 
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As shown in Chapter 3, anti-GD1b antibody binds to pSCs at the NMJ in GalNAcT-
/--Tg(glial) mice. Mice expressing GFP in their glial cells (with highest expression 
in the pSCs) were used for this experiment to enable quantification, which 
normally uses BTx alone as a marker of the nerve terminal. Following 30 and 60 
minutes at physiological temperatures the glial antibody staining disappears 
(Figure 5.3A). The intensity of antibody at the junction is decreased significantly 
from a median of 226.5 AU at 0 minutes to 11.0 AU at 30 minutes and further to 
0.0 by 60 minutes (p<0.0001 in both cases, Figure 5.3B). After permeabilisation 
at the 30 minutes timepoint an increase is seen in antibody intensity compared 
to unpermeabilised tissue, though this figure is still significantly lower than 0 
minutes (p<0.0001, median 237 AU vs. 107 AU). Unlike wildtype and GalNAcT-/--
Tg(neuronal) mice however, staining does not reappear at the 60 minutes 
timepoint following permeabilisation, either in the pSC body or in the nerve 
terminal. Levels of antibody intensity remain lower than the 0 minutes timepoint 
(p<0.0001, median 237.00 AU vs. 10.00 AU, Figure 5.3C). 
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Figure 5.3: Internalisation of anti-GD1b antibody occurs at the nerve terminal after 
30 minutes at 37oC in GalNAcT-/--Tg(glial) mice. GalNAcT-/--Tg(glial) mice (n=3) TS 
muscle was labelled with anti-GD1b antibody for 30 minutes at 4oC then rinsed and 
either fixed immediately (0 minutes) or moved to 37oC for 30 minutes or 60 minutes. 
Junctions were analysed for presence of antibody. The preparations were then 
permeabilised, reprobed with secondary antibody and re-analysed. A: Illustrative 
images show the NMJs were labelled at 0 minutes with anti-GD1b antibody, but upon 
incubation at 37OC, labelling is no longer present. Permeabilisation of the membrane 
with Triton X-100 reveals presence of antibody within the motor nerve terminal. B: 
Quantification of antibody binding shows that after 30 and 60 minutes at 37oC there was 
a significant decrease in presence of anti-GD1b antibody compared with 0 minutes. C: 
Following permeabilisation, a significant difference still existed between 30 and 60 
minute timepoints and 0 minutes. Scale Bar = 20 µm. **** = p<0.0001 vs. 0 minutes, 
Kruskal-Wallis with Dunn’s multiple comparisons test. Controls are secondary antibody 
only. A minimum of 122 NMJs were analysed per group. Non-parametric data displayed 
as Tukey box plot (see section 2.20). 
 
As expected, no binding was seen at the 0 minutes timepoint in GalNAcT-/- mice 
which lack GD1b target (median 0 AU). Therefore following 30 and 60 minutes at 
37oC, the NMJs were still negative for anti-GD1b (medians of 0 AU also). 
Critically, when tissue is permeabilised, NMJs remain vacant of anti-GD1b 
antibody, indicating that uptake into nerve terminal was reliant on the presence 
of GD1b on the plasma membrane. 
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Figure 5.4: Internalisation of anti-GD1b antibody does not occur at nerve terminals 
lacking GD1b ganglioside. GalNAcT-/- mice (n=3) TS muscle was labelled with anti-GD1b 
antibody for 30 minutes at 4oC then rinsed and either fixed immediately (0 minutes) or 
moved to 37oC for 30 minutes or 60 minutes. Junctions were analysed for presence of 
antibody. The preparations were then permeabilised, reprobed with secondary antibody 
and re-analysed. A: Illustrative images show the GalNAcT-/- NMJs showed no binding at 0 
minutes with anti-GD1b antibody, and also no binding was seen following incubation at 
37OC. Permeabilisation of the membrane with Triton X-100 shows no antibody presence 
in the nerve terminal. B: Quantification of antibody binding, shows that after 30 and 60 
minutes at 37oC there were slight but significant differences in presence of antibody 
over the NMJ, however the level of binding is almost non-existent at all timepoints. C: 
Following permeabilisation, a similar slight but significant difference still existed but 
binding was still non-existent at all timepoints. Scale Bar = 20 µm. *=p<0.05, ***=p<0.01, 
**** = p<0.0001 vs. 0 minutes, Kruskal-Wallis with Dunn’s multiple comparisons test. 
Controls are secondary antibody only. A minimum of 55 NMJs were analysed per group. 
Non-parametric data displayed as Tukey box plot (see section 2.20). 
 
5.2.1 Fate of antibody at the nerve terminal 
As antibody presence in the nerve terminal after 30 and 60 minutes appeared 
punctate in wildtype, GalNAcT-/--Tg(neuronal) and, where present, in GalNAcT-/-
-Tg(glial) mice, it was thought likely that the antibody would co-localise with 
some part of the vesicle trafficking system. A preliminary attempt was made to 
find where the antibody localises to in the nerve terminal. This required a 
labelled monoclonal antibody; however attempts to label MOG1 and MOG16 
failed or resulted in antibody not binding successfully as tested by glycoarray 
(data not shown). 
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5.2.2 Autophagy inhibition in GalNAcT-/--Tg(glial) mice 
As the GalNAcT-/--Tg(glial) mice showed no restoration of antibody intensity at 
the 60 minute timepoint following permeabilisation and had low values even at 
30 minutes, it was thought that the antibody may have been degraded in these 
preparations. To inhibit lysosomal breakdown of antibody by preventing vesicle 
acidification, Ringer’s was modified to contain NH4Cl (see Chapter 2.1.4.1) 
during the incubation period at 37oC.  
However, the prevention of vesicle acidification did not result in a significant 
difference in antibody presence following permeabilisation when compared with 
tissue incubated in normal Ringer’s (Figure 5.5). 
 
Figure 5.5: Inhibition of vesicle acidification does not increase presence of MOG1 in 
GalNAcT-/--Tg(glial) mouse perisynaptic Schwann cells following incubation at 
physiological temperatures. GalNAcT-/--Tg(glial) mouse (n=3) TS muscle was labelled 
with anti-GM1 antibody for 30 minutes at 4oC then rinsed and either fixed immediately 
(0 minutes at 37oC) or moved to 37oC for 60 minutes. Junctions were analysed for 
presence of antibody. The preparations were then permeabilised, reprobed with 
secondary antibody and re-analysed. Tissue where antibody had been incubated at 37oC 
in normal Ringer’s or Ringer’s containing NH4Cl were both statistically lower than at 0 
minutes, with even lower values seen with NH4Cl tissue. **** = p<0.0001 vs. 0 minutes, 
Kruskal-Wallis with Dunn’s multiple comparisons test. A minimum of 244 junctions were 
analysed. Control was secondary antibody only. A minimum of 244 NMJs were analysed 
per group. Non-parametric data displayed as Tukey box plot (see section 2.20). 
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5.3 In vivo uptake of anti-GD1b antibody  
To see whether the clearance of these antibodies at nerve terminals is sufficient 
to affect levels of antibody in the circulation, MOG1 antibody was injected into 
wildtype, GalNAcT-/- and GalNAcT-/--Tg(neuronal) mice i.p. and circulating levels 
of antibody monitored over a seven day time period. As the half-life of IgG3 in 
mice serum is seven days, no timepoints after this were monitored. Sera from 
mice were run on plates alongside monoclonal antibody control and the results 
expressed as a percentage of the control OD at 5 µg /ml. 
5.3.1 Serum levels of anti-GD1b antibody 
At baseline, all mice showed no GD1b reactivity by ELISA. Serum antibody levels 
peaked for all genotypes at day 1 following the injection (Figure 5.6) but 
wildtype mice showed significantly lower values than both the GalNAcT-/- and 
the GalNAcT-/--Tg(neuronal) mice even at this early timepoint (p<0.001 and 
p<0.05, mean 11.67% of control). From this time point onwards, wildtype levels 
continued to decrease culminating in values 4.00% of that of the control at day 
7. These mice therefore appear to clear the antibody from their circulation 
rapidly. Conversely, serum levels of MOG1 in GalNAcT-/- mice remained 
significantly higher than wildtype at all timepoints, peaking at day 1 (mean 
31.12% of control) then maintaining a high level of circulating antibody 
throughout the experiment (mean 24.47% of control on day 7). Comparing this 
with wildtype results, this indicates that the lack of target in these mice 
prevents their clearing the antibody from the bloodstream. Levels of antibody in 
GalNAcT-/--Tg(neuronal) mice sera lay somewhere in between levels of wildtype 
and GalNAcT-/- mice. Values in these mice were significantly higher than 
wildtype, but not GalNAcT-/- mice on day 1 (mean 24.41% of control) but on day 
2 values had decreased so as to be neither significantly different from wildtype 
or GalNAcT-/- mice. From day 6 levels of antibody in GalNAcT-/--Tg(neuronal) 
mice had reached levels significantly lower than GalNAcT-/- mice (p<0.01) (mean 
9.03% of control). Therefore, like the wildtype mice, these mice also appear to 
be able to clear the circulating antibody however at a much slower rate than 
their counterparts. 
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Figure 5.6: MOG1 serum presence by ELISA over 7 days. Data normalised to MOG1 
antibody as a positive control. Wildtype mice (n=9) clear antibody quickly from their 
circulation, most being cleared even at the day 1 timepoint.  GalNAcT-/- mice (n=8) do 
not clear the antibody and show high levels even at day 7. GalNAcT-/--Tg(neuronal) mice 
(n=8) show a peak at day 1 and a decline over the remaining days, indicating a slow 
clearance of antibody. *=p<0.05, ***=p<0.001, ****=p<0.0001 vs. wildtype. ##=p<0.01 vs. 
GalNAcT-/-, two-way ANOVA with Tukey’s multiple comparison test. 
 
5.3.2 Tissue analysis 
Mice which had been injected with antibody and sacrificed after 7 days showed 
no presence of antibody at the diaphragm, regardless of mouse strain (data not 
shown). Spinal cord was taken at C3-C5, where the phrenic nucleus is located 
(Qiu et al., 2010), and stained for antibody. Wildtype and GalNAcT-/- mice were 
negative for any antibody but in GalNAcT-/--Tg(neuronal) mice, a weak pattern 
of staining was present which was not seen in the other mouse strains (Figure 
5.7). When co-stained with NeuN, the neuron cell bodies appeared negative for 
this staining (not shown) and as such, antibody presence was quantified by 
analysing the average TRITC intensity in the field of view (FOV), with at least 3 
images taken per animal. There was no significant difference in the intensity 
when measured in this manner. 
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Figure 5.7: Presence of IgG3 antibody in the cervical cord 7 days after injection. 
Only GalNAcT-/--Tg(neuronal) mice showed any IgG3 in their cord 7 days after i.p. 
injection of 250 µg of MOG1 antibody. The antibody showed a distinct staining pattern 
which was not present in large neurons. 
Attempts were made to identify where the antibody was localised to in the 
spinal cord after 7 days. Co-staining for MAP2 for dendrites and synaptophysin 
for synapses showed no co-localisation, indicating the antibody localisation was 
probably non-specifically distributed in the neuropil (Figure 5.8).  
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Figure 5.8: Antibody found in the ventral horn of GalNAcT-/--Tg(neuronal) mice does 
not co-localise with MAP2 or synaptophysin. Spinal cords taken from GalNAcT-/--
Tg(neuronal) mice 7 days after MOG1 injection show antibody in the ventral horn but 
the antibody does not appear to be in neuronal cell bodies or processes. Co-stain with 
MAP2 shows the antibody is not present in dendrites and with synaptophysin shows that 
antibody is not in synapses. Scale bar = 20 µm  
 
As antibody had been trafficked to the spinal cord, it was thought likely that it 
had come there by retrograde transport, however by the 7 day timepoint this 
antibody may have been further trafficked out of the cell body, in a similar 
manner to tetanus toxin. Therefore, MOG1 presence in the cord was probed for 
after 1 day using the spinal cords of mice which had been given 1 mg of MOG1 
injected i.p. for passive immunisation (see section 4.2). In this case, antibody 
was found in the ventral horn neurons of GalNAcT-/--Tg(neuronal) mice, but not 
in GalNAcT-/- mice. Antibody was only very occasionally seen in wildtype mice 
but, when present, was always weaker than in GalNAcT-/--Tg(neuronal) mice. 
Spinal cords of GalNAcT-/--Tg(glial) mice were also analysed and were negative 
for antibody in the cord. Antibody presence was quantified by both 
positive/negative cell counts and fluorescent intensity of antibody overlying the 
NeuN-positive signal of the neuron. When analysed by positive/negative cell 
counts, a chi squared test showed significant differences between positive and 
negative cells among groups. Multiple Fisher’s exact tests showed GalNAcT-/--
Tg(neuronal) mice had a significantly higher number of positive cells than 
wildtype, GalNAcT-/- and GalNAcT-/--Tg(glial) mice by Fisher’s exact test (Figure 
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5.9, data displayed as percentage positive cells/total cells counted). A similar 
result was seen when the antibody intensity was measured in NeuN positive 
cells, with GalNAcT-/--Tg(neuronal) mice having higher intensity antibody 
staining than wildtype, GalNAcT-/- and GalNAcT-/--Tg(glial) mice (median of 10 
AU vs. median of 0 for all other mouse strains, Kruskal-Wallis, p<0.0001 against 
wildtype and GalNAcT-/-, p<0.001 vs GalNAcT-/--Tg(glial)). 
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Figure 5.9: Presence of IgG3 in cervical cord 1 day following injection of 1 mg of 
MOG1. No antibody was present in GalNAcT-/- or GalNAcT-/--Tg(glial) mice and some 
weak staining was occasionally present in wildtype mice. GalNAcT-/--Tg(neuronal) mice 
showed clear presence of antibody in ventral horn neurons. This was quantified in 2 
ways: B: Percentage of positive cells per FOV were significantly higher in GalNAcT-/--
Tg(neuronal) mice compared with wildtype, GalNAcT-/- and GalNAcT-/--Tg(glial) mice 
(chi squared test followed by multiple Fisher’s exact tests). C: Antibody staining 
intensity in NeuN positive cells was significantly higher in GalNAcT-/--Tg(neuronal) mice 
compared with wildtype, GalNAcT-/- and GalNAcT-/--Tg(glial) mice (Kruskal-Wallis with 
Dunn’s multiple comparison test). ****=p<0.0001 vs. wildtype, ####=p<0.0001 vs. 
GalNAcT-/-, +++=p<0.001 vs. GalNAcT-/--Tg(glial). Non-parametric data displayed as 
Tukey box plot (see section 2.20). 
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To attempt to address whether the antibody was localised to a specific 
subcellular compartment the antibody in the neurons, spinal cords from 
GalNAcT-/--Tg(neuronal) mice were re-stained with anti-Lamp-2 antibody to look 
for co-localisation with lysosomes, as the staining appeared vesicular. Lamp-2 
staining often overlapped with IgG3, but many “vesicles” of IgG3 were not Lamp-
2 positive. Pearson’s correlation coefficient was calculated using co-localisation 
module of AxioVision software. When the cells were selected within a ROI, 
Pearson’s coefficient was zero, indicating the co-localisation was random (Figure 
5.10).  
 
Figure 5.10: Antibody was only occasionally co-localised with Lamp-2 in ventral horn 
neurons. Neurons from GalNAcT-/--Tg(neuronal) mice which were shown to contain 
presence of IgG3 were co-stained with an anti-Lamp2 antibody to indicate presence of 
lysosomes.  Although antibody did occasionally co-localise with lysosomes (white 
arrowheads), it was also seen in vesicular structures which were not Lamp positive (red 
arrowheads). When cells were selected as ROI, Pearson’s coefficients were 0.00.  
 
5.4 Discussion 
Previously published data have shown that following incubation at physiological 
temperatures, anti-GD1b antibody is cleared rapidly from the NMJ in wildtype 
mice in ex vivo muscle preparations. This antibody is then found in the nerve 
terminal following permeabilisation of the tissue (Fewou et al., 2012). In the 
present study, there was not quite a significant decrease at 30 and 60 minutes, 
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though this may have been due to low staining at 0 minutes in one wildtype 
mouse. Following permeabilisation, staining intensity following 30 or 60 minutes 
at 37oC did not quite reach levels equivalent to 0 minutes. However, as observed 
visually and as shown in the illustrative images, many NMJs which showed no 
staining at 60 minutes before permeabilisation, showed intracellular antibody 
following permeabilisation and reprobing with secondary. Additionally, this work 
has been done before showing a clear internalisation in these mice (Fewou et 
al., 2012). Expanding on previous work, this study also showed that GalNAcT-/--
Tg(neuronal) mice, which express complex gangliosides on neuronal membranes, 
also take up antibody, confirming the nerve terminal’s ability to endocytose 
bound antibody. These mice did on occasion show staining in pSCs at 0 minutes 
(unlike wildtype which do not have GD1b on pSCs), but this did not seem to 
hinder the uptake into the nerve terminal. Conversely, in GalNAcT-/--Tg(glial) 
mice, pSCs were the only cells which displayed presence of antibody at 0 
minutes. Following permeabilisation, tissue displayed some sparse, punctate 
staining in pSCs at the 30 minutes timepoint. However, by 60 minutes there was 
no clear antibody presence in either the pSCs or the nerve terminal. This may be 
explained either by the antibody being recycled to the pSC surface and released 
from the cell, or that the antibody is taken up by these cells and degraded 
within 60 minutes at 37oC. The sparse, punctate staining at 30 minutes 
supported the latter theory. Perisynaptic Schwann cells have previously been 
shown to have lysosomal activity in the context of nervous system development 
and injury (Holtzman and Novikoff, 1965;Jung et al., 2011;Song et al., 2008), 
but it has never been shown at healthy NMJs. An attempt to inhibit lysosomal 
activity using NH4Cl did not result in the presence of more antibody at the NMJ 
following permeabilisation, indicating this is perhaps not the mechanism by 
which antibody is cleared in these mice following incubation at 37oC. However 
other mechanisms of lysosome inhibition may be employed to confirm that 
lysosomes do not contribute to antibody degradation, for example Bafilomycin, a 
V-ATPase inhibitor, which also prevents acidification of lysosomes (Yoshimori et 
al., 1991). The fate of anti-GD1b antibody taken up by pSCs requires further 
investigation but it is clear that at earlier timepoints during incubation at 
physiological temperature the antibody is present in the pSC cell body. 
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To investigate if this uptake phenomenon could affect levels of circulating 
antibody in vivo, wildtype, GalNAcT-/- and GalNAcT-/--Tg(neuronal) mice were 
injected with MOG1 and serum levels were monitored over time. It was shown 
that wildtype mice clear the antibody very quickly, with very low levels even 1 
day after injection. GalNAcT-/- mice however, do not show any ability to clear 
the antibody and GalNAcT-/--Tg(neuronal) mice clear the antibody much slower 
than wildtype mice. Wildtype mice, which had cleared a lot of the antibody even 
by the one day timepoint, have a high global expression of target GD1b as, 
though enriched in the nervous system, gangliosides are ubiquitously expressed 
on plasma membranes. GD1b has been shown to be expressed in tissues such as 
the liver and kidney (Holthofer et al., 1994;Rodrigo et al., 1987). Therefore it is 
likely that this ubiquitous distribution of target, has resulted in widespread 
antibody binding and internalisation along with their target ganglioside by 
clathrin-independent endocytosis (Crespo et al., 2008;Fewou et al., 2012), 
thereby rapidly clearing MOG1 from the circulation. It may be argued that this 
difference in clearance rate may be due to the higher GalNAcT enzyme activity 
in wildtype mice (100%) compared with GalNAcT-/--Tg(neuronal) mice (5.3%) (Yao 
et al., 2014). However, as discussed in Yao et al, the reduction in enzyme 
expression may be due to a dilution factor as tests were performed on whole 
brain, thus wildtype enzyme expression levels would include all non-neuronal 
complex ganglioside expression (Yao et al., 2014). Further, the staining intensity 
is similar at wildtype mouse NMJs to that of GalNAcT-/--Tg(neuronal) mice as 
demonstrated in Chapter 3, indicating that ultimately ganglioside presence is 
similar in these mice at the relevant sites. In addition, preliminary staining work 
in other peripheral tissues (spleen, kidney, heart and liver) from GalNAcT-/--
Tg(neuronal) mice showed an absence of antiganglioside antibody reactivity, 
implying that other non-neuronal tissues are free of complex gangliosides 
(unpublished observations). GalNAcT-/- mice, which lack GD1b target, showed 
prolonged presence of MOG1 antibody. Considering the rapid clearance in 
wildtype mice, this indicates that the lack of clearance is related to the absence 
of target ganglioside. This again coincides with ex vivo results where no non-
specific uptake of antibody was seen in GalNAcT-/- mice. Like the wildtype mice, 
the GalNAcT-/--Tg(neuronal) mice also express GD1b target but in this instance 
only in neuronal membranes. Expression is therefore restricted compared with 
wildtype mice and uptake is less widespread. This results in a more prolonged 
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exposure to circulating antibody. In wildtype mice the in vivo uptake was 
widespread due to the large availability of GD1b. However, in GalNAcT-/--
Tg(neuronal) mice, the uptake can almost solely be attributed to motor nerve 
terminal clearance, as node of Ranvier lack the same ability to internalise 
antibody (Fewou et al., 2012). The consequences of internalisation at the motor 
nerve terminal were not known using ex vivo preparations alone (Fewou et al., 
2012), however using in vivo techniques it appears that the antibody is 
retrogradely transported to the spinal cord. In wildtype mice, comparatively 
little antibody will likely be taken up at the nerve terminals due to the wide 
availability and access to GD1b elsewhere. It was therefore unsurprising to see 
very little antibody in wildtype ventral horn neurons. However, in GalNAcT-/--
Tg(neuronal) mice, visible amounts of GD1b have been trafficked from the 
periphery to the motor neurons. Only the anti-GD1b antibody trafficked from the 
diaphragm was looked for, by imaging the C3-5 portion of the cord. However, 
antibody would likely be present throughout the cord as an i.p. injection was 
given, therefore any skeletal muscle which was exposed to circulating antibody 
could have taken it up. Intraperitoneal injection allowed much higher amounts 
of antibody to be injected, due to the limitations in intramuscular injection 
volume in mice. Previous studies looking at retrograde antibody trafficking have 
been done in rats which have a larger muscle volume than mice and therefore 
can be injected with larger volumes of antibody i.m. The retrograde transport of 
antibodies against synaptic membrane components has been shown before 
(Fabian and Ritchie, 1986;Fabian and Petroff, 1987;Fabian, 1988;Fabian, 
1991;Ritchie et al., 1985;Ritchie et al., 1986;Wenthold et al., 1984) therefore it 
was an unsurprising, yet novel finding that anti-ganglioside antibodies are also 
transported to the spinal cord. Following the serum clearance study, which 
extended out 7 days since the initial injection, antibody appeared to be in the 
phrenic nucleus neuropil. The same result was seen previously with monoclonal 
antibodies targeting synaptosome components (Ritchie et al., 1986), where the 
authors could not further localise the antibody but surmised that it either be in 
fine dendrites or to have been further transferred out of motor neurons 
following retrograde transport. The latter option seems the most likely 
considering that antibody presence did not coincide with MAP2 staining, 
indicating no presence in dendrites. Further, at the 1 day timepoint antibody 
was visible in the neuron cell bodies in GalNAcT-/--Tg(neuronal) mice and, 
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though some antibody was present in lysosomes, some antibody appeared to be 
localised in other punctate structures in the cell. It is surmised that this other 
antibody was localised to recycling endosomes, which would carry the antibody 
to the cell surface, explaining its presence in the neuropil at the 7 day 
timepoint. The recycling of anti-ganglioside antibody has been shown previously 
in CHO-K1 cells (Iglesias-Bartolome et al., 2006;Iglesias-Bartolome et al., 2009). 
The consequences of antibody being transported to the spinal cord are as yet 
unknown. Hyper-reflexia, a symptom seen occasionally in the recovery phase in 
cases of AMAN (Baheti et al., 2010;McKhann et al., 1991;Yuki et al., 2012), has 
been shown by electrophysiological tests to be associated in some cases with 
increased motor neuron excitability. This has been suggested to be caused by 
disruption of the inhibitory interneurons, which mediate the activity of spinal 
cord motor neurons (Kuwabara et al., 1999;Yuki et al., 2012). If anti-ganglioside 
antibody is trafficked to the spinal cord in GBS patients, and then trans-
synaptically transported outwith the neuron, it is conceivable that it may bind to 
the membrane of inhibitory interneurons, as is the pathway of tetanus toxin. 
Withal, patients who suffer from BBE, a condition which shares diagnostic 
features with MFS, present with drowsiness and coma in addition to ataxia and 
ophthalmoplegia. These features are thought to be due a transient, 
inflammatory brainstem injury (Shahrizaila and Yuki, 2013). Both BBE and MFS 
are associated with anti-GQ1b antibodies, suggesting a common immune-
mediated mechanism in both diseases. Anti-GQ1b antibodies are thought to bind 
to the oculomotor nerve paranodes and NMJs to cause ophthalmoplegia and 
ptosis which occurs with both of these conditions. The current hypothesis of 
inflammatory brainstem injury in BBE is the entrance of anti-GQ1b antibody into 
the CNS via the circulation, but the uptake of anti-GQ1b antibodies by the motor 
nerve terminals may result in retrograde trafficking to the brainstem, where it 
may be trans-synaptically spread to bind to surrounding nuclei. The oculomotor 
nerve (the third cranial nerve) is thought to be the main nerve affected in MFS, 
and has a high GQ1b content (Chiba et al., 1993).  This nerve projects to the 
periphery from the oculomotor nucleus which in the human brainstem is located 
close by to the midbrain reticular formation, the dorsal raphe nucleus and the 
mesencephalic trigeminal nucleus (Allen Institute for Brain Science, 2014). These 
are all components of the reticular activating system (RAS), a circuit of several 
connected nuclei originating in the brainstem and connecting to the cortex. It is 
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involved in the control of arousal and wakefulness (Yeo et al., 2013). If trans-
synaptic spread of anti-GQ1b antibody is occurring in BBE patients, the antibody 
may be binding to these RAS components, causing inflammatory injury. Damage 
to these regions has been shown to be associated with coma (Garcia-Rill, 1997). 
Further study of the retrograde and potentially trans-synaptic transport of 
antibody is warranted to discover the effects of intraneuronal anti-ganglioside 
antibody. As preliminary studies were proof of antibody clearance, no 
behavioural or functional tests were employed in these mice to test whether 
intra-neuronal IgG had a detrimental effect.  
To our knowledge, this is the first time that pathogenic anti-ganglioside 
antibodies such as MOG1, which bind and injure tissue in the presence of a 
source of complement, have been shown to be regulated by the ability of cell 
membranes to internalise these antibodies. The implication of this is that the 
availability of the target antigen may regulate how long the antibody is present 
in the circulation. In patients this may mean that antibodies which target 
epitopes which are widely expressed (the equivalent of wildtype mice) are 
cleared quickly and are less available to cause extensive injury. However 
antibodies which target epitopes which are expressed at a lower level (the 
equivalent of GalNAcT-/--Tg(neuronal) mice), will circulate longer. This 
prolonged exposure may not affect the NMJs as they are able to endocytose 
antibody, but the NoR, which have less capacity for antibody uptake (Fewou et 
al., 2012) may be more vulnerable to antibody attack. This may provide 
evidence as to why the node of Ranvier is thought to be a site of damage in 
axonal GBS, (Griffin et al., 1996;Hafer-Macko et al., 1996a;Kuwabara et al., 
1998) but evidence of damage to motor nerve terminals has been conflicting (Ho 
et al., 1997;Kuwabara et al., 2007;Kuwabara et al., 2011;Spaans et al., 2003). 
Antibody binding does not reduce the number of gangliosides available, 
suggesting that gangliosides are recycled to the cell surface following 
internalisation (Fewou et al., 2012). Antibodies may therefore still be able to 
bind and injure the nerve terminal at high serum concentrations, when 
endocytic machinery is likely to be saturated. The effect this uptake 
phenomenon may have in patients would therefore depend on antibody 
specificity (the epitope to which it binds), and availability (the serum 
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concentration of this antibody), as well as the relative availability of the target 
epitope, and the endocytic capacity of the target membrane. 
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6 Ability of the NMJ to clear anti-GM1 antibody 
6.1 Introduction 
The previous chapter demonstrated that the ability of MOG1, an anti-GD1b 
antibody, to be internalised by GD1b-expressing membranes, especially the 
motor nerve terminals, can affect the amount of circulating MOG1 available in 
vivo. It therefore seemed prudent to demonstrate this ability with other 
antibodies. GM1 is commonly a target for autoantibodies in AMAN (Ho et al., 
1995;Kuwabara et al., 1998;Ogawara et al., 2000). Therefore DG2, an anti-GM1 
antibody which is known to bind well to wildtype mouse tissue (Greenshields et 
al., 2009) and was shown in Chapter 3 to successfully bind to GalNAcT-/--
Tg(neuronal) and GalNAcT-/--Tg(glial) mouse tissue, was used to determine 
whether antibodies against GM1 behaved in a similar fashion to anti-GD1b 
antibody. Previous work using other anti-GM1 antibodies has suggested they are 
internalised when bound to GM1 in a variety of cell types, but are subsequently 
recycled back to the cell surface (Iglesias-Bartolome et al., 2009). The first 
paper demonstrating the ability of anti-ganglioside antibodies to be internalised 
at motor nerve terminals demonstrated the presence of DG2 in motor nerve 
terminals of GD3s-/- mice following internalisation (Fewou et al., 2012), but has 
not demonstrated the internalisation dynamics of DG2 in wildtype or GalNAcT-/--
Tg(neuronal) mice.  
6.2 Ex vivo uptake of anti-GM1 antibody 
As the principle of antibody uptake had already been demonstrated with MOG1, 
where the most thorough uptake in ex vivo preparations had occurred following 
60 minutes at 37oC, the 30 minute timepoint was left out of this experiment.  
As shown in Chapter 3, DG2 antibody often bound to NMJ-capping kranocytes in 
wildtype mice. These cells were identified by their shape and are known to have 
GM1 due to the binding of cholera toxin (Court et al., 2008). The staining of 
these cells with DG2 often obscured true nerve terminal binding, though 
kranocytes were not present over all NMJs. In these kranocyte-lacking NMJs, it 
was clear that at 0 minutes there was antibody present on the motor nerve 
terminal, node of Ranvier and on the terminal myelinating SC (Figure 6.1A, 
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white arrowhead). Staining of these structures was not present at every NMJ 
however. Quantitatively, the DG2 was significantly reduced at the wildtype 
nerve terminal following 60 minutes at physiological temperatures (p<0.0001, 
median of 25.75 AU vs. 3.00 AU respectively, Figure 6.1B). Visually, the staining 
on kranocytes, nodes of Ranvier and terminal Schwann cell remained (Figure 
6.1A,B). When the membrane was permeabilised with Triton X-100 and reprobed 
with secondary antibody, NMJs which had appeared negative for antibody before 
permeabilisation, still appeared negative (Figure 6.1A). When this was 
quantified, a discrepancy still remained between antibody intensity at the 
endplate at 0 minute and 60 minute timepoints, with higher intensity staining at 
the 0 minutes timepoint (p<0.0001, median of 11.00 AU vs. 0.00 AU, Figure 
6.1C). 
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Figure 6.1: Anti-GM1 antibody is cleared from the nerve terminal after 60 minutes 
at 37oC in wildtype mice. Wildtype mice (n=3) TS muscle was labelled with anti-GM1 
antibody for 30 minutes at 4oC then rinsed and either fixed immediately (0 minutes at 
37oC) or moved to 37oC for 60 minutes. Endplates were analysed for presence of 
antibody. The preparations were then permeabilised, reprobed with secondary antibody 
and re-analysed. A: Examples of NMJs which were not obscured by kranocyte staining. 
NMJs were labelled weakly at 0 minutes with anti-GM1 antibody, but upon incubation at 
37OC, labelling is no longer present at the nerve terminal but is still present on the 
terminal myelinating SC (white arrowhead). Permeabilisation of the membrane with 
Triton X-100 reveals no reappearance of antibody in the nerve terminal. B: Examples of 
kranocyte staining at NMJs. Kranocytes are labelled at 0 minutes but fail to internalise 
antibody by 60 minutes at 37oC. Staining appears very similar post-permeabilisation. C: 
Quantification shows that after 60 minutes at 37oC there was a significant decrease in 
presence of anti-GD1b antibody overlying the BTx signal, compared with 0 minutes. D: 
Following permeabilisation, a significant difference still existed between the 60 minute 
timepoint and 0 minutes. Scale Bar = 20 µm. **** = p<0.0001 vs. 0 minutes, Mann-
Whitney test. A minimum of 192 NMJs were analysed per group.  Non-parametric data 
displayed as Tukey box plot (see section 2.20). 
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In GalNAcT-/--Tg(neuronal) mice, no antibody was seen on kranocytes but was 
detectable at the nerve terminal as well as occasionally on the same terminal 
myelinating SCs seen in the wildtype mice (Figure 6.2A). After 60 minutes at 
37oC, staining overlying the BTx signal is significantly reduced compared to 0 
minutes (p<0.0001, median of 33 AU vs. 0.0 AU respectively, Figure 6.2B). Once 
again however, the staining does not reappear following permeabilisation and 
reprobing with secondary antibody, and a significant difference still exists 
between 0 and 60 minutes (p<0.0001, median of 127.0 AU vs. 9.0 AU, Figure 
6.2C).  
 
Figure 6.2: Anti-GM1 antibody is cleared from the nerve terminal after 60 minutes 
at 37oC in GalNAcT-/--Tg(neuronal) mice. GalNAcT-/--Tg(neuronal) mice (n=3) TS muscle 
was labelled with anti-GM1 antibody for 30 minutes at 4oC then rinsed and either fixed 
immediately (0 minutes at 37oC) or moved to 37oC for 60 minutes. Endplates were 
analysed for presence of antibody. The preparations were then permeabilised, reprobed 
with secondary antibody and re-analysed. A: Nerve terminals and terminal Schwann 
cells were labelled at 0 minutes with anti-GM1 antibody, but upon incubation at 37OC, 
labelling is no longer present at the nerve terminal. Permeabilisation of the membrane 
with Triton X-100 reveals no reappearance of antibody in the nerve terminal. B: 
Quantification shows that after 60 minutes at 37oC there was a significant decrease in 
presence of anti-GM1 antibody compared with 0 minutes. C: Following permeabilisation, 
a significant difference still existed between the 60 minute timepoint and the 0 minutes 
timepoint. Scale Bar = 20 µm. **** = p<0.0001 vs. 0 minutes, Mann-Whitney test. A 
minimum of 191 NMJs were analysed per group.  Non-parametric data displayed as 
Tukey box plot (see section 2.20). 
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As shown in chapter 3, GalNAcT-/--Tg(glial) mice, show only occasional, weak 
staining over the pSCs following incubation with DG2. Quantification of antibody 
signal overlying the BTx was therefore not performed in GalNAcT-/--Tg(glial) 
mice.  Instead, most staining is seen over the internodal and paranodal myelin. 
The terminal myelinating Schwann cell labelled in wildtype and GalNAcT-/--
Tg(neuronal) mice is also DG2 positive (Figure 6.3).  As seen with wildtype and 
GalNAcT-/--Tg(neuronal) mice, this nodal and SC staining is still present at 60 
minutes and therefore does not appear to have been internalised.  
 
Figure 6.3: Anti-GM1 antibody does not bind at the NMJ in GalNAcT-/--Tg(glial) mice, 
but binds the myelin sheath and terminal myelinating SC.  GalNAcT-/--Tg(glial) mouse 
TS muscle was labelled with anti-GM1 antibody for 30 minutes at 4oC then rinsed and 
either fixed immediately (0 minutes at 37oC) or moved to 37oC for 60 minutes. Junctions 
were analysed for presence of antibody. The preparations were then permeabilised, 
reprobed with secondary antibody and re-analysed. A: No antibody labelling was present 
overlying the BTx signal immediately following anti-GM1 antibody incubation. Instead 
only the myelin sheath and the terminal myelinating SC are labelled. Upon incubation at 
37OC, labelling is still present on the terminal myelinating SC (white arrowhead) and 
NoR. Permeabilisation of the membrane with Triton X-100 therefore made no difference 
to the surface-bound antibody signal at 60 minutes. Scale bar = 20 µm. 
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In GalNAcT-/- mice, no anti-GM1 antibody binding is seen at the NMJ at 0 
minutes. After tissue was washed and placed at 37oC for 60 minutes, there was 
still no binding of antibody over the junction. This was reflected in the 
quantitation which showed median values of 0.00 AU for both 0 and 60 minutes 
and no significant difference between these timepoints. As was the case with 
GD1b, when the tissue was permeabilised no antibody was seen within the nerve 
terminal in GalNAcT-/- mice at either 0 minutes or 60 minutes timepoint (Figure 
6.4A). This indicated that once again initial binding to the target ganglioside is 
needed before internalisation at the nerve terminal can occur. Quantitatively, a 
significant increase was seen in the 0 minute timepoint, but binding was still 
visually negative (median of 0.00 AU for both). 
 
Figure 6.4: Internalisation of anti-GM1 antibody does not occur at nerve terminals 
lacking GM1 ganglioside. GalNAcT-/- mice (n=3) TS muscle was labelled with anti-GM1 
antibody for 30 minutes at 4oC then rinsed and either fixed immediately (0 minutes) or 
moved to 37oC for 30 minutes or 60 minutes. Junctions were analysed for presence of 
antibody. The preparations were then permeabilised, reprobed with secondary antibody 
and re-analysed. A: Illustrative images show the GalNAcT-/- NMJs showed no binding at 0 
minutes with anti-GM1 antibody, and also no binding was seen following incubation at 
37OC. Permeabilisation of the membrane with Triton X-100 shows no antibody presence 
in the nerve terminal. B: Quantification of antibody binding shows that before Triton, 
there was no antibody present over the NMJ. C: Following permeabilisation, a slight rise 
in intensity at the 0 minutes timepoint meant a slight but significant difference arose 
between 0 and 60 minutes, however binding was still virtually non-existent at both 
timepoints. Scale Bar = 50 µm. **** = p<0.0001 vs 0 minutes, Mann-Whitney test. A 
minimum of 200 NMJs were analysed per group.  Non-parametric data displayed as 
Tukey box plot (see section 2.20). 
C le a n e d  d a ta : Id e n t ify  o u tlie r s  o f R e p e a t e x  v iv o  D G 2  K O  -  T R IT O N  X
t  (m in )
D
G
2
 i
n
te
n
s
it
y
 (
A
U
)
0
 m
in
s
6
0
 m
in
s
0
1 0 0
2 0 0
3 0 0
C le a n e d  d a ta :  Id e n tify  o u tlie rs  o f R e p e a t e x  v iv o  D G 2  K O  +  T R IT O N  X
t  (m in )
D
G
2
 i
n
te
n
s
it
y
 (
A
U
)
0
 m
in
s
6
0
 m
in
s
0
1 0 0
2 0 0
3 0 0
0 mins 60 mins
B
TX
/p
SC
/A
xo
n
/α
-G
M
1
α
-G
M
1
60 min
+ Triton-X100
0 60
0 60
t(min)
t(min)
α
-G
M
1
 A
b
 
in
te
n
si
ty
 (A
U
)
α
-G
M
1
 A
b
 
in
te
n
si
ty
 (A
U
)
- Triton X-100
+ Triton X-100
0
B
C
A
300
20
10
α
-G
M
1
 A
b
 
in
te
n
si
ty
 (A
U
)
300
200
100
****
144 
 
 
6.2.1 Autophagy inhibition in GalNAcT-/--Tg(neuronal) mice 
The apparent disappearance of DG2 from the nerve terminal may be due to 
recycling of the antibody back to the cell surface, or by degradation within the 
nerve terminal or nearby structure. To examine the latter possibility, a pilot 
attempt (n=1) was made to inhibit potential breakdown of DG2 by preventing 
vesicle acidification using NH4Cl. This was done in the GalNAcT
-/--Tg(neuronal) 
mouse to ensure that staining on the nerve terminal was not obscured by 
kranocyte staining. This initial study appeared to show some restoration of 
antibody intensity when NH4Cl is added to Ringer’s solution for the 60 minute 
incubation at 37oC suggesting that DG2 may be at least partially degraded by the 
nerve terminal. The presence of DG2 in tissue incubated with NH4Cl+ Ringer’s 
was punctate. Only images and quantification of permeabilised tissue are shown 
(Figure 6.5).
 
Figure 6.5: Pilot study indicates inhibition of vesicle acidification increases DG2 
presence following incubation at physiological temperatures. GalNAcT-/--Tg(neuronal) 
mouse (n=1) TS muscle was labelled with anti-GM1 antibody for 30 minutes at 4oC then 
rinsed and either fixed immediately (0 minutes at 37oC) or moved to 37oC for 60 
minutes. Junctions were analysed for presence of antibody. The preparations were then 
permeabilised, reprobed with secondary antibody and re-analysed. Only images and 
quantification from permeabilised tissue is shown. A: Surface DG2 is present at the 
nerve terminal and on terminal SCs at the 0 minutes timepoint. Very little antibody was 
present within the nerve terminal at the 60 minutes timepoint following 
permeabilisation. In tissue where antibody had been incubated at 37oC in Ringer’s 
containing NH4Cl, more antibody appeared to be present in the nerve terminal at 60 
minutes. B: Quantification of DG2 intensity implied a slight increase in antibody 
presence in NH4Cl treated group. Control was secondary only. Non-parametric data 
displayed as Tukey box plot (see section 2.20). 
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6.2.2 Fate of antibody following disappearance at the NMJ 
Attempts were made to track DG2’s movement over time at the NMJ and 
pinpoint where it is cleared to. Firstly DG2 was labelled with Alexa Fluor 488 
fluorescent dye which was tested by array and tissue preps to confirm its binding 
to GM1 (Figure 6.6)
 
Figure 6.6: Testing of labelled DG2 antibody on glycoarray and in whole mount TS 
tissue. A: Glycoarray analysis was performed using the standard protocol but for DG2-
488 the secondary antibody step was missed out. Binding patterns were similar for both 
antibodies, though intensity levels were higher using labelled antibody (array shown is 
saturated for DG2-488 but weak for unlabelled DG2. B: TS was probed with primary 
antibody (either labelled or unlabelled DG2). For labelled DG2 the secondary antibody 
step was removed. Comparable binding is seen between DG2-488 and unlabelled DG2 
followed by secondary antibody. 
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Firstly an attempt was made to look at the DG2 binding in tissue at 0, 30 and 60 
minutes to distinguish whether there was a movement of antibody from apparent 
surface binding to internalisation, using both wildtype and GalNAcT-/--
Tg(neuronal) mice (n=3). In wildtype mice, most NMJs were obscured by 
kranocyte staining, which appeared to vary in intensity from junction to junction 
(Fig 6.4). As shown in section 6.2, this staining remained present even at the 60 
minute timepoint (images not shown). Where nerve terminal binding is not 
obscured by kranocytes, the binding appeared punctate at 30 minutes and had 
completely disappeared by 60 minutes (Figure 6.7).  
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Figure 6.7: Binding of DG2-488 in wildtype TS muscle following 0, 30 and 60 minutes 
at physiological temperatures. TS tissue was labelled with DG2-488 at 4oC then either 
fixed immediately or incubated at 37oC for 30 or 60 minutes. At 0 minutes kranocyte 
staining is seen over some NMJs and weakly over the nerve terminal. At 30 minutes 
kranocytes are still stained and nerve terminal staining looks punctate. At 60 minutes 
nerve terminal staining had disappeared completely (junction shown did not have a 
kranocyte present, however kranocyte staining was seen over other NMJs). 
 
In GalNAcT-/--Tg(neuronal) mice (Figure 6.8), staining was initially present over 
the nerve terminal, though again this varied in intensity between junctions with 
some NMJs showing very weak staining even at the 0 minutes timepoint, perhaps 
due to the lower enzyme activity in these mice (Yao et al., 2014). After 30 
minutes, the antibody appeared punctate and in some junctions, presumably 
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those which would have shown weaker staining at 0 minutes, had completely 
disappeared. By 60 minutes all antibody had disappeared in these mice.  
 
Figure 6.8: Binding of DG2-488 in GalNAcT-/--Tg(neuronal) TS muscle following 0, 30 
and 60 minutes at physiological temperatures. TS tissue was labelled with DG2-488 at 
4oC then either fixed immediately or incubated at 37oC for 30 or 60 minutes. At 0 
minutes weak nerve terminal and occasionally pSC staining is seen at the NMJs. At 30 
minutes nerve terminal staining looks weaker and more punctate. At 60 minutes nerve 
terminal staining has disappeared completely.  
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6.3 In vivo uptake of anti-GM1 antibody 
6.3.1 Serum levels of anti-GM1 antibody 
As it was successfully demonstrated that MOG1 was cleared from the circulation 
in mice which had high amounts of target, the same paradigm was explored with 
DG2. The ex vivo results dictated that the DG2 antibody was cleared from the 
NMJ as seen with MOG1, but not trafficked to inside the nerve terminal in the 
same way. Even though the antibodies were trafficked differently from the 
nerve terminal, it was thought likely that a change in serum presence would still 
be detectable. 
The opportunity to explore differences between tissue-binding and non-tissue 
binding anti-GM1 was afforded by using DG1 in addition to DG2 in the 
experiment. As shown in chapter 3, DG2 binds the nerve terminals of wildtype 
and GalNAcT-/--Tg(neuronal) mice, but not those of GalNAcT-/- mice. GalNAcT-/--
Tg(glial) mice show only very occasional and very weak pSC binding and 
therefore were excluded from this experiment. DG1 on the other hand does not 
bind in any of the genotypes due to its inhibition of GM1 binding by surrounding 
GD1a ganglioside (Greenshields et al., 2009) (see Chapter 3 and Figure 6.9). The 
convenient fact that these two anti-GM1 antibodies are of different IgG subtypes 
meant that both antibodies could be injected simultaneously into the mice, and 
the serum presence of each of them monitored using the same experimental 
paradigm as used in Chapter 5. Serum was tested in ELISA and subtype-specific 
HRP-conjugated secondary antibodies were used to detect antibody presence. 
This would allow us to confirm the importance of pathogenicity in an antibody’s 
ability to be cleared. 
The experiment was initially conducted in wildtype mice alone (n=3). As 
different secondary antibodies were used, statistics were performed vs. baseline 
levels for each antibody as levels between antibodies are not directly 
comparable. Results showed that levels of DG2, the pathogenic, tissue-binding 
antibody, were not significantly higher than baseline at the day 1 timepoint 
(mean 0.007 OD vs. 0.001 OD) and remained so over the course of the 
experiment. This appeared to be similar to the levels of MOG1 in the serum at 
day 1 in wildtype mice. Conversely, levels of DG1 were significantly higher than 
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baseline values at day 1 (1.26 OD vs. 0.02 OD) and remained so over the rest of 
the experiment.
 
Figure 6.9: Difference in tissue-binding ability of DG1 and DG2 affects their 
clearance from serum in wildtype mice. A: DG1 does not bind the NMJ in live wildtype 
TS whereas DG2 does. B: Although not directly comparable as they were detected with 
different secondary antibodies, there is a large difference between presence of DG1 and 
DG2 in wildtype mice even as soon as 1 day post-injection. Statistics shown for each 
antibody are compared with day 0, preinjection, by two-way ANOVA with Dunnett’s 
multiple comparison test. DG1 presence in the serum remained statistically higher than 
preinjection values over the 7 day time course, whereas DG2 is rapidly cleared, never 
differing from baseline values. DG1: ****=p<0.0001 vs. day 0.  DG2: ns=p>0.05 vs. day 0. 
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The experiment was then repeated, this time including GalNAcT-/- and GalNAcT-
/--Tg(neuronal) along with wildtype mice (n=3 per group). The use of these mice 
allowed confirmation that DG2 was making its way into the circulation in 
wildtype mice before being cleared by comparing binding in mice with less/no 
target antigen (Figure 6.10). Values of DG1 OD were high 1 day following 
injection and remained high throughout the experiment in the sera of all three 
mouse strains. No significant difference existed among the  sera OD values of 
any mouse strains at any timepoint with the exception of GalNAcT-/- vs. wildtype 
at the day 3 timepoint (two way ANOVA, p<0.05). DG2 showed much the same 
pattern of clearance as MOG1; Wildtype mice clear the antibody very quickly, 
with very low OD values seen in the sera even at the one day timepoint. 
GalNAcT-/- mice have a high peak in OD at day 1, which remains high throughout 
the remainder of the experiment (the slight decrease seen over the 7 days is 
likely due to the normal half-life of IgG in mice). GalNAcT-/--Tg(neuronal) mice 
cleared DG2 from their serum at a much slower rate than wildtype mice. 
GalNAcT-/--Tg(neuronal) mice sera show a significantly higher OD value on day 
one than wildtype mice (p<0.001, Two-way ANOVA), which then dips by day 3 to 
be statistically similar to wildtype mice sera, and continues to decrease over the 
remainder of the experiment. Values of OD in GalNAcT-/--Tg(neuronal) sera were 
consistently lower than GalNAcT-/- mice. 
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Figure 6.10: DG1 and DG2 serum presence by ELISA over 7 days in wildtype, 
GalNAcT-/- and GalNAcT-/--Tg(neuronal) mice. Mice (n=3 per group) were injected i.p. 
with both antibodies (250 µg each) on day 0, following baseline blood sample. DG1 
remained in the circulation of all mice over the 7 days. Contrastingly, DG2 was quickly 
cleared in wildtype mice and more slowly in GalNAcT-/--Tg(neuronal) mice. DG2 levels in 
GalNAcT-/- mice sera remained high over the 7 days, two-way ANOVA with Dunnett’s 
multiple comparison test.  
 
6.3.2 Tissue analysis 
As with MOG1 in Chapter 5, an attempt was made to look for DG2 in the spinal 
cord of mice following i.p. injection. This was done in a separate experiment as 
part of a project carried out by A. Cunningham as part of an undergraduate 
honours project. Only GalNAcT-/--Tg(neuronal) mice were used to increase the 
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chances of finding intraneuronal antibody. GalNAcT-/--Tg(neuronal) mice were 
injected with 2 mg of DG2 and antibody was searched for after 1 day and after 7 
days (n=3 per group) at both the diaphragm and in the spinal cord. Diaphragm 
was positive for antibody after 1 day but negative for antibody after 7 days. 
Spinal cord gave very negligible results with no distinctly obvious DG2 presence 
at either timepoint (data not shown). This was not unexpected due to the 
absence of internalised antibody at the nerve terminal in whole mount TS 
preparations. 
6.4 Discussion 
The concept that anti-ganglioside antibodies are internalised has already been 
established both in cell culture, and ex vivo at the motor nerve terminals of 
wildtype mice (Fewou et al., 2012;Iglesias-Bartolome et al., 2006;Iglesias-
Bartolome et al., 2009). Chapter 5 demonstrated that antibodies against GD1b 
can be rapidly taken up by motor nerve terminals when GD1b is present on the 
presynaptic membrane (i.e. in wildtype and GalNAcT-/--Tg(neuronal) mice). 
MOG1 can also be cleared by pSCs (as shown in GalNAcT-/--Tg(glial) mice), 
though the fate of the antibody following clearance in these mice is less certain. 
It was also shown that this clearance by the nerve terminal, and by other GD1b-
presenting membranes, can have a significant effect on levels of circulating 
antibody in vivo. Due to the significance of anti-GM1 antibodies in relation to 
disease, the same paradigms were investigated using DG2, an anti-GM1 antibody. 
Previously, anti-GM1 antibodies have been shown to be internalised by a variety 
of cell lines, only to be recycled back to the plasma membrane (Iglesias-
Bartolome et al., 2009). Contrastingly, previous work in this laboratory using 
DG2 has shown that this anti-GM1 antibody is taken up by PC12 cells, and co-
localises with lysosomes, indicating its fate is degradation rather than recycling 
(Fewou et al., 2012). Nerve terminal studies in GD3s-/- mice using DG2 indicated 
that the antibody was taken up by the nerve terminal following incubation at 
physiological temperature, and is found there following permeabilisation (Fewou 
et al., 2012). However, chapter 6 has demonstrated that in wildtype mice anti-
GM1 antibody DG2, is cleared from the nerve terminal within 60 minutes at 
physiological temperature, but is not present following permeabilisation of the 
nerve terminal membrane. In light of previous work in cell culture, this may 
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have meant that the antibody is either being recycled to the cell surface, or is 
being degraded somehow within the nerve terminal. A pilot study indicated that 
lysosomal inhibition by NH4Cl resulted in increased antibody presence in the 
nerve terminal following permeabilisation of tissue incubated at physiological 
temperature for 60 minutes. It is difficult to draw conclusions from only one 
experiment however the results warrant further investigation into the potential 
degradation of DG2 at the nerve terminal. Lysosomes have been shown to be 
present in peripheral axons and in nerve terminals, and increase in response to 
peripheral nerve injury (Jung et al., 2011;Jung et al., 2014;Song et al., 2008;Xu 
et al., 2002). Additionally, if DG2 antibody was instead being recycled back out 
of the nerve terminal, it would be expected that in vivo, the presence of DG2 in 
the serum would have been prolonged, especially in GalNAcT-/--Tg(neuronal) 
mice. This was not the case as when DG2 was injected i.p. into mice, it was 
cleared from the serum in a much similar fashion to anti-GD1b antibody MOG1; 
Wildtype mice cleared DG2 within 1 day and GalNAcT-/--Tg(neuronal) mice, in 
which serum clearance can be mostly attributed to the nerve terminal, cleared 
the serum within 6 days of injection. It therefore seems more likely that DG2 is 
being degraded or further trafficked from within the terminal. It is possible that 
DG2 and MOG1 share a trafficking pathway but that DG2 is trafficked much 
faster; MOG1 may perform a similar vanishing act if incubated for a longer 
period of time. On the other hand, gangliosides have been shown to be 
differentially trafficked following binding and internalisation (Crespo et al., 
2008), therefore the two antibodies may be destined for different fates upon 
their arrival in the nerve terminal. This would certainly explain the lack of DG2 
detected in the spinal cord following i.p. injection, despite MOG1 being 
detectable in a similar experimental paradigm. 
Importantly, as demonstrated previously (Fewou et al., 2012), anti-GM1 antibody 
binding at the node of Ranvier was not internalised, and still remained present 
at the 60 minute timepoint. As well as nerve terminal and node of Ranvier 
staining, DG2 was also seen on a terminal myelinating SC, present immediately 
proximal to the nerve terminal and appearing to be located between the last 
two nodes of Ranvier (ensheathing the final internode). This cell is S100 positive, 
as demonstrated by presence of cytoplasmic GFP in fluorescent mice, and 
sulphatide-positive, as demonstrated by anti-sulphatide antibodies (G. Meehan, 
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unpublished data). DG2 binds sulphatide in addition to GM1, both in ELISA (D. 
Nicholls, unpublished data) and glycoarray. It was thought that this cell was 
therefore showing sulphatide staining, however the presence of high cholesterol 
can inhibit DG2-sulphatide binding and in CST-/- mice, this cell is still labelled 
with DG2. Additionally, in CST-/- x GalNAcT-/- mice, no staining is present. It was 
concluded that the staining was in fact of DG2 binding GM1, and therefore it 
appears GM1 is not internalised at this site. 
This chapter demonstrated the importance of antibody pathogenicity by utilising 
two antibodies which bind GM1 in ELISA, but only one of which binds in live 
tissue (Greenshields et al., 2009). DG2, a tissue-binding antibody, is cleared 
from wildtype and GalNAcT-/--Tg(neuronal) mice serum in much the same way as 
MOG1, indicating a similar dependence on target availability. Likewise, GalNAcT-
/- mice, which could not clear MOG1 from their serum, also fail to clear DG2 as 
they lack the target GM1. DG1 does not bind live tissue due to cis inhibition by 
nearby GD1a (Greenshields et al., 2009). Consequently, following injection of 
DG1, wildtype, GalNAcT-/- and GalNAcT-/--Tg(neuronal) mice all failed to clear 
this antibody from their sera over 7 days. This experiment highlights the 
potential discrepancy between the antibodies found in the serum and the 
antibodies which cause disease (summarised in Figure 6.11).  
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Figure 6.11: Anti-ganglioside antibodies detectable in patient sera by ELISA do not 
necessarily represent the disease-causing antibodies. (1) Polyclonal antibodies 
mounted in response to c jejuni infection. One antibody type can bind to its target 
antigen, termed cis independent (purple). Another antibody type is blocked from its 
target binding site by surrounding lipids, termed cis inhibition (yellow). (2) If it is on a 
membrane which does not allow for internalisation, such as the NoR, this antibody can 
activate complement and cause MAC pore formation, leading to injury. If it is on a 
membrane which is endocytically active, the antibody is taken into the cell. (3) In 
either case, the non-binding antibody has nowhere to go and continues to circulate in 
the blood. (4) When serum is screened, the tissue-binding antibody has been removed 
from the circulation, resulting in a negative or weak ELISA result, whereas the non-
binding antibody shows up strongly positive. 
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It is now widely accepted that anti-ganglioside antibodies have a pathogenic role 
in GBS and in chronic variations such as MMN, but it has often proven difficult to 
show direct pathogenicity of patient sera in mouse models of autoimmune 
neuropathy without overexpression of target antigen (Goodfellow et al., 
2005;Jacobs et al., 2002;Zitman et al., 2011b). Similarly, when monoclonal 
antibodies are cloned from patient peripheral blood mononuclear cells, they 
provide a spectrum of different binding patterns in the rodent nervous system 
(O'Hanlon et al., 1996), with some antibodies binding well to neuronal 
structures, and some not binding at all. Although differences exist between the 
neuronal membrane composition of rodent and human nerves, the clearance of 
pathogenic antibodies by internalisation may explain this failure to induce injury 
in mouse models. Studies which have successfully found anti-GM1, GD1a or 
GM1/GD1a complex positive patient sera to be pathogenic, have done so in 
GD3s-/- mice, which overexpress a-series gangliosides. In this instance the 
membrane organisation is altered, and the target which is normally masked from 
the remaining serum antibodies, may be presented in a fashion which allows 
antibody binding.  
It is an important finding that the antibodies found in the serum are not 
necessarily pathogenic, though it is likely that they bind to either the same 
ganglioside target, or a structurally similar ganglioside.   
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7 Uptake of anti-GD1b antibody is activity dependent 
7.1 Introduction 
The motor nerve terminal has a high ability to take up anti-GD1b ganglioside, as 
demonstrated in chapter 5, though the mechanisms behind this are unclear. In 
various cell culture experiments, ganglioside recycling and the resulting anti-
ganglioside antibody uptake, has been shown to occur by clathrin independent, 
caveolin-mediated endocytosis. In in vivo anti-ganglioside uptake experiments 
(Chapter 5 and 6) wildtype mice were able to clear antibody at a much faster 
rate than GalNAcT-/--Tg(neuronal) mice, indicating that non-neuronal cells are 
taking up antibody. On the evidence of cell culture experiments, this non-
neuronal uptake is presumed to be caveolae-dependent. As ex vivo preparations 
have shown, the motor nerve terminal rapidly endocytoses anti-ganglioside 
antibody, but the node of Ranvier  does not, (Fewou et al., 2012) and Chapter 
6), indicating that most of the clearance seen in GalNAcT-/--Tg(neuronal) in vivo 
experiments (Chapter 5 and 6) was due to clearance by the nerve terminal. As 
the motor nerve terminal is a highly active membrane which lacks caveolae, it 
was hypothesised that the uptake of this antibody may be enhanced, or 
dependent on, nerve terminal activity. This would also further explain the 
previous observation that the NoRs, which are relatively stable structures with a 
slow membrane turnover to maintain their specialised function of action 
potential propagation (Zhang et al., 2012), may not have the ability to 
internalise antibody at the same rate (Fewou et al., 2012). Previously, entry of 
botulinum neurotoxin, which binds to surface GT1b and GD1b gangliosides, was 
shown to be activity dependent at motor nerve terminals in both nerve 
stimulation and KCl-induced membrane activity paradigms (Dong et al., 
2003;Rummel et al., 2009). This chapter therefore aimed to demonstrate 
whether the internalisation of anti-ganglioside antibody at the nerve terminal is 
enhanced by nerve terminal activity. As this is a proof of concept study, 
experiments thus far have only been carried out on wildtype mice. 
7.2 Stimulation of nerve terminals with KCl 
Initially, to study the effect of activity dependent uptake, the internalisation of 
MOG1 antibody was compared in unstimulated tissue and tissue stimulated with 
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the addition of KCl into the Ringer’s medium. A high extracellular concentration 
of K+ causes depolarisation of the nerve terminal and initiates calcium-induced 
release of acetylcholine-containing vesicles, followed by their subsequent 
recycling by endocytosis. Following labelling with MOG1, wildtype TS tissue was 
incubated in a Ringer’s solution with an increased K+ concentration (56 mM vs 
4.5 mM in standard Ringer’s solution) to induce membrane activity for 10 
minutes (n=3). Compared with unstimulated tissue, tissues exposed to high K+ 
showed significantly lower MOG1 staining at the nerve terminal (p<0.0001, 
medians of 35.00 AU vs. 6.00 AU respectively). Instead, high KCl-treated tissue 
showed equivalent staining to unstimulated tissue which had been incubated in 
Ringer’s for a further 20 minutes at room temperature (median of 12.00 AU, 
p>0.05), where, based on previous observations, endocytosis would have been 
expected to occur in a temperature dependent manner (Figure 7.1).  
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Figure 7.1: Internalisation of anti-GD1b antibody is accelerated by K+ induced nerve 
terminal stimulation. Wildtype (n=3) TS muscle was labelled with anti-GD1b antibody 
MOG1, then washed and either incubated at room temperature for 10 minutes with 
normal Ringer’s (unstimulated) or high K+ Ringers (high K+ stimulated) or with normal 
Ringer’s for 30 minutes at room temperature (Unstimulated +20 minutes) . A: 
Illustrative pictures show the MOG1 signal, which overlies the endplate in unstimulated 
tissue, is reduced in stimulated tissue and tissue which had a further 20 minute 
incubation at room temperature. B: Quantitatively, high K+ stimulated tissue shows 
significantly reduced staining compared with unstimulated tissue, and shows equivalent 
levels to unstimulated tissue which has been incubated for an extra 20 minutes at room 
temperature. Scale bar = 20 µm. ***=p<0.001, ****=p<0.0001, Kruskal-Wallis with Dunn’s 
multiple comparison test. A minimum of 226 NMJs were analysed per group. Non-
parametric data displayed as Tukey box plot (see section 2.20). 
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To investigate whether this high K+ induced acceleration was enough to reduce 
the amount of damage caused by complement activation, stimulated and 
unstimulated tissue were subsequently washed and incubated with 40% NHS for 
30 minutes at 37oC (n=3). Neuromuscular junctions were then analysed for 
deposition of MAC (Figure 7.2). There was no significant difference between MAC 
deposition in unstimulated tissue and tissue which had been stimulated with a 
high K+ concentration (medians of 86.00 AU vs 68.00 respectively, p>0.05). Both 
of these tissues had statistically higher staining than unstimulated tissue which 
had been incubated at room temperature for a further 50 minutes (p<0.0001, 
median of 2.00 AU). The deposition of MAC in both cases was accompanied by a 
loss of CFP in the motor nerve terminal, indicating the disruption of the nerve 
terminal integrity. 
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(Figure on previous page) 
Figure 7.2: Accelerated internalisation of anti-GD1b antibody by K+ induced nerve 
terminal stimulation does not reduce MAC deposition at motor nerve terminals. 
Wildtype (n=3) TS muscle was labelled with anti-GD1b antibody MOG1, washed and 
incubated at room temperature for 10 minutes with normal Ringer’s (unstimulated) or 
high K+ Ringers (high K+ stimulated) or with normal Ringer’s for 60 minutes at room 
temperature (Unstimulated +50 minutes). Tissue was then incubated with 40% NHS for 
30 minutes at 37oC. A: Illustrative pictures show MAC deposition over the endplates of 
unstimulated and stimulated tissue, which is accompanied by loss of axonal CFP. White 
arrow head indicates expected CFP presence indicated by BTx signal. MAC deposition is 
lower in tissue which was incubated for a further 50 minutes at room temperature. B: 
Quantitatively, unstimulated and high K+ stimulated tissue show equivalent levels of 
MAC intensity overlying the BTx signal. Unstimulated tissue incubated for an extra 50 
minutes at room temperature, showed significantly reduced MAC intensity compared to 
both other tissues. Scale bar = 20 µm. ****=p<0.0001, Kruskal-Wallis with Dunn’s 
multiple comparison test. A minimum of 363 NMJs were analysed per group. Non-
parametric data displayed as Tukey box plot (see section 2.20). 
 
7.3 Electrical stimulation of intercostal nerves  
To further study the effect of stimulation-induced uptake of anti-GD1b antibody, 
wildtype TS muscle was incubated with MOG1 antibody, washed with Ringer’s 
then the intercostal nerves, which supply the TS, were electrically stimulated to 
induce membrane activity. Electrical stimulation was confirmed by muscle 
twitching in response to nerve stimulation only, (rather than direct muscle 
stimulation). If stimulation in this manner could not be confirmed tissue was not 
included in the experiment. Nerve terminals from stimulated tissues (n=3) 
showed weaker anti-GD1b antibody staining than those from unstimulated tissue 
(n=3)(Figure 7.3A). Nodes of Ranvier (example shown by white arrowhead in 
Figure 7.3A) appeared to still show staining following stimulation. Quantitatively 
(Figure 7.3B), the antibody intensity at unstimulated nerve terminals was 
significantly higher than TS muscle which had been electrically stimulated 
(p<0.0001, median of 53 AU vs. 5 AU respectively). 
To demonstrate that the clearance of antibody was indeed due to uptake into 
the nerve terminal, membrane was permeabilised with Triton X-100 and 
reprobed with secondary. When reanalysed, previously weakly or negatively 
stained NMJs were shown to be highly positive for antibody and this staining 
appeared to be within the nerve terminal, indicating the antibody had been 
taken into the nerve terminal following stimulation. Quantitatively, there was no 
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difference between antibody intensity between stimulated and unstimulated 
tissue following permeabilisation (median of 97 AU vs. 81 AU respectively). 
 
Figure 7.3: Electrical stimulation of intercostal nerves increases the uptake of anti-
GD1b antibody at wildtype TS motor nerve terminals. Wildtype (n=3) TS muscle was 
labelled with anti-GD1b antibody MOG1, then washed and the intercostal nerves of one 
TS per mouse was stimulated, while the other remained unstimulated. Once analysed, 
tissue was permeabilised, reprobed with secondary antibody and reanalysed for 
antibody presence. A: Unstimulated NMJ showing anti-GD1b antibody deposition at the 
nerve terminal and stimulated NMJ showing much fainter anti-GD1b presence at the 
nerve terminal and brighter antibody staining at the terminal node of Ranvier (white 
arrowhead). When permeabilised and restained with secondary antibody, the same 
stimulated nerve terminal showed strong antibody presence B: Quantitatively, the nerve 
terminals of stimulated TS tissue showed significantly reduced anti-GD1b antibody 
staining. C. When tissue was permeabilised, levels of antibody were no different in 
stimulated tissue compared to unstimulated tissue. Scale bar = 20 µm.  ****=p<0.0001 vs 
unstimulated, Mann-Whitney test. A minimum of 230 NMJs were analysed per group. 
Non-parametric data displayed as Tukey box plot (see section 2.20). 
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Figure 7.4: Accelerated internalisation of anti-GD1b antibody by intercostal nerve 
stimulation results in reduced MAC deposition at motor nerve terminals and 
increased presence of healthy NMJs. Wildtype (n=3) TS muscle was labelled with anti-
GD1b antibody MOG1, then washed and the intercostal nerves of one TS per mouse was 
stimulated, while the other remained unstimulated. A: Illustrative pictures show strong 
MAC deposition at unstimulated nerve terminals, whereas MAC deposition is weak over 
the endplates of stimulated muscle. This is accompanied by retention of CFP in the 
nerve terminal.  White arrow head indicates where CFP should be as indicated by BTx 
signal. B: Quantitatively, stimulated tissue shows statistically reduced MAC staining at 
the NMJ when compared with unstimulated tissue (****=p<0.0001 vs. unstimulated, 
Mann-Whitney test). A minimum of 182 NMJs were analysed per group. Non-parametric 
data displayed as Tukey box plot (see section 2.20). C: Fisher’s exact test indicated that 
stimulated TS had more healthy NMJs than unstimulated as indicated by the presence of 
CFP (displayed as mean % of total junctions analysed). Scale bar = 20 µm. ****=p<0.0001 
vs. unstimulated. 
To determine whether the reduced anti-GD1b antibody intensity evoked by 
intercostal nerve stimulation resulted in protection of the nerve terminal from 
complement-mediated injury, unstimulated and stimulated tissue was this time 
washed then treated with 40 % NHS for 30 minutes at 37oC and stained for MAC 
deposition to indicate terminal complement pathway activation. The intensity of 
MAC deposition was analysed and the number of healthy NMJs were also counted 
by the presence or absence of CFP (n=3). Stimulated TS muscle showed 
significantly lower MAC deposition (Figure 7.4B) than unstimulated tissue 
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(median of 68 AU vs. 167 AU respectively, p<0.0001). This reduction in MAC 
deposition was accompanied by a reduction in the number of nerve terminals 
which were negative for CFP. Total CFP positive and CFP negative nerve 
terminals were compared by Fisher’s exact test, which showed a significantly 
higher presence of CFP-positive NMJs in stimulated tissue  compared with 
unstimulated (p<0.0001). Data is displayed as the mean percentage of healthy 
NMJs (Figure 7.4C). 
7.4 Discussion 
Previously, it has been shown that at physiological temperatures anti-ganglioside 
antibody can be taken up at the nerve terminal by a previously undefined 
mechanism. Contrastingly, these antibodies remains surface-bound on other 
structures such as the NoR, a stable membrane with slow turnover of its 
components, to maintain its specialised function (Fewou et al., 2012;Zhang et 
al., 2012). This has subsequently been confirmed in chapter 5 and 6 of this 
thesis. When considering these differences in anti-ganglioside antibody 
internalisation, it was considered that the specialised nature of the nerve 
terminal for vesicle release and recycling, may account for its enhanced uptake 
ability. Many studies have looked at the uptake of toxins which bind gangliosides 
at the motor nerve terminal. Botulinum toxin, a GD1b-binding toxin (Schiavo et 
al., 2000), is taken into the nerve terminal in a temperature and activity-
dependent manner (Black and Dolly, 1986), with internalisation being prevented 
at temperatures of 4oC. So far, work on anti-ganglioside antibody uptake at the 
nerve terminal has been investigated using physiological temperatures, but this 
chapter has demonstrated that internalisation of antibody is also increased by 
nerve terminal activity. The increase in uptake by temperature and activity may 
both be neurotransmitter release-associated as spontaneous vesicle release has 
been shown to increases at higher temperatures (Gansel et al., 
1987;Greenshields et al., 2009;Nishimura, 1986). As the motor nerve terminal is 
a specialised membrane with no caveolae and high vesicular cycling, it is 
unsurprising that the antibody internalisation mechanisms at this site differs 
from the caveolin-mediated endocytosis which has been demonstrated in cell 
work (Fewou et al., 2012;Sharma et al., 2003;Singh et al., 2003). This does not 
exclude the possibility that antibody uptake at other membranes in vivo is not 
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mediated by caveolae; as discussed in chapter 5, despite the difference in whole 
brain enzyme expression levels between wildtype and GalNAcT-/--Tg(neuronal) 
mice, levels of ganglioside expression at the membrane appear consistent as 
demonstrated by similar staining intensities of anti-ganglioside antibodies (see 
chapter 3). Therefore the rapid clearance of MOG1 and DG2 by wildtype mice in 
chapter 5 and 6 when compared with GalNAcT-/--Tg(neuronal) mice indicates a 
contribution of clearance by non-neuronal cells. These non-neuronal cells may 
be clearing the antibody via caveolae. Vascular endothelial cells are known to 
express gangliosides (Cho et al., 2012) and often blood vessels are detected in 
muscle-nerve preparations using in-house anti-ganglioside antibodies (Willison 
lab, unpublished observations). These cells are also sites of high caveolae 
presence (Frank et al., 2003); therefore, it is possible that the endothelial cells 
are responsible for a large portion of non-neuronal antibody clearance. 
Increased nerve terminal uptake of botulinum toxin by nerve stimulation results 
in increased paralytic halftime as it is within the nerve terminal that the toxin 
exerts its pathologic effects (Rummel et al., 2009). In contrast, removal of anti-
ganglioside antibody from the plasma membrane surface will prevent its 
interaction with complement, thus alleviating the extent of nerve terminal 
injury. The use of KCl to depolarise the nerve terminal membrane has previously 
been shown to be sufficient to increase botulinum toxin entry into PC12 cells 
and mouse motor nerve terminals (Dong et al., 2003), and was therefore used to 
initially demonstrate whether anti-ganglioside antibody underwent the same 
activity-dependent uptake. In this chapter, high K+ concentration did indeed 
result in a significantly decreased presence of anti-GD1b antibody on the nerve 
terminal surface, indicating an increased uptake of antibody at this site. 
However, when tissue stimulated with a high K+ concentration was then exposed 
to NHS, this increased uptake was not sufficient to result in decreased MAC 
deposition on the endplate. More physiologically relevant however, is the 
stimulation of the nerves supplying the TS. This resulted in a more obvious 
decrease in surface antibody presence, which was shown to be present within 
the nerve terminal following tissue permeabilisation and reincubation with 
secondary antibody. In an NHS-mediated injury paradigm, this reduction in 
surface antibody was enough to result in significantly reduced terminal 
complement pathway activation, as indicated by a reduction in MAC deposition. 
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The resulting decrease in MAC deposition was accompanied by the presence of 
more CFP-positive NMJs. While at early timepoints, the absence of CFP does not 
always coincide with the destruction of axonal NFil following a MAC-mediated 
injury (Rupp et al., 2012); it can be equated with a breach of axonal membrane 
integrity. Therefore, if a NMJ still retains CFP in its motor nerve terminal, it is 
safe to assume that the axon has been spared from membrane damage.  
Therefore, it appears that increased nerve terminal activity results in its self-
preservation from antibody and complement mediated attack. 
Thus far this effect has only been demonstrated ex vivo and in wildtype mice 
due to time constraints; however, a robust animal model is still needed to 
determine the impact of this effect in vivo. Stimulation has been shown to 
increase botulinum toxin uptake at its target site, reducing the spread of toxin 
to nearby muscles (Horisberger et al., 2013;Hughes and Whaler, 1962). By the 
same principle, it is possible that voluntary muscle contraction or even 
peripheral nerve stimulation may be able to enhance anti-ganglioside antibody 
uptake and thus reduce the available pathogenic anti-ganglioside antibody. It is 
hypothesised that animals which are more active (i.e. by using a forced exercise 
treadmill paradigm) may be able to clear antibody from their serum faster than 
less active (unexercised) animals. A similar study has been performed in rats 
using the established P2-peptide induced EAN model of GBS. In the group of 
exercised animals, the clinical score, CMAP amplitudes and motor conduction 
velocities were significantly improved compared to the non-exercised group 
(Calik et al., 2012). The authors hypothesise that exercise-induced changes in 
immune cell activation, quantity, cytokine secretion or trafficking are 
responsible for the improvements. Conceivably, a reduction in anti-P2 antibody 
could account for the subsequent immune cell changes. It is difficult to draw too 
much from this model as it is so different from our proposed model (the use of 
rats instead of mice, P2 peptide instead of ganglioside, myelin injury instead of 
axonal injury, and the training of only the exercised rat group before injury 
induction) but provides some background data supporting the effect of exercise 
on immune-mediated neuropathies. If a forced-exercise model can demonstrate 
an effect on circulating antibodies, and antibody and complement-mediated 
injury, the effect of nerve terminal activity on antibody clearance may have 
important clinical consequences. 
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For an acute condition such as AMAN, the effect of activity-dependent 
internalisation of antibody would presumably be dependent on how much 
damage has already been caused. In this proof-of-principle, ex vivo study, NHS 
was administered after the antibody incubation and stimulation so it is unclear 
whether this would have any major effects in patients where acute antibody 
attack had already occurred. Presumably, if exercise or nerve stimulation was 
able to reduce circulating antibody levels, the incidence of ongoing injury in GBS 
would be reduced, thus allowing a faster recovery time. This may theoretically 
be especially useful in patients who have chronic autoimmune neuropathies, 
such as MMN, who have prolonged motor weakness due to circulating anti-GM1 
IgM antibodies (Pestronk et al., 1988). However, evidence of the effects of 
exercise in autoimmune neuropathy patients has been conflicting, Most GBS 
studies have been conducted in patients who are in the recovery phase, where 
antibodies are still present but at a much lower titre than immediately after GBS 
onset (Odaka et al., 2003). Some studies have shown that exercise in the 
recovery phase of GBS results in improved prognosis, though this may be due to 
an improvement of physical fitness. Withal, some studies have found an 
improvement in physical fitness, but no improvement in the patients’ perceived 
fatigue (Bussmann et al., 2007;Fisher and Stevens, 2008;Mobbs et al., 2007). 
Following intense exercise, both MMN and GBS patients can experience 
prolonged weakness and potential muscle damage, resulting from the overwork 
of the few muscle fibres which are still receiving stimulation (Bassile, 1996). 
Additionally, studies have shown that in MMN, nerve stimulation can cause 
activity-dependent conduction block due to hyperpolarisation of the axonal 
membrane (Nodera et al., 2006). 
Before effects in patients are considered, it is clearly important to first establish 
whether forced exercise can affect in vivo models of disease and whether the 
activity dependency is common to antibodies targeting other gangliosides. 
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8 Discussion 
Infection with C.jejuni can, in rare cases, lead to the generation of antibodies 
which cross-react with peripheral nerves. In the case of motor axonal and 
sensory forms of GBS, as well as chronic variants CIDP and MMN, circulating 
antibodies have been shown to be directed towards gangliosides, while the 
target antigen in AIDP remains elusive. Currently there is no mouse model which 
mimics GBS, though rabbits which have been immunised with gangliosides GM1 
and GD1b go on to develop peripheral motor and sensory neuropathy 
respectively (Yuki et al., 2001;Yuki et al., 2004;Kusunoki et al., 1996). This lab 
has created GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mice which have 
the synthesis of complex ganglioside restricted to their neurons or glia 
respectively. These mice were developed with the original aim of being used as 
part of active immunisation models of GBS. This restriction of GalNAcT enzyme 
expression, and thus the expression of complex gangliosides, was hoped to 
overcome the tolerance to ganglioside immunisation which has been shown 
previously in wildtype mice (Bowes et al., 2002;Lunn et al., 2000), with the view 
to demonstrate the differences between neuronal and glial-directed antibody 
attack. These mice can also be used in determining the role and significance of 
neuronal or glial complex ganglioside expression at specialised nervous system 
membrane domains (Yao et al., 2014). In GalNAcT-/- mice, the global loss of 
complex gangliosides results in an age-dependent degenerative phenotype 
accompanied by neurodegeneration, demyelination and nodal disruption 
(Chiavegatto et al., 2000;Sheikh et al., 1999;Susuki et al., 2007a). The 
restoration of neuronal complex ganglioside expression is enough to save this 
phenotype (Yao et al., 2014). These mice have many potential roles in the 
investigation of anti-ganglioside antibody mediated binding and injury at specific 
membrane sites. In patients, anti-ganglioside mediated injury occurs only on 
peripheral nerve membranes (neuronal and potentially also glial), despite the 
fact that gangliosides are present ubiquitously. Therefore, the use of these mice 
can mimic the site-specific antibody targeting that is seen in human disease. 
The aims of this thesis were to use these mice as tools to create an active 
immunisation model of GBS, and subsequently to investigate the injury caused 
by an endogenous antibody response to ganglioside liposome immunisation. In 
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addition, the membrane-specificity of complex ganglioside expression also 
allowed an investigation into the effect of antibody internalisation at specific 
sites. In particular, interest lay in the internalisation of anti-ganglioside antibody 
at the nerve terminal, which was previously demonstrated to occur ex vivo in 
wildtype and GD3s-/- mice (Fewou et al., 2012). This latter aim was met with the 
novel finding that circulating anti-ganglioside antibody levels can be affected by 
their internalisation by ganglioside-expressing membranes and that the 
circulating antibodies which remain are not necessarily pathogenic. 
8.1 Main findings 
The work detailed in the first part of this thesis aimed to demonstrate that 
GalNAcT-/--Tg(neuronal) and GalNAcT-/--Tg(glial) mice, could be actively 
immunised and show a neuronal or glial injury upon the introduction of NHS. This 
was done with the hope of creating a model of disease where anti-ganglioside 
antibody and complement mediated injury could be achieved in vivo with 
endogenously produced antibodies. Previously, to mimic disease in vivo in mice, 
a passive transfer protocol was used, where a high affinity monoclonal antibody 
is injected directly into the mice, followed by NHS 16 hours later (Halstead et 
al., 2005a;Halstead et al., 2008). While this approach is effective in 
demonstrating the effect of anti-ganglioside antibody and complement on the 
peripheral nervous system of mice, it does not faithfully mimic the clinical 
situation. In patients, an antecedent infection or vaccination initiates an 
immune response which results in an endogenous antibody and complement 
mediated attack of gangliosides on peripheral nerves. An active immunisation 
model of disease would more accurately imitate this situation. This would allow 
us to more authentically study disease pathogenesis, with the ultimate goal of 
developing and testing new therapeutics. A similar study was attempted by a 
previous lab member who demonstrated an immune response to GT1b following 
immunisation with GT1b-containing liposomes. However, a robust injury was not 
detected following NHS injection, with only a slight reduction in tidal volume 
and negligible complement deposition (S. Rinaldi, unpublished data). GT1b was 
chosen as a target in this previous study as thin layer chromatography had 
demonstrated a comparable restoration of GT1b presence in GalNAcT-/--
Tg(neuronal) mice to wildtype mice. A passive transfer model confirmed that an 
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injury could be demonstrated following injection of the in-house monoclonal 
antibody MOG16, which targets both GT1b and GD1b. After demonstrating in 
chapter 3 that GD1b was highly present at the nerve terminal of GalNAcT-/--
Tg(neuronal) and GalNAcT-/--Tg(glial) mice using anti-GD1b antibody MOG1, it 
was considered that GD1b may be a better target, and that perhaps the injury 
previously demonstrated using MOG16 may be due to its target of GD1b rather 
than GT1b. Thus, it was had hoped that immunising the mice with this antigen, 
rather than GT1b, would result in a more robust injury. This was supported by 
the evidence that injury can be induced by passive transfer of anti-GD1b 
antibody MOG1 and NHS in Chapter 4. As in the previous study with GT1b, it was 
demonstrated that, unlike wildtype mice, GalNAcT-/--Tg(neuronal) and GalNAcT-
/--Tg(glial) mice responded well to immunisation with GD1b-containing 
liposomes, though neither strain responded as well as the GD1b-lacking GalNAcT-
/- mice. However, even with modification of the immunisation procedure to 
include the adjuvant MPLA, once again a robust injury was not detectable in 
these mice in response to the circulating antibodies, even when NHS was 
injected as a source of complement. ELISpot data from two different GD1b 
liposome immunisation experiments implied that at the B-cell level, no 
significant difference existed between wildtype and GalNAcT-/- response to 
immunisations. This led to the belief that another factor was affecting the 
amount of detectable antibody in the serum of these different mouse strains. A 
previous study had already demonstrated that anti-ganglioside antibodies can be 
internalised at the nerve terminals of wildtype or GD3s-/- mice in ex vivo TS 
preparations (Fewou et al., 2012). It was therefore felt that an investigation was 
warranted into whether this phenomenon may be reducing circulating antibody 
levels, and subsequently the likelihood of an effective injury. The aims of these 
investigations were to expand on the knowledge already gained from wildtype 
and GD3s-/- mice, using the GalNAcT-/--Tg(neuronal) and occasionally GalNAcT-/--
Tg(glial) mice to demonstrate the effects of site-specific uptake. Here I will 
summarise what I consider to be the main novel findings of this thesis and their 
implications in the wider field of GBS research. 
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8.1.1 Receptor-dependent internalisation can affect circulating levels 
of anti-ganglioside antibody 
To date, the primary mechanisms by which antibody levels have been shown to 
be cleared from the circulation is by non-specific pinocytic uptake, followed by 
lysosomal degradation (Mould and Sweeney, 2007). The FcRn has been shown to 
prolong IgG half-life in the serum, by salvaging IgG scavenged in this way and 
recycling it back to the circulation (Lobo et al., 2004). This thesis has 
emphasized the importance of receptor-mediated endocytosis as another major 
mechanism of antibody regulation. Specifically, this thesis has looked at the 
uptake of anti-ganglioside antibodies, which are elevated in the sera of patients 
with GBS (Ilyas et al., 1988b;Ilyas et al., 1988a;Ho et al., 1995;Kuwabara et al., 
1998;Ogawara et al., 2000). Using a passive immunisation protocol whereby 
monoclonal anti-ganglioside antibody was injected i.p., it was shown that 
antibody against ganglioside may be cleared from the circulation in wildtype and 
GalNAcT-/--Tg(neuronal) mice, but not in GalNAcT-/- mice. This lack of clearance 
in GalNAcT-/- mice demonstrates that the binding of the antibody to target is 
required for the effect (Figure 5.5). This is a crucial piece of insight into 
antibody handling, especially in the context of our animal models, where, even 
in passive immunisation experiments, antibody levels may be being rapidly 
reduced within 1 day of injection, as in the wildtype mice. This may not be of 
major importance when injecting large quantities of antibody. For example, 
when 1 mg of MOG1 was passively injected to demonstrate injury in Chapter 4, 
injury and (although not shown) serum antibody levels in wildtype mice and 
GalNAcT-/--Tg(neuronal) mice were similar. In this case, it is assumed that levels 
of antibody were so high (1 mg) as to saturate the internalisation machinery. 
When considering the active immunisation model attempted in this thesis, a 
chronic but presumably lower level of antibody is produced, therefore not 
saturating the process of internalisation. It was proposed that the effect of 
antibody internalisation is responsible for the low levels of antibody seen in 
actively immunised wildtype mice. Similarly, in GalNAcT-/--Tg(neuronal) mice, 
which showed an intermediate level of antibody production against GD1b,  
internalisation prevents a sufficient level of pathogenic antibody presence in the 
serum to result in a robust, detectable injury either by in vivo testing methods, 
or at the immunohistological level. Further optimisation of the immunisation 
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procedure may be required to gain such a level of antibody. The concept that 
receptor-dependent uptake may affect serum levels of antibodies is supported 
by, and may help explain, the fact that polyreactive monoclonal antibodies have 
a shorter half-life than monoreactive monoclonal antibodies; Polyreactive 
antibodies may bind and be internalised at more sites than monoreactive 
antibodies, thus monoreactive antibodies remain for longer in the serum 
(Sigounas et al., 1994). 
The idea that wildtype mice may not be immunologically tolerant to glycolipid 
immunisation is also a novel concept. It has been demonstrated that, when 
immunised with gangliosides, wildtype mice respond much more poorly than 
mice which have disrupted target ganglioside synthesis (Bowes et al., 2002;Lunn 
et al., 2000). It has been presumed that these mice are simply tolerant to 
glycolipid immunisation with a self-antigen. Tolerance exists to prevent an 
immune reaction against host cells, thus preventing autoimmune conditions such 
as GBS from developing. Although in wildtype mice gangliosides are more 
enriched in nervous system tissues, their expression is ubiquitous. It is therefore 
likely that any auto-reactive T and B cells have been removed in these mice. In 
GalNAcT-/- mice however, no complex gangliosides are expressed, therefore their  
naïve T and B cells will recognise them as “foreign” antigens upon exogenous 
delivery of ganglioside-expressing liposomes. The resulting immune response in 
these mice will therefore be unhindered by tolerance. In this thesis, the 
difference in the serum antibody level in wildtype and GalNAcT-/- mice was 
shown once again, with the additional observation that responses in GalNAcT-/--
Tg(neuronal) and GalNAcT-/--Tg(glial) mice, which have restricted GalNAcT 
expression, are intermediate. It was considered that these mice may have 
intermediate levels of tolerance either because antigen levels were below some 
critical threshold (Thomas, 2001) or because their B cells were not being 
exposed to the “self” antigen as it was restricted to tissue-specific sites, a 
problem overcome by T cells through the autoimmune regulator gene Aire 
(Liston et al., 2003). However, GD1b-specific ELISpots indicated that the anti-
GD1b IgG and IgM immune responses were statistically similar in all mouse 
strains. As this seemed to contradict what was thought about tolerance in 
wildtype mice, the experiment was repeated again using freshly immunised 
wildtype mice and GalNAcT-/- mice. Once again no significant difference existed 
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between the anti-GD1b IgG or IgM producing cells, though less IgG was being 
produced in both strains (unsurprising at such an early timepoint following 
immunisation). While a role for tolerance on the levels of antibody seen in the 
serum cannot be completely ruled out, the new knowledge that antibodies can 
be cleared at a rate which is dependent on the expression levels of their target 
receptor, suggests the possibility that any antibodies produced by wildtype and 
GalNAcT-/--Tg(neuronal) mice may be cleared in the same manner. The low 
levels of antibody seen in wildtype mouse serum would therefore be due to 
faster rates of clearance rather than higher tolerance. This could mean that 
antibody clearance by receptor-mediated internalisation could confer another 
means of tolerance by removing the antibody produced by autoreactive B cells. 
8.1.2 Motor nerve terminal is a major site of activity dependent 
antibody clearance 
Although the concept that circulating pathogenic antibody can be regulated by 
receptor-dependent internalisation is interesting in itself, the use of GalNAcT-/--
Tg(neuronal) mice in the clearance studies allowed us to account for the 
clearance by neuronal cells only. GalNAcT-/--Tg(neuronal) mice cleared the 
antibody from the circulation at a slower rate than wildtype mice. Enzyme 
expression has been shown to be lower in GalNAcT-/--Tg(neuronal) mice when 
compared to wildtype mice. However, as discussed in Chapter 5, these levels 
were measured in whole brain, therefore including non-neuronal cells in the 
assay. These non-neuronal cells will have normal ganglioside expression in 
wildtype mice but intentionally lack the GalNAcT enzyme in GalNAcT-/--
Tg(neuronal) mice. Further, staining profiles in Chapter 3 showed similar levels 
of anti-ganglioside antibody intensity between wildtype and GalNAcT-/--
Tg(neuronal) mice, indicating that levels of ganglioside are similar on the 
neuronal membranes of these mice. It is therefore more likely that the faster 
rate of clearance in wildtype mice is due to non-neuronal uptake. Subtracting 
the differences to account for non-neuronal cells, uptake by neuronal cells still 
accounted for a great proportion of clearance, and alone managed to clear the 
antibody from the circulation within 6 days. The node of Ranvier has previously 
demonstrated an inability to clear antibody (Fewou et al., 2012). Even the distal 
nodes in TS preparations, which have only weak BNB protection (McGonigal et 
176 
 
al., 2010) were shown in Chapter 6 to be unable to internalise bound anti-GM1 
antibody (see Figure 6.1 and 6.3 for examples) as well as in Chapter 7 for anti-
GD1b antibody (Figure 7.3). Antibody may also be binding at the nerve roots in 
GalNAcT-/--Tg(neuronal) mice, a region of the PNS which lacks BNB protection 
(Weerasuriya and Mizisin, 2011) and has been shown to be affected in rabbit 
models of AMAN (Susuki et al., 2003). However, it is more likely that the nerve 
roots would act in a similar manner to the node of Ranvier as these sites lack the 
same active membrane of the nerve terminal. Therefore, it is likely that the 
clearance seen in GalNAcT-/--Tg(neuronal) mice is almost solely attributable to 
clearance by the motor nerve terminal, making it a major scavenger of 
pathogenic antibody. This concept has been discussed previously with the ex 
vivo observations of anti-ganglioside antibody uptake at wildtype and GD3s-/- 
mouse motor nerve terminals (Fewou et al., 2012;Fewou et al., 2014), however 
the use of GalNAcT-/--Tg(neuronal) mice alongside wildtype and GalNAcT-/- mice 
in vivo clearly demonstrates how major the effect neuronal uptake truly has on 
antibody levels. This lends more credence to the hypothesis that this motor 
nerve terminal internalisation is the key factor differentiating why nodal injury 
is more apparent in patients than motor nerve terminal injury (Ho et al., 
1997;Kuwabara et al., 2011;Spaans et al., 2003;Griffin et al., 1996;Hafer-Macko 
et al., 1996a;Kuwabara et al., 1998), despite the nerve terminal’s ability to be 
injured by anti-ganglioside antibodies and complement in ex vivo muscle-nerve 
preparations (Goodfellow et al., 2005;Goodyear et al., 1999;Halstead et al., 
2004;Halstead et al., 2005b). In wildtype mice, although GD1b is enriched on 
neurons, it is also present in many other tissues, hence the rapid uptake seen in 
these mice. Gangliosides, and their associated antibody ligands, have been 
shown previously in cell work to be mostly internalised via clathrin independent, 
mainly caveolin-mediated, endocytosis (Crespo et al., 2008;Singh et al., 
2003;Fewou et al., 2012). It is hypothesised that the non-neuronal uptake of 
antibodies in wildtype mice, which accounts for their rapid ability to clear 
antibody, is mostly due to caveolin-mediated uptake. It is likely that much of 
this uptake may occur in vascular endothelial cells, where gangliosides are 
widely expressed (Cho et al., 2012) and where caveolae are most abundant 
(Frank et al., 2003). This widespread non-neuronal uptake may offer an 
explaination as to why, in patients, antibodies directed against ubiquitously-
expressed gangliosides do not result in injury to tissues other than peripheral 
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nerves. Contrastingly, uptake at the nerve terminal was shown to be activity 
dependent, implying that the uptake at this site is reliant rather on the vesicle 
recycling pathways which occur following neurotransmitter release.  
The question may be asked: why are patient anti-ganglioside antibodies not 
cleared rapidly if they, like wildtype mice, have ubiquitous ganglioside 
expression? Although the situation in patients is clearly more complex and not as 
fully understood as in the simplified mouse model, two explanations are brought 
to mind. Firstly, the levels of pathogenic antibody in patients may simply be too 
high for clearance to occur effectively, thereby allowing binding of sites which 
cannot effectively internalise antibody, such as the NoR. Secondly, the antibody 
MOG1 has been shown to bind GD1b in a cis-independent manner (Rinaldi et al., 
2009), presumably allowing the widespread GD1b binding and subsequent 
internalisation observed in wildtype mice. In patients, antibodies with the same 
cis-independent binding may also be quickly cleared from the circulation. 
However, patients will also likely produce antibodies which are cis-inhibited by 
surrounding glycolipids, or bind neoepitopes formed by gangliosides in complex 
with other lipids. The clearance of these antibodies will therefore be restricted 
to precise sites where the local microenvironment permits binding. In this case, 
the effect of uptake is likely to be similar to that of GalNAcT-/--Tg(neuronal) 
mice, where the target is restricted to the neurons. This restricted uptake would 
therefore lead to prolonged presence of circulating antibody. While this 
prolonged exposure may not affect the nerve terminal which can clear the 
antibody before injury can take place, the node of Ranvier remains vulnerable to 
circulating antibody.  
8.1.3 Uptake may result in spinal cord trafficking 
Following injection of 1 mg of MOG1, presence of this antibody was detectable 
in the ventral motor neurons after 1 day. This is the first time this has been 
demonstrated with antibodies which target gangliosides. Although shown only 
with one anti-ganglioside antibody in this thesis, the supporting evidence of anti-
synaptosome monoclonal antibodies and antisera uptake from previous studies 
serves to highlight the possibility that anti-ganglioside antibodies may be 
retrogradely transported to the spinal cord following uptake at the motor nerve 
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terminal (see chapter 5) (Fabian and Ritchie, 1986;Fabian and Petroff, 
1987;Fabian, 1988;Fabian, 1991;Ritchie et al., 1985;Ritchie et al., 
1986;Wenthold et al., 1984). The consequences of this are as of yet unknown. 
However, the demonstration that 7 days following antibody injection in GalNAcT-
/--Tg(neuronal) mice, antibody was seen in the cord neuropil outwith the motor 
neuron, implies that these antibodies are not fully degraded following their 
uptake. Instead some may be released from the motor neuron to bind to nearby 
neurons and potentially have pathogenic effects within the CNS. Inhibitory 
interneuron damage has been implicated in the hyper-reflexia seen in some 
AMAN cases (Kuwabara et al., 1999;Yuki et al., 2012). Similarly, damage to the 
brainstem has been implicated in the alteration of consciousness seen in BBE 
patients (Shahrizaila and Yuki, 2013). The retrograde transport of anti-
ganglioside antibody to the spinal cord, followed by the potential trans-synaptic 
spread to surrounding spinal cord or brainstem nuclei may result in antibody-
mediated damage to these areas. It would be interesting to further investigate 
whether trans-synaptic spread of retrogradely transported antibody could be 
responsible for the damage seen in these subsets of disease. 
8.1.4 Antibodies in patient serum may not be pathogenic 
One of the most significant findings of this thesis is that pathogenic, tissue 
binding antibodies are quickly cleared from the circulation at points where 
antibodies may bind and be endocytosed. In contrast, antibodies which react 
with gangliosides in ELISA but do not bind in tissue cannot be internalised in the 
same receptor-dependent manner as pathogenic antibodies. These antibodies 
thereby remain in the circulation for longer periods of time (Figure 6.9). The 
two antibodies used to demonstrate this, DG1 and DG2, were first shown to have 
differing abilities to bind GM1 in the living membrane by Greenshields et al. The 
authors showed that, despite both antibodies having been raised against GM1 in 
mice, only DG2 could bind to its target uninhibited, while DG1 binding was 
hindered by the presence of nearby GD1a (Greenshields et al., 2009). This 
inhibitory GD1a effect was also demonstrated with human anti-GM1 IgM 
monoclonal antibodies isolated from MMN patients. The authors concluded that 
the binding of antibodies seen in ELISA or glycoarray does not mimic their 
pathogenic potential in living tissue. The demonstration that only the tissue-
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binding DG2 antibody can be cleared from the circulation serves to establish the 
effects of this finding in vivo. The clinical consequence of this finding is that the 
patient antibodies detected by solid-phase diagnostic assays do not represent 
the same cohort of antibodies which can cause neuropathology. This may explain 
why the detection of anti-ganglioside antibodies in the serum does not always 
correspond with the progression of disease (for example Press et al showed peak 
antibody during the recovery phase of GBS) (Odaka et al., 2003;Press et al., 
2001), a fact which had led to some debate as to whether anti-ganglioside 
antibodies are the disease-causing agent in GBS. It also presents a justification 
as to why serum from GBS patients, while highly positive for anti-ganglioside 
antibodies by ELISA, has rarely been found to cause damage when used in mouse 
studies even with significant modulation of the membrane, either by using mice 
which overexpress target ganglioside, and/or neuraminidase treatment to 
unmask hidden epitopes (Goodfellow et al., 2005;Jacobs et al., 2002;Zitman et 
al., 2011b). Following the study by Greenshields et al, patient sera would be 
expected to contain both pathogenic and non-pathogenic antibody and therefore 
should still have pathogenic potential when exogenously added to tissue. 
However, in light of the ability of pathogenic antibody to be cleared from the 
circulation, it is more likely that patient sera contain a considerably lower 
proportion of pathogenic antibody in comparison to non-pathogenic. This 
principle may also be used as a possible explanation as to why antibody binding 
was hard to show in the active immunisation studies shown in chapter 4, despite 
anti-GD1b antibody presence being confirmed by ELISA and glycoarray.  
8.2 Additional insight and future work 
8.2.1 Parallel studies supporting the concept of antibody 
internalisation 
Originally intended as part of this thesis, it soon became clear that time 
constraints would prevent me from undertaking some experiments which would 
expand the scope of investigation of anti-ganglioside antibody clearance. For 
instance, when it was shown that levels of MOG1 (an IgG) could be rapidly 
depleted in wildtype and GalNAcT-/--Tg(neuronal) mice, it became of interest to 
show that this concept is also true of pentameric IgM molecules. It was assumed 
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that this would be the case based on a pilot study carried out by myself in the 
early stages of investigation, but also by a previous study showing monoclonal 
IgM antibody targeting thy1.1 (which is highly enriched at the neuronal plasma 
membrane), can be retrogradely transported to the spinal cord, implying its 
uptake at the nerve terminal (Fabian, 1990). Using the same protocol set out in 
this thesis, MOM8 (an anti-GD1b IgM monoclonal antibody) was injected into 
wildtype, GalNAcT-/- and GalNAcT-/--Tg(neuronal) mice. This IgM antibody was 
also rapidly cleared in wildtype mice, with intermediate rate of clearance in 
GalNAcT-/--Tg(neuronal) mice and in GalNAcT-/- mice (Figure 8.1). Antibody is 
significantly higher than wildtype mice in GalNAcT-/- and GalNAcT-/--Tg(neuronal) 
mice at day 1, but decreases to similar levels from day 3 onwards. This was 
unsurprising since the half-life of IgMs in mouse circulation is around 3 days 
(Vieira and Rajewsky, 1988;Zuckier et al., 1989). This work was performed by C. 
Paton as fulfilment of her degree of Master of Science.  
 
Figure 8.1: MOM8 serum presence by ELISA over 7 days. Wildtype mice (n=3) clear 
antibody quickly from their circulation, most being cleared even at the day 1 timepoint. 
GalNAcT-/- (n=2) and GalNAcT-/--Tg(neuronal) mice (n=3) show a peak at day 1 and a 
decline over the remaining days, indicating a slow clearance of antibody. IgM half-life in 
mice is around 3 days explaining the low levels at day 6 and 7. *=p<0.05 vs. wildtype. 
Two-way ANOVA with Tukey’s multiple comparison test. 
 
To link this work back to patient studies it is important that this phenomenon 
can be demonstrated using patient-derived antibodies. If, as shown with the 
mouse monoclonal antibody DG1, non-pathogenic antibodies are left to circulate 
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in the serum, then the serum antibodies detected by ELISA in patients, which 
are likely not pathogenic, would therefore be unlikely to bind in mouse tissue. In 
contrast, monoclonal antibodies derived from patient PBMCs in theory represent 
an entire repertoire of antibodies produced by the patient, including both 
pathogenic and non-pathogenic. Using an anti-GM1, IgM monoclonal antibody 
derived from an MMN patient which was previously shown to bind mouse NMJs 
(G. Meehan, unpublished data), plus serum taken from the same patient, we 
were able to show ex vivo that the patient serum neglected to bind to GD3s-/-TS 
(even with neuraminidase treatment to strip nearby sialic acid-bearing 
gangliosides), whereas the monoclonal antibody bound to the NMJ (R. 
McGonigal, unpublished data). However, the monoclonal antibody still required a 
GD3s-/- mouse which overexpress GM1, plus neuraminidase treatment in order to 
bind. Thus, although the serum did not show any ability to bind tissue, the 
monoclonal would not bind without membrane manipulation. Additionally, 
although patient serum is polyclonal, the concentration of the multiple 
antibodies is unknown and likely to be lower than the monoclonal antibody. To 
address this, another human monoclonal antibody will be used which can bind 
wildtype mouse membrane without membrane manipulation. This antibody is 
from a patient with Chronic Ataxic Neuropathy, Ophthalmoplegia, Monoclonal 
IgM protein, cold Agglutinins and Disialosyl antibodies (CANOMAD) and targets b-
series gangliosides (Willison et al., 1996). The ability of these two antibodies to 
be cleared from the mouse circulation will be compared. This experiment is 
ongoing.  
8.2.2 Future work 
8.2.2.1 Active immunisation model of GBS 
The results of this thesis offer a new outlook on antibody processing in 
autoimmune neuropathies. However, one of the initial goals I had aimed to 
achieve was to develop an active immunisation model of GBS using GalNAcT-/--
Tg(neuronal) and GalNAcT-/--Tg(glial) mice. This was only partially completed 
as, though the immunised animals developed an antibody response, no injury 
was detectable upon transfer of exogenous complement. As part of the 
investigation into why this may have been the case, the phenomenon of antibody 
internalisation was explored. It is thought that the removal of pathogenic 
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antibody from the circulation by receptor-dependent uptake may have resulted 
in too low a level to cause injury. In order to develop a model whereby injury 
can be detectable following an immune response, further modifications to the 
immunisation protocol may be needed to a) induce a higher immune response 
and b) increase the likelihood of complement activation by injecting NHS at 
more than one timepoint. The knowledge that the motor nerve terminal is such 
a scavenger of anti-ganglioside antibody warrants that immunohistological 
evidence of antibody and complement deposition is likely to be difficult to find 
here and therefore looking for said evidence at nodes may prove more prudent.  
8.2.2.2 Investigation of antibody uptake at places other than the motor nerve 
terminal 
Wildtype mice clear anti-ganglioside antibody from their circulation more rapidly 
than GalNAcT-/--Tg(neuronal) mice. The difference between the abilities of 
wildtype and GalNAcT-/--Tg(neuronal) mice to clear anti-ganglioside antibody  is 
therefore likely due to the expression of ganglioside on non-neuronal cells 
contributing to the receptor-dependant uptake of said antibody.  The use of 
fluorescent ganglioside analogues, ganglioside-binding toxins and antibodies 
targeting gangliosides have all been used to study the internalisation of 
gangliosides in cells (Crespo et al., 2008;Singh et al., 2003;Fewou et al., 2012). 
These studies have suggested that the gangliosides are internalised by clathrin-
independent endocytosis, mainly by caveolae. It is therefore hypothesised that 
the clearance of antibodies in wildtype mice is mostly due to caveolae-mediated 
endocytosis at non-neuronal sites. To investigate this hypothesis we will employ 
the use of caveolin 1-/- mice which lack any caveolae (Razani et al., 2001). In 
collaboration with the lab of Dr Ben Nichols, these mice will be used as part of a 
clearance study using the same protocol as detailed in this thesis. Previously, 
the internalisation of gangliosides has been shown to be impaired in cells which 
lack caveolin 1 (Iglesias-Bartolome et al., 2009). Therefore, it is expected that, 
if antibodies are indeed being cleared mainly by caveolae in non-neuronal cells, 
the rate of clearance will not be as rapid in caveolin 1-/- mice as in wildtype 
mice.  
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8.2.2.3 Retrograde transport and trans-synaptic spread of antibody 
The potential that antibody can be retrogradely transported and spread trans-
synaptically to nearby neurons is one of the most interesting possibilities to 
explore in the future. In this thesis, the weak presence of anti-GD1b antibody 
MOG1 was shown outwith the neuron in GalNAcT-/--Tg(neuronal) mice 7 days 
after an i.p. injection of 250 µg. At the earlier timepoint of 1 day (following a 
larger, 1 mg dose of antibody), antibody was shown within the motor neuron. 
The anti-GM1 antibody DG2 was, however, not found distinctly in the neurons 
either at 1 day or 7 days post injection of 2 mg antibody. Due to issues with 
tissue staining at the time, it would be of importance to repeat this study, this 
time using the same protocol as with MOG1, to absolutely rule out DG2 being 
trafficked to the spinal cord. On a similar note, repeating the inhibition of DG2 
breakdown using NH4Cl (assuming similar results are obtained) would justify the 
absence of DG2 in the cord. It would also be of interest to use the more precise 
method of intramuscular injections for both MOG1 and DG2. This will result in a 
larger amount of antibody being taken up by one particular muscle, thus 
increasing the likelihood of finding a substantial amount in a particular spinal 
nucleus. Future investigations would require further evidence showing the 
location of antibody presence at different timepoints following the initial arrival 
in the spinal cord. Behavioural tests could also be employed to determine 
whether the antibody presence is having any central nervous system effects such 
as is seen in some cases of AMAN and BBE. As an immune-mediated attack on the 
brainstem has been implicated in BBE (Shahrizaila and Yuki, 2013), staining for 
complement activation and infiltration of immune cells would also be useful, to 
see if the antibodies are having similar pathogenic effects in the CNS as in the 
PNS.  
8.2.2.4 Can exercise increase the clearance of antibody from the circulation? 
With the new finding that motor nerve terminal activity can increase the speed 
of antibody uptake in wildtype ex vivo muscle nerve preparations, it would be of 
interest to determine the effect of stimulation in GalNAcT-/-, GalNAcT-/--
Tg(neuronal) and GalNAcT-/--Tg(glial) mice. It would be expected that, like in 
wildtype mice, stimulation of the nerve terminal in GalNAcT-/--Tg(neuronal) 
mice would also result in activity-dependent uptake. This is because the target 
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ganglioside is only expressed in the neurons of these mice and it is the 
specialised vesicular cycling in the nerve terminal which results in the effect. 
However, as GalNAcT-/- and GalNAcT-/--Tg(glial) mice do not bind antibody on 
their neuronal membranes, there would be no effect expected. Nevertheless, 
the GalNAcT-/--Tg(glial) mice may show some increase in uptake in response to 
stimulation due to the pSC’s ability to sense nerve terminal activity and their 
own ability to release neurotransmitter (Jahromi et al., 1992;Robitaille et al., 
1997;Rochon et al., 2001). 
Forced exercise paradigms, such as treadmill running, are widely used to study 
the benefits of exercise. Therefore, to determine whether the activity-
dependent uptake of antibody is relevant in vivo, this type of experiment would 
be ideal for measuring the clearance over time in exercise and non-exercised 
animal groups. For this type of study it would be more prudent to use GalNAcT-/-
-Tg(neuronal) mice (if, as mentioned, ex vivo studies show the same effect as in 
wildtype mice) for two reasons: firstly, wildtype mice clear the antibody so 
quickly anyway that no difference would be able to be seen at the current dose 
of antibody. Secondly, using GalNAcT-/--Tg(neuronal) mice we will be able to 
ensure that the clearance seen is almost solely due to the nerve terminal 
uptake.  
8.3 Concluding remarks 
In the end, this thesis has investigated the regulation of anti-ganglioside 
antibodies by receptor-dependent internalisation, and how this can affect the 
circulating antibodies in the serum of mice. Expanding on work which previously 
demonstrated anti-ganglioside antibody’s ability to bind and be internalised in 
both cell culture experiments and at the mouse motor nerve terminal (Fewou et 
al., 2012), this thesis has demonstrated ex vivo that both neuronal and glial 
membranes have the ability to clear the antibody, though the fate of antibody 
following uptake into the pSCs is still unclear. The effect of this internalisation 
has also now been demonstrated in vivo, with a clear, rapid internalisation 
which is dependent on the presence of target, and can result in the retrograde 
transport of antibody to the spinal cord. Additionally, it has been shown that 
while pathogenic anti-ganglioside antibodies can be cleared from the circulation 
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by this receptor-dependent mechanism, non-pathogenic anti-ganglioside 
antibodies are left to circulate for longer. A summary of this hypothesised 
regulation of anti-ganglioside antibody by endocytosis is displayed in Figure 8.2 
on the following page. These are novel observations in the context of GBS, the 
true effects of which are yet to be fully explored.  
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Figure 8.2: Schematic representation of the hypothesis of anti-ganglioside antibody 
internalisation. A: Pathogenic and non-pathogenic antibodies arrive at the nerve 
terminal from the circulation (1). Vesicles containing ACh fuse with the membrane (2), 
where pathogenic antibody has bound to gangliosides. During vesicle retrieval, 
gangliosides and their attached antibodies are taken into the cell (3). Antibodies may be 
returned to the surface at this point (4), or can undergo retrograde transport up the 
axon to the motor neuron in the spinal cord (5). Pathogenic anti-ganglioside antibody 
which binds at the node of Ranvier cannot be internalised here and instead activates 
complement resulting in C5b-9 (MAC) deposition (6). Meanwhile, non-pathogenic 
antibody cannot bind ganglioside at the nerve terminal and therefore is not internalised 
(7). B: Retrogradely transported antibody now present in ventral horn motor neurons 
may be degraded in lysosomes (8), or recycled to the neuron surface (9) where it may 
be free to bind to adjacent neurons and cause pathogenic effects (10). C: Elsewhere in 
the body, circulating pathogenic antibody may bind to its target ganglioside in the 
membrane of non-neuronal cells, particularly vascular endothelial cells which are rich in 
caveolae. Once bound, antibodies may be endocytosed via the caveolae and thus 
cleared from the circulation (11). Exocytic pathways are shown by green arrows while 
endocytic pathways are shown by red arrows. 
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